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Carbohydrates are crucial biomacromolecules found in organisms across all domains of 
life and play pivotal roles in biological processes. To better understand the biological function of 
glycans, structurally-defined glycopeptides/glycoproteins and glycans are highly demanded. In 
this dissertation, the study has been focusing on acquiring homogenous 
glycopeptides/glycoproteins and glycans which are good candidates for decoding their function.   
Chapter 1 provides a brief introduction of function of glycosylation for proteins, 
significance of glycosylation for therapeutic protein and artificial glycosylation approaches; 
glycan synthetic approaches and glycan microarray and an overview of synthesis of 
oligosaccharides in large scale in vitro and in vivo.  
Chapter 2 describes two techniques for synthesis of glycopeptide/glycoprotein. (1) A 
facile and efficient method for site-directed glycosylation of peptide/protein. The method 
contains two sequential steps: generation of a GlcNAc-O-peptide/protein, and subsequent 
ligation of a eukaryotic N-glycan to the GlcNAc moiety. (2) Peptides can be GlcNAcylated at 
one or two natural N-glycosylation sites via two-step enzymatic reactions catalyzed by an 
evolved N-glycosyltransferase (ApNGT Q469A) and a glucosamine N-acetyltransferase (GlmA), 
respectively. Then, the resulting GlcNAc-peptides were further modified by an endo-β-N-
acetylglucosaminidase M mutant (EndoM N175Q) to generate glycopeptides carrying complex-
type N-glycans.  
In Chapter 3, two focused glycan libraries were synthesized which were N-glycans 
containing tandem epitopes and a new class of asymmetric N-glycans. (1) A focused library of 
36 biantennary asparagine (Asn)-linked glycans with some presenting tandem glycan epitopes 
was synthesized and glycan microarray study showed that the internal epitopes and/or 
modifications of terminal epitopes influence the binding of glycans. (2) A class of asymmetric N-
glycans was synthesized by coupling glycan-oxazoline and N-glycans. Branch-biased binding 
and spacial inhibition caused by bulky group on the other branch were observed in glycan 
protein interactions involving lectins and these glycans. 
In Chapter 4, a microbial glycosyltrasferases Hp1,3FTα66 were readily expressed in 
Escherichia coli (E. coli) was biochemically characterized and applied as a diverse catalyst in the 
facile synthesis of fucosylated human milk oligosaccharides. In addition, multi-gram scale of 
fucosylated human milk oligosaccharides, lacto-N-fucopentaose (LNFP) III and lacto-N-
neofucopentaose (LNnFP) V were synthesized by three major combined engineered E. coli 
strains. 
INDEX WORDS: Structurally-defined, Glycopeptides/Glycoproteins, Glycans, Enzymatic and 
chemoenzymatic synthesis, Decoding glycan function, Engineered Escherichia coli. 
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1.1 Function of glycosylation for proteins and artificial glycosylation approaches  
1.1.1 Introduction of protein glycosylation 
Glycosylation is a ubiquitous post-translational modification of protein in most 
eukaryotes and some prokaryotes. Glycan structures play important roles in biological and 
physiological function of proteins, such as contributions in protein folding, quality control and 
involvement in biological recognition events [1, 2]. It is reported that the full diversity of 
mammalian glycans (estimated to be ≥7,000 structures), which are assembled from only ten 
monosaccharides: fucose (Fuc), galactose (Gal), glucose (Glc), N‑acetylgalactosamine 
(GalNAc), N-acetylglucosamine (GlcNAc), glucuronic acid (GlcA), iduronic acid (IdoA), 
mannose (Man), sialic acid (Sia) and xylose (Xyl), are generated by around 700 proteins [3, 4]. 
Four types of glycosylated proteins are known as glycoproteins: glycans are linked to 
proteins through (1) amide linkages to asparagine (Asn) side chains which is N-glycosylation, (2) 
glycosidic linkages to Ser/Thr which is O-glycosylation, (3) glycosaminoglycans, and (4) 
glycosylphosphatidylinositol (GPI)-anchored proteins [5-7] (Table 1.1 and Figure 1.1). 
Structures of glycans attached to proteins are highly complex because of numerous possibilities 
for branching and anomeric linkage, which lead to greater structural diversity than linear nucleic 
acid or polypeptide[3] (Figure 1.1). Complexity and diversity of glycans is due to potential 
competition among multiple enzymes for the same glycan substrates in intricate biosynthetic 
pathways [5, 8]. The complexity of glycan is relevant to the stability and recognition of protein. 
Sialic acids on glycans form highly hydrophilic structures, which can increase the solubility of 
the proteins by shielding hydrophobic residues and extend the half-life of proteins which are very 
important for protein [9, 10]. Compared to fucosylated therapeutic antibodies, glycoengineered 
2 
 
antibody with addition of bisecting GlcNAc or lacking core fucose residue exhibit strong 
antibody-dependent cell-mediated cytotoxicity (ADCC) at lower concentrations with much 
higher efficacy, which means that core fucosylation significantly influence ADCC [11-13]. 
Table 1. 1 Four types of glycoprotein. 
Type Consensus Sugar structures  Synthetic 
Location 
N-linked Asn-Xaa-Ser/Thr 





















Figure 1. 1 Four types of glycosylated proteins. 




For the past decades, protein based drugs have developed fast because of their great 
economic and clinical importance. Protein therapeutics have many advantages in therapeutically 
favorable properties, such as higher target specificities, lower side effects and better 
pharmacological potencies, however, their development is hindered by intrinsic limitations in 
their physicochemical and pharmacological properties [14-16]. The strategic manipulation of the 
protein’s surface glycosylation is a promising method now [7, 17]. Also, glycosylation plays a 
crucial role in the safety of protein therapeutics. Therapeutic proteins being modified by N-
glycan have demonstrated increased efficacy in patients and is considered as a safe way during 
process development [18, 19]. 
Glycans plays crucial roles from four aspects in therapeutic glycoproteins: (1) physical 
properties; (2) biological activity; (3) serum half-life and clearance; (4) immunogenicity.  
(1) Physical properties 
Glycosylation is important for protein to maintain molecular integrity, increase solubility 
and reduce the possibility of proteolysis. For example, fibronectin can be easily hydrolyzed if 
glycans are removed[20]; thermal stability of glycosylated interferon beta (IFN-beta 1a, Avonex) 
is higher than unglycosylated form (IFN-beta 1b, Betaseron) which is expressed by Escherichia 
coli (E. coli) [21]. Only 11% biological activity of fully deglycosylated recombinant human 
erythropoietin (rHuEPO) can be kept after heat treatment, however, the activity of glycosylated 
rHuEPO remains the same. Non-glycosylated rHuEPO can be easily denatured to be aggregates 
and precipitates by heat, pH and guanidine-HCl, while glycosylated rHuEPO can be reversibly 
folded and remains soluble [22-24]. In addition, glycans can protect rHuEPO from oxygen free 
radical damage [25].  
 (2) Biological activity 
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Glycosylated form (IFN-beta 1a, Avonex) had a 10-fold increased anti-viral activity as 
compared to the E. coli-expressed product (IFN-beta 1b, Betaseron) [21]. It was reported that 
research of glycoengineered EPO analogs demonstrated that a direct and positive relationship 
between number of glycans and in vivo activity. Although Aranesp (glycoengineered rHuEPO) 
with five N-glycans exhibits similar conformation and stability compared to Epogen (rHuEPO) 
with three N-glycan chains, to keep similar erythropoietic response, 3-fold more Epogen than 
Aranesp was required at three times per week dosing in mice [26, 27], which increased to 13-fold 
at weekly intervals.  
Mpl ligand is hormone (glycoprotein) involved in maturation, megakaryocyte growth, 
and platelet production. Glycosylated analogs of the Mpl ligand, N39 (four additional N-linked 
glycans) and N40 (a total of six N-linked glycans) can increase duration and amount of platelet in 
mice compared to native rHuMpI ligand [28].  
(3) Serum half-life and clearance 
Aranesp has an approximately 3-fold longer terminal half-life than Epogen and more than 






Figure 1. 2 Aranesp has a 3-fold increase in serum half-life compared to rHuEPO. 
Aranesp administered intravenously (IV) or subcutaneously (SC), and rHuEPO administered IV 
in dialysis patients are shown. Serum half-lives were: Aranesp IV, 25.3±2.2 h; 
Aranesp SC, 48.8±5.2 h; and rHuEPO IV, 8.5±2.4 h. Modified figure[7]. 
Follicle stimulating hormone (FSH) is used clinically for the treatment of anovulatory 
conditions and of infertility. FSH1208 which had extended N-linked glycosylation sequence had 
an increased half-life (3- to 4-fold) and AUC (4- to 6-fold) compared to native FSH [29].  
Glycosylated interleukin 3 (IL-3) can be bound by the extracellular matrix (ECM), which 
leads to glycosylated IL-3 slowly released into the circulation and increase 30%–40% activity to 
stimulate histidine carboxylase activity in bone marrow compared with non-glycosylated IL-3 
because of a 2-fold increase in serum half-life [30].  
But it was reported that not all glycans can increase the half-life of therapeutic proteins. 
The following important aspects are the relationship between glycan types and the circulatory 
behavior of glycoproteins. (a) By specific receptor-based mechanisms, improperly glycosylated 
proteins can be quickly removed from circulation; (b) Sialic acid terminated glycoproteins 
(negative charge) have longer half-life compared with non-glycosylated proteins or partially 
glycosylated proteins; (c) The more sialic acid, the longer half-life of therapeutic proteins; (d) 
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Some specific glycan patterns on the surface of therapeutic proteins can be targeted to certain 
tissue or organs [31].  
 (4) Immunogenicity 
Protein therapeutics can lose efficacy through neutralization of activity. It was reported 
that immunoreactivity of antibodies to rHuEPO increased in pure red cell aplasia (PRCA) patient 
serums if N-glycans were removed from rHuEPO, which may be explained by that glycans can 
block the binding between antibody and rHuEPO by shielding the protein molecule from 
immune system [32]. In addition, carbohydrate can increase the solubility and stability of 
proteins by shielding hydrophobic residues, which may reduce the possibility of protein 
aggregation and lead to decreased immunogenicity of proteins[33]. In summary, glycosylation of 
protein therapeutics is a practical approach to reduce the possibility of immunogenicity.  
Although glycosylation is well accepted for increasing the stability and efficacy of 
therapeutic protein, technique still challenge the artificial homogeneous glycosylation of 
therapeutic proteins because of complex structure of glycans. Chemical and enzymatic glycan 
synthesis or remodeling strategies are currently pursued in academic and industrial area, which 
may be alternative approaches for acquiring homogenous target glycoproteins which can be used 
for long-term therapeutics and decoding fundamental effects and mechanism of protein 
physicochemical and pharmacological properties. 
1.1.3 Chemical and chemoenzymatic synthesis of glycoproteins 
From the point of view of chemical synthesis, the synthesis of glycoproteins is one of 
most challenging technique because of the very large size (normally over 15 kDa), complex 
structure of glycans, the heterogeneity of glycosylation. Small to middle size N- and O-
glycopeptides can be synthesized by the conventional solid-phase peptide synthesis (SPPS) 
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strategy[34, 35]. However, synthesis of larger glycopeptides or glycoproteins by the strategy is 
difficult because of low coupling efficiency, poor solubility of protected glycopeptides and 
strong acid hydrolysis (TFA and HF treatment) for deprotection of final product[36]. The solve 
the above problems, three major strategies have been developed, which include (1) native 
chemical ligation (NCL), (2) direct enzymatic glycosylation, and (3) chemoenzymatic 
transformation for synthesis of homogenous larger glycopeptides and glycoproteins.  
(1) Native chemical ligation 
In reaction of native chemical ligation, the thiol group in N-terminal Cys from peptide b 
can attack the thioester in C-terminal from peptide a to form a new larger peptide (Figure 1.3). 
Bertozzi group firstly reported that they synthesize an glycoprotein with 82 amino acid and two 
O-GalNAc residues [37]. Unverzagt group reported synthesis of a glycopeptide thioester using 
alkanesulfonamide “safety-catch” linker for NCL strategy [38]. Then, Kajihara group firstly 
synthesize a full size glycoproteins, monocyte chemotactic protein-3 (MCP-3) with 76 amino 
acid and a complex type N-glycans and acquire the native glycoproteins by folding approach 
[39]. However, Cys residues for ligation in NCL still limit the synthesis of glycoproteins because 
many targets are lack of Cys residues. Therefore, different strategies have been developed to 
mimic the cysteine ligation. A series of thiolated amino acids as potential residues for Lys, Phe, 
Pro, Ala, Gln, Leu, Val and Thr have been tried and then the thiol group can be selectively 
removed, which significantly expanded application of NCL for synthesis of glycoprotein [40, 
41]. Recent research on synthsis of glycoprotein hormone α- and β-subunits [42, 43], human 
interferon-β [44] and human EPO [45, 46] demonstrated that NCL is powerful strategy for 





Figure 1. 3 Mechanism of native chemical ligation. 
(2) Direct enzymatic glycosylation 
Naturally, N-glycoprotein can be synthesized by the oligosaccharyl transferases (OST) 
which can transfer glycans from a dolichol-phosphate glycolipid to Asn in a consensus Asn-Xaa-
Ser/Thr (Xaa ≠ Pro) sequon of the nascent protein. OST can transfer glycans to proteins to form 
glycoproteins in vitro [47-49], however, OST is hard to handle for in vitro protein glycosylation 
because it is a nine-subunit enzyme and is membrane-bound. In contrast, PglB, is a single 
subunit transferase that was discovered for protein N-glycosylation in Campylobacter jejuni, 
which can be used as a tool for glycoprotein glycosylation [50-54]. PglB is capable to transfer 
relaxed polysaccharide substrate to a protein to acquire polysaccharide-protein conjugates for 
application of bacterial glycoconjugate vaccines [55, 56]. But it needs strict sequence (Asp/Glu-
Xaa-Asn-Xaa-Ser/Thr) in protein as a substrate [51] and cannot efficiently use mammalian N-
glycan as donor [53], which limit its application in protein glycosylation.  
N-glycosyltransferase (NGT) from a pathogenic bacterium was reported to transfer a 
glucose residue to Asn-Xaa-Ser/Thr (Xaa ≠ Pro) consensus sequence in a polypeptide from 
UDP-Glc, rather than glycolipids as a donor [57]. Wang group reported that glycosylated 
polypeptides harboring complex glycans can be synthesized by combination of NGT and 
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endoglycosidase-catalyzed transglycosylation, however, the product was not a natural complex 
type N-glycan because NGT cannot transfer GlcNAc residue to protein due to strict substrate 
specificity [58]. 
Alternatively, direct enzymatic glycosylation of proteins in vitro maybe a very promising 
and attractive method to synthesize homogenous glycoproteins if the enzymes can be engineered 
to have board substrate specificity by protein engineering and directed evolution. 
(3) Glycosylation remodeling of glycoproteins  
 Glycosylation remodeling of heterogeneous glycoproteins is a promising approach for 
synthesis of homogenous glycoproteins in vitro. The approach involved two key steps: (a) 
GlcNAc-glycoproteins preparation by enzymatic hydrolysis to remove N-glycan from 
glycoproteins or chemical synthesis; (b) Protein transglycosylation by endoglycosidases mutant 
[59] (Figure 1.4).  
  
Figure 1. 4 Glycosylation remodeling of glycoproteins. 
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Endoglycosidases is a class of enzymes that release oligosaccharides from glycoproteins 
to produce GlcNAc- or GlcNAc-(Fuc)-proteins. After site-directed mutagenesis (SDM), the 
enzymes lose or decrease activity of hydrolysis and largely increase activity of 
transglycosylation. After mutation, several endoglycosidases from bacteria and fungus, including 
EndoA [59], EndoH [60], EndoM [59], EndoD [61], EndoS [62, 63], EndoS2 [64] and EndoF3 
[65] were applied for synthesis of homogenous glycoproteins (Table 1.2).  
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Throughout the strategy, HIV-1 glycopeptide antigens [66-68], glycan remodeling of 
homogeneous glycoproteins harboring natural or modified N-glycans [67-74], glycoengineering 
of intact IgG antibodies [61, 62, 75, 76] and antibody-drug conjugates (ADC) [77, 78] were 
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developed. A novelty of the strategy is relatively easy for synthesizing homogenous and larger 
glycoproteins, antibodies, e.g. which can be applied for deciphering biological functions. 
1.2 Glycan function, structure-defined glycan synthesis approaches and glycan array  
1.2.1 Function of glycans 
  Glycans commonly existed on cell surfaces. In addition to their effect on protein 
folding and properties, they also mediate numerous biological processes, including but not 
limited to signaling, fertilization, embryogenesis, cell proliferation and differentiation[79] 
(Figure 1.5). Plentiful data have shown that glycosylation is related to pathogen recognition, 
inflammation, innate immune response, autoimmune diseases and development of cancer 
[80, 81]. For instance, glycan-binding protein CD22 on the surface of activated B 
lymphocytes can recognize terminal Neu5Ac-α-2,6-Gal sequence in Asn-linked glycans 
[82]. Another example is that sialyl Lewis x tetrasaccharide can mediate cell adhesion, 
which has been used for drug development to treat common diseases such as rheumatoid 
arthritis and heart diseases [83]. However, more glycan functions are yet to be discovered, 




Figure 1. 5 Interactions between glycans and receptors mediate biological processes. 
1.2.2 Structural diversity and classification of glycans 
(1) Structural diversity of glycans 
  Glycans are monosaccharide chains linked by glycosidic linkages. Since (1) each 
monosaccharide has several hydroxyl groups that can form glycosidic linkage with other 
monosaccharides, (2) the formed glycosidic linkages can be in α or β configuration, (3) the 
glycans can be linear or branched, (4) there are over ten common monosaccharides, when 
glycans are formed by certain number of monosaccharides, the sequence of sugar residues, 
the position where glycosidic bonds form, the configuration of anomeric carbons in the 
formed glycosidic bond, and the types of monosaccharides can all vary, and will result in 
very diversified glycan structures. The structural diversity endows glycans the ability to 
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encode and carry numerous information, and deliver the information by interacting with 
specific molecules. 
(2) Classification of glycans 
  In nature, glycans can exist as unbonded compounds, e.g. human milk 
oligosaccharides (HMOs) and hyaluronan, or in glycoconjugates by covalent bonding to 
protein or lipid. Among these glycans, the ones that exist in glycoconjugates (glycoproteins 
and glycolipids) are the glycans function mostly in intercellular interactions. In this work, 
we focus on the glycans in glycoproteins. Per the linkage between glycan and 
protein/peptide, glycans in glycoproteins can be sub-grouped into N-glycans and O-glycan. 
  N-glycans are linked to protein/peptide by linkages between the anomeric carbon of 
N-acetylglucosamine (GlcNAc) at its reducing end and the amino group on the side chain 
of Asn residue. They exist widely in immunoglobulin and other therapeutic proteins. The 
structures of N-glycans are relatively clearly examined. Almost all N-glycans contain a 
common pentasaccharide core structure, composing of three mannose (Man) residues and 
two GlcNAc residues. They are further divided into high-mannose type, complex type and 
hybrid type, depending on the detailed structures of the appendages on the N-glycan core 
[84].  
  O-glycan are connected to protein/peptide through the glycosidic bond between the 
anomeric carbon of the reducing sugar and the hydroxyl group in the side chain of Ser, Thr, 
4-hydroxylproline (Hyp) or 5-hydroxylysine (Hyl). O-glycans are also structurally 
diversified. For example, the O-glycans rich in mucin are linked to the hydroxyl group in 
amino acid through α-glycosidic bond from N-acetylgalactosamine (GalNAc) [85]. Eight 
core structures have been identified for these O-GalNAc glycans, and the core structures 
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can be further extended with galactose (Gal), GlcNAc, fucose (Fuc) and/or sialic acid (Sia) 
[84]. Many antigenic epitopes and cancer-related glycan epitopes exist in the extension 
structure of O-GalNAc glycans [86]. Another type of O-glycans, O-Man glycans, forms 
linkages between the Man residue at the reducing end and protein. The aberrant structure 
will lead to congenital muscular dystrophies [87, 88] and cancer [89-91]. In addition, many 
proteins are modified by O-Fuc, O-glucose (Glc) and O-xylose (Xyl) glycans through α-
Fuc, β-Glc and β-Xyl linkages to Ser/Thr residue For instance, the epidermal growth factor 
(EGF)-like repeats of Notch protein are O-glucosylated [92], while the EGF-like repeats in 
Notch receptor are O-fucosylated, and the O-fucosylation is related to protein folding [93]. 
1.2.3 Preparation of structurally defined glycans 
  Although the critical functions of protein glycosylation have attracted researchers’ 
attention, it is still challenging to fully interpret the molecular mechanisms under their 
functions. The lack of structurally defined complex glycans as standard has hindered the 
analysis of accurate structures of glycans in complicated mixtures [94, 95], and hampered 
the specificity and characterization study of glycan-binding proteins (GBPs) existed in 
nature [96-98]. Therefore, structurally defined homogeneous glycans are a prerequisite and 
are highly demanded for structural and functional study of glycans. Currently, isolation and 
synthesis are two main approaches for glycan preparation. 
(1) Isolation of glycans 
  Glycans isolated from natural sources include that human milk oligosaccharides, 
glycans from glycolipids and glycoproteins by chemical hydrolysis or endoglycosidases, 
proteoglycans (GAGs) and fragments obtained by chemical or enzymatic degradation, and 
bacterial polysaccharides and plants glycans [124, 131-134]. In the case of isolation of 
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glycans from glycoproteins/glycopeptides, natural sources that are rich in glycans (highly 
glycosylated proteins/peptides) are required, but usually only limited amount of glycan can 
be obtained by this method [99]. In addition, except for a few glycoproteins which contain 
glycans with relatively homogeneous structures such as Man9GlcNAc2 N-glycan from 
soybean agglutinin [100] and complex type N-glycan from sialylglycopeptide (SGP) from 
egg yolk [101], glycans isolated from most glycoproteins are mixtures and further 
separation of glycans with similar structures is very challenging [99]. Therefore, isolation 
from natural sources is not a reliable strategy to afford substantial structurally defined 
glycans. 
(2) Synthesis of glycans 
  Preparation of glycan library by chemical, chemoenzymatic or enzymatic synthesis 
has been widely applied to perform biological and structural studies [97, 98, 102-104]. In 
chemical synthesis, a series of protecting groups with different reactivities have been 
developed to selectively protect the hydroxyl groups located at different positions in the 
sugar ring but have similar properties. Then, the protecting group at the target site is 
removed to expose the hydroxyl group for glycosidic linkage formation. Also, protecting 
groups with different properties are used to create specific spatial hindrance near the 
anomeric carbon and force the formation of glycosidic linkage with specific configuration 
(α or β) [105]. Furthermore, to simplify the synthetic approach and omit purification 
process, one-pot solution-based synthesis and solid-phase synthesis have been developed. 
In the former strategy, glycosyl donors with different reactivities are mixed into one reactor. 
The synthesis of complex glycans is achieved by controlling the reaction condition to 
enable donors with high reactivity react first and those with low reactivity react later [106]. 
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Two hexosaccharyl tumor-associated carbohydrate antigens (TACAs) Globo-H and GM1 
have been accomplished by this strategy [107-109]. In the latter strategy, glycosyl acceptors 
are immobilized to the surface of solid-phase, and are well exposed to solutions containing 
glycosyl donors to react. Based on this strategy, Seeberger group developed automated 
glycan synthesis, and generated histo-blood antigen Lewis x and Lewis y, TACAs Gb-3 
and Globo-H and so on [110, 111]. 
  Despite its major progress, chemical synthesis of complex glycans is still time-
consuming, especially in the cases when the target glycans are very complicated [97]. 
Therefore, chemoenzymatic strategy with higher efficiency has been developed, in which 
a glycan precursor is synthesized chemically, and then is extended by a set of 
glycosyltransferases (GTs) to provide more complex glycans [103, 104]. The GTs used 
here are a group of enzymes that can transfer saccharide (usually monosaccharide) from 
glycosyl donor to glycosyl acceptor and form a glycosidic linkage between them[103]. 
Most GTs require sugar nucleotides as their donor, while a minority of GTs can use sugar 
phosphate, glycolipid or glycan itself as sugar donor. The reactions catalyzed by most GTs 
have strict stereo-selectivity and regio-selectivity with only a few exceptions [103]. In 
addition, some GTs can also recognize and utilize analogs of their natural sugar donors[103] 
and provide glycans containing bioorthoganol groups which can assist the study of 
biological functions of glycans. 
  Many research groups have been focusing on synthesizing branching glycans 
chemically or chemoenzymatically [99, 112-116]. Majority of these work dealt with 
symmetric glycans, i.e. the glycan structures of each branch are the same, the best synthetic 
approach of which is enzymatic synthesis. Regarding to asymmetric glycans in which the 
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glycan structures on different appendages are different, chemical synthesis is employed. To 
achieve this, protecting groups with different reactivities are used at the branching point, 
and suitable conditions are used to sequentially deprotect each protecting group followed 
by extension of the branch to generate the final asymmetric glycans [99], which can better 
mimic natural branching glycans that usually carry different appendages at each branching 
point [2]. 
  However, both chemical and chemoenzymatic synthesis is dependent on expertise 
related to chemical synthesis. If no chemists are available, enzymatic synthesis is the only 
option. With glycopeptide isolated from egg yolk as precursor, Kajihara et al prepared a 
series of asymmetric bi-antennary complex-type N-glycans by using glycosidases and GTs 
[117, 118]. The glycosidases used can partially hydrolyze some sugar residues from natural 
glycans, and GTs can selectively extend the glycans. Nevertheless, structures of glycans 
generated solely by enzymatic synthesis are usually limited. 
1.2.4 Glycan microarray 
Glycans on the surface of living cells is diverse structures and mediate biological 
function by glycan binding proteins (GBPs) [119-124]. Recently, glycan microarray provides 
high-throughput approaches for decoding the biological function of glycans in vitro and is 
applied as a tool to screen many sugar-biomolecular interations. Glycan microarray was firstly 
reported in 2002 and various approaches for glycan immobilization have been developed by 
several research group [125-131]. So far, all glycans that have been applied for glycan 
microarray were synthetic glycans or/and glycans isolated from natural sources.  
When structure-defined glycans are obtained, an appropriate approach for functional 
installation of glycan library on the chip is needed. Glycan immobilization can be broadly 
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categorized into two methods: (1) non-covalent immobilization: nitrocellulose and oxidized 
polystyrene coated glass slides normally designed for immobilization, and (2) covalent 
immobilization: the most covalent methods for glycan microarray have employed robust amine 
and thiol chemistries, which provide more specific attachment for the structure-defined glycan 
probes [132]. Amine chemistry is the most widely applied for glycan microarray now (Figure 
1.6). 
 
Figure 1. 6 Mechanism of glycan-amine bound to slides. 
Glycan microarray can be successfully applied to analyze the binding specificity between 
glycans and proteins (e.g. lectins and antibodies), pathogens, as well as cells (Figure 1.7). Plant 
lectins can recognize specific epitopes in glycans. However, some plant lectins have specific 
requirement for binding research. For example, conconavalin A (ConA), a plant lectin with 
different concentration showed similar binding affinity to mannose when concentration of 
glycans in the slide was high. But it can only bind the high affinity glycans when concentration 
of glycan was low [133]. Glycan microarray were applied to study infectious disease because 
viruses and bacteria bind glycans on the surface of human cells as initial recognition [134, 135]. 
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For instance, by glycan microarray analysis, it was reported that seasonal H1N1 virus only bound 
α2–6 sialyl sequences, however, H1N1 pandemic virus can bind α2–6 and α2–3 sialyl sequences 
[136]. The clinical application of glycan microarrays has also been developed. For example, a 
glycan microarray containing 37 glycans was applied for identification of changes of glycan 
structure that can initiate humoral immune response in classical Hodgkin's lymphoma (cHL) 
patients [137]. 
 
Figure 1. 7 Glycans can be specific bound by proteins, pathogens and cells. 
So far, a major issue for microarray is how to design a library to unveil biological 
functions of glycans. Due to complexity of glycans, the availability of structure-defined glycans 
is very limited, which is an obstacle for glycan microarray application. Focused libraries which 
are composed of a small group of glycans are relatively easy to prepare and can address a 
specific issue, however, it has limitation for broad application in biological research. Glycans 
libraries with large size of structure-defined glycans are still hard to acquire. Therefore, a glycan 
microarray which can cover most of the natural glycan structural space of the glycome are highly 
desired for biologist to understand biological function of glycans in living cells.  
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1.3 Synthesis of oligosaccharides in large scale 
1.3.1 Significance of oligosaccharide synthesis in large scale 
Some significant functional complex oligosaccharides are required in large scale in 
industry, such as Globo-H and HMOs. The presence of Globo-H oligosaccharide in glycolipids 
is strongly associated with the aggressiveness of several types of tumors [138]. As a result, the 
Globo-H oligosaccharide has been used in a glycoconjugate vaccine, which is under Phase II 
clinical trials for its immunotherapy activity in patients with metastatic breast cancer. Human 
milk oligosaccharides (HMOs), which are unconjugated and unique to human breast milk, are 
another group of structurally diverse glycans. HMOs function as prebiotics that facilitates the 
establishment of commensal bacteria in the human gut [139]. Studies have shown that 
inflammatory bowel diseases or their chronic manifestation might be prevented in breast-fed 
infants, due to interactions between HMOs and mucosal leukocytes [140]. Abbott Nutrition 
launched New Similac® which is cow milk-based infant formula supplemented with the simple 
HMO 2’-fucosyllactose (2’-FL), and clinical results demonstrated that infants fed by formula 
containing 2’-FL showed lower plasma and ex vivo inflammatory cytokine profiles, comparable 
to a breast-fed reference group [141]. Oligosaccharides are therefore a promising area of study 
for biological evaluation and roles in human disease. However, the availability of large amounts 
of structurally complex, pure oligosaccharides at low cost has lagged behind the demand of 
research and applications. There is an urgent need to develop efficient large-scale production 
strategies to meet the demand for structurally defined oligosaccharides in pharmaceutical and 
nutritional food area.  
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1.3.2 Challenges for current large-scale oligosaccharide production 
Generally, three strategies are employed for large-scale oligosaccharide production: (1) 
chemical synthesis, (2) enzymatic synthesis, and (3) whole-cell synthesis/living cell factory. 
Each strategy has distinct challenges.  
(1) Chemical synthesis.  
Chemical synthesis of oligosaccharides from tetrasaccharides to octasaccharides have 
been reported [142]. But the difficulty of chemical synthesis is associated with the intrinsic 
structural complexity of oligosaccharides, and has long hindered their production. For simple 
trisaccharides, such as 2’-FL (Fucα1–2Galβ1–4Glc) and 6’-SL (Siaα2–6Galβ1–4Glc), total 
chemical synthesis has been developed in large scale. However, for large-scale synthesis of more 
complex oligosaccharides, lengthy synthetic steps and relatively low overall yield impair the 
practicality of pure chemical synthesis. In addition, chemical synthesis of oligosaccharide in 
large scale is still challenging due to toxic reagents which are not suitable for applications in 
pharmaceutical and nutritional food area.  
(2) Enzymatic synthesis.  
Bacterial glycosyltransferases (GTs) have been used as suitable tool for oligosaccharide 
synthesis beucause of their relaxed substrate specificity. The high regioselectivity and 
stereoselectivity of enzyme-catalyzed reactions have made one-pot multi-enzyme (OPME) 
reactions an attractive method for oligosaccharide synthesis. OPME simultaneously combines 
several enzymes in a pathway for sugar nucleotides synthesis and transfer, and synthesizes 
oligosaccharides with relatively high yield and low cost. Using OPME, Wong and coworkers 
combined sugar nucleotide regeneration enzymes and glycosyltransferases (GTs) to achieve 
multi-gram synthesis of cancer-associated carbohydrate antigens [138]. The cost of synthesis was 
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reduced by replacing expensive sugar nucleotides sugar with nucleotide regenerating enzymes, 
however, preparation of multitude of enzymes required for the addition of a single sugar to the 
antigen made the whole process very time- and labor- intensive. Chen and coworkers employed a 
similar strategy, including sugar nucleotide generating enzymes instead of regenerating enzymes 
[143], but a large number of enzymes were still required and likely to hinder scaled-up 
production of oligosaccharides (Figure 1.8).  
 
Figure 1. 8 OPME strategy for oligosaccharides synthesis. 
(3) Whole-cell synthesis/living cell factory.  
In a third strategy to bypass protein purification, whole cells containing the necessary 
enzymes are used as whole-cell catalysts by freeze-and-thaw application, or directly as “living 
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cell factories” during cell growth. Using whole-cell catalysts by freeze-and-thaw strategy, 
Kyowa Hakko Kogyo Co., has established a 10-100 gram-scale oligosaccharide production 
platform by combining low-cost starting materials and metabolically engineered bacteria to 
specialize in the production of nucleotides, sugar nucleotides, or oligosaccharides [144-146]. 
Similarly, Wang and coworkers achieved multi-gram scale production of lactose-based 
trisaccharides using “superbugs,” which contained recombinant enzymes responsible for sugar 
nucleotide regeneration or generation in one E. coli strain [147, 148]. Neverthless, the Kyowa 
Hakkko and Wang whole-cell strategies were limited to oligosaccharides with relatively simple 
structures.  
To synthesize oligosaccharides by whole-cell strategy, sugar donor and acceptor need to 
be prepared. In E. coli, uridine-5’-diphosphate N-acetylglucosamine (UDP-GlcNAc) and uridine-
5’-diphosphate galactose (UDP-Gal), the donor substrates that are required by 
glycosyltransferases (GTs) for oligosaccharide synthesis, can be produced in the growing cells as 
required precursors of lipopolysaccharide (LPS) and peptidoglycan polysaccharide for cell wall 
construction. Therefore, the intracellular UDP-GlcNAc and UDP-Gal can be “borrowed” by the 
recombinant GTs for extending oligosaccharide in E. coli. For acceptor, lactose is an inexpensive 
candidate for oligosaccharide biosynthesis in E. coli [149]. LacY is a transporter which can 
transfer lactose from the medium into cytosol [150]. The activity of LacZ, a β-galactosidase that 
can hydrolyze lactose, should be diminished while the lactose uptake must be retained or even 
enhanced [151, 152]; therefore, LacZ-, LacY+ E. coli is chosen as preferred strains for using 
lactose as an acceptor to synthesize oligosaccharide in E. coli. Based on this technology, many 
groups attempted to produce oligosaccharide by direct fermentation. Samain et al attempted to 
synthesize larger oligosaccharides from lactose by simply fermenting an oligosaccharide 
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substrate with a single genetically engineered E. coli strain containing all GTs needed for 
oligosaccharide synthesis (Figure 1.9). By Samain’s strategy, lacto-N-triose (LNT) II (6 g/L), 
GD3 (0.83 g/L) and lacto-N-neofucopentaose (LNnFP)-I (1.5 g/L) can be produced[153-155]. 
  
Figure 1. 9 Biosynthetic pathway of LNnFP I from lactose in engineered E. coli cells. 
2'-FL, a trisaccharide, can be synthesized in engineered E. coli by two pathways: (1) de 
novo pathway and (2) salvage pathway, which are reported by different research groups [155-
160]. (Figure 1.10). The de novo pathway is the natural metabolic pathway in E. coli. In this 
pathway, five recombinant enzymes (Man A. ManB, ManC, Gmd, WcaG/Fcl) were utilized to 
synthesize GDP-Fuc from fructose-6-phosphate. Under catalysis of recombinant α1–2 
fucosyltransferase in E. coli, 2’-FL can be produced in large scale in vivo. By this strategy, 
Albermann group produced 2’-FL with concentration of 20.28±0.83 g/L [157]. Salvage pathway 
is naturally present in some Bacteroides strains and mammalian cells. In this pathway, the key 
enzyme is L-fucose 1-kinase/GDP-fucose pyrophosphorylase (FKP), a bifunctional enzyme from 
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Bacteroides fragilis which can synthesize GDP-fucose from L-Fucose. By this strategy, Seo 
group synthesized 2’-FL with concentration of 23.1 g/L [159]. 
 
  
Figure 1. 10 Biosynthesis of 2’-FL by de novo pathway and salvage pathway in engineered E. 
coli. 
Unfortunately, this “living cell factory” strategy had two major restrictions for production 
of oligosaccharides larger than trisaccharides: (a) Larger oligosaccharide substrates could not be 
transported into living E. coli for additional single-step extensions; (b) Several intermediates 
were formed along the biosynthetic pathway when multiple GTs were coexpressed for mono- or 
disaccharide acceptor extension, leading to difficulty in purifying the intended product. For 
example, LNT-II, lacto-N-neotetraose (LNnT) and 2'-FL were produced as intermediates when 
LNnFP I were synthesized in E. coli (Figure 1.9). 
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Based on the challenges described above, a practical, cost-effective strategy for large-
scale synthesis of structurally complex oligosaccharides remains a high-priority for driving 
advances in the glycoscience field. 
1.4 Outline of the work in this dissertation 
The work in this dissertation mainly focuses on investigating the significance of glycans 
by synthesis of structurally-defined glycopeptiedes/glycoproteins and glycans. More specifically, 
in Chapter 2, two techniques were developed for synthesis of glycopeptide/glycoprotein. (1) O-
linked-N-glycan-peptide/protein were synthesized and GLP-1 with O-linked N-glycan kept 
unchanged secondary structure after glycosylation, suggesting the potential application of this 
approach for peptide/protein drug production. (2) By three steps of enzymatic catalysis, 
glycopeptides carrying complex-type N-glycans can be efficiently synthesized. In Chapter 3, two 
focused glycans libraries were synthesized which were N-glycans containing tandem epitopes 
and a new class of asymmetric N-glycans. By glycan microarray study, N-glycans containing 
tandem epitopes library showed when interpreting the binding between glycans and 
GBPs/viruses, not only the structure of the terminal glycan epitopes, but also the internal 
epitopes and/or modifications of terminal epitopes need to be taken into account; a new class of 
asymmetric N-glycans library showed that branch-biased binding and spacial inhibition caused 
by bulky group on the other branch when glycans were bound to GBPs. In Chapter 4, a microbial 
glycosyltrasferase Hpα1–3/4FT was characterized and applied in the facile synthesis of 
fucosylated human milk oligosaccharides (HMOs). In addition, multi-gram scale of fucosylated 



























































































































































































































































































































































































2 CHEMOENZYMATIC OR ENZYMATIC SYNTHESIS OF 
GLYCOPEPTIDES/PROTEINS 
2.1 Site-directed glycosylation of peptide/protein with homogeneous O-linked eukaryotic 
N-glycans 
2.1.1 Introduction 
Glycans attached to proteins are closely related to protein stability [1], trafficking 
[2],signaling [3] and cell-cell interaction [4]. N-linked glycosylation of proteins, one of the most 
prevalent post-translational modifications in eukaryotes, significantly affects protein folding, 
stability and function [5, 6]. However, the heterogeneity of N-glycan in natural and recombinant 
glycoproteins greatly hampered the investigation of the roles of glycan in various biological 
processes. Therefore, access to homogeneous glycopeptides or glycoproteins is a prerequisite for 
their functional studies as well as biomedical application. To date, several strategies have been 
developed to produce uniform N-glycan modifications, including in vitro chemical and 
chemoenzymatic synthesis of glycoproteins [7, 8] and in vivo glycoengineering methods [9-
11].9-11 Herein, we alternatively proposed a facile approach for site-directed glycosylation of 
peptide/protein (Figure 2.1). The method contains two sequential processes: (1) introduction of 
O-linked N-acetylglucosamine (O-GlcNAc) modification on a target peptide/protein by chemical 




Figure 2. 1 Site-directed glycosylation of peptide/protein with uniform eukaryotic N-glycan. 
a. Chemically synthesized GlcNAc-O-peptide can be glycosylated by EndoM N175Q with 
complex-type glycan oxazoline (SCT-oxa) as a donor. b. GlcNAc-O-protein can be generated by 
co-expression with OGT and then linked with homogeneous eukaryotic N-glycan. 
2.1.2 Experimental Methods 
Synthesis of GlcNAc-O-peptides 
GlcNAc-O-peptides were synthesized through Fmoc-strategy. Automated peptide 
synthesis was performed on Liberty Blue Peptide Synthesizer. Peptides were synthesized under 
microwave-assisted protocols on Wang resins. HBTU was used as activator and DIEPA as base. 
Double coupling was performed with microwave under 50oC. Each coupling cycle took 10 min. 
The deblock mixture was 20% piperidine in DMF. Resins were purchased from Novabiochem. 
The Fmoc protected amino acids were purchased from Chempep. The corresponding glycoamino 
acids were synthesized according to previous report [12]. Cocktail of TFA/TIS/Dodt/H2O 
(92.5:2.5:2.5:2.5) was used to cleave peptides off the resin. For glycopeptides, 5% aqueous 
hydrazine was used to deprotect acetyl to give free hydroxy of GlcNAc. Crude peptides were 
purified through Xbridge Peptide BEH C18 column (10 µm, 10 mm × 250 mm) and analyzed by 
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Eclipse XDB-C18 (5 µm, 4.6 mm × 250 mm) column. The purified O-GlcNAc-Peptides are 
identified by HPLC and MALDI-TOF MS.  
Preparation of sialylglycopeptide (SGP) and complex-type glycan oxazoline (SCT-oxa) 
Preparation of sialylglycopeptide (SGP) was followed by reported method in our lab [13].  
SGP was digested by endo-β-N-acetylglucosaminidase M (EndoM) to acquire SCT. SCT-oxa 
was prepared by reported method [14].   
Protein expression and enzymatic reaction 
1) Preparation of EndoM and EndoM N175Q and GlcNAc-O-peptide glycosylation by EndoM 
N175Q 
The gene of EndoM and EndoM N175Q were codon-optimized and synthesized by 
Genewiz Co. (Suzhou, China) and were inserted into pET22b vector. EndoM N175Q with a C-
terminal His-tag was over-expressed in E. coli BL21 (DE3) cells and purified by Ni-NTA 
affinity column [15]. 
The reaction mixtures contained 50 mM PBS (pH 6.5), 5 nM GlcNAc-O-peptide as 
acceptor, 20 nM SCT-oxa as donor, and 20 µg EndoM N175Q, and was incubated at 30°C for 15 
min. After optimization of reaction condition for EndoM N175Q, we chose to carry out 15 min 
incubation for peptide transglycosylation, which are consistent with previous published results 
using natural GlcNAc-N-peptide as acceptors [15]. The reaction was terminated by boiling for 5 
min and then analyzed by HPLC-C18 and ESI-MS. 
2) Preparation of OGA and reaction of OGA 
Sequence optimized truncated OGA (short OGA, sOGA) was expressed in E. coli BL21 
(DE3) cells as previously described[16]. The reaction mixtures contained 100 mM PBS (pH 5.5), 
5 μg GlcNAc-O-peptide or glycan-O-peptide, and 5 μg OGA, and was incubated at 37°C 
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overnight. The reactions were terminated by boiling for 5 min and were analyzed by HPLC-C18 
and MALDI-TOF MS. 
3) Preparation of O-GlcNAcylated Crys-A mutants and transglycosylation of GlcNAc-O-Crys-A 
by EndoM N175Q 
E. coli BL21 (DE3) harboring either pET28a-Crys-A (sequence shown below) alone or 
with pMAL-sOGT [17] were cultured in 20 mL LB medium overnight and were used to seed 1 L 
fresh LB medium in flasks. The flasks were continuously shaken at 250 rpm at 37°C till OD600 of 
the culture reached 0.6–0.8. Protein expression was induced with 0.5 M IPTG at 25°C for 20 h. 
The E. coli cells were collected, re-suspended in 20 mM Tris-HCl buffer and disrupted via 
sonication. The Crys-A protein with a C-terminal fused His-tag was purified by Ni-NTA affinity 
column. The reaction mixtures containing 50 mM PBS (pH 6.5), 5 nM GlcNAc-O-Crys-A as 
acceptor, 20 nM SCT-oxa as donor, and 20 µg EndoM N175Q were incubated at 30°C for 60 
min and were stopped by heating in boiling water for 5 min. After optimization of reaction 
condition for EndoM N175Q, incubation was performed for 60 min, which is consistent with 
previous published results using natural GlcNAc-N-protein as acceptors [18]. 
Amino acids sequence of bovine Crys-A used in this work: 
MSEVRSDRDKFVIFLDVKHFSPEDLTVKVQEDFVEIHGKHNERQDDHGYISREFHRRYR
LPSNVDQSALSCSLSADGMLTFSGPKIPSGVDAGHSERAIPASSAEKPSSAPSSLEHHHHH
H (S is glycosylation site) 
Method of MALDI-TOF MS analysis  
MALDI-TOF MS analysis were performed on UltrafleXtreme MALDI TOF/TOF Mass 
Spectrometer (Bruker). Scan range of MS1 was set according to the molecular weight of 
glycopeptides, and reflector mode was used for analysis. Mass spectra were obtained in positive 
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mode with the following voltage settings: ion source 1 (19.0 kV), ion source 2 (15.9 kV), and 
lens (9.3 kV). The reflector voltage was set to 20 kV. The laser was pulsed at 7 Hz and the 
pulsed ion extraction time was set at 400 ns. The laser power was kept in the range of 25–40%. 
ESI-MS-MS analysis 
Nano UHPLC-MS/MS assays were performed on an LTQ-Orbitrap Elite mass 
spectrometer (Thermo Fisher) equipped with EASY-spray source and nano-LC UltiMate 3000 
high performance liquid chromatography system (Thermo Fisher). EASY-Spray PepMap C18 
Column (3 μm, 75 μm × 15 cm, Thermo Fisher) was used for separation. LTQ-Orbitrap Elite 
mass spectrometer was operated in the data dependent mode. A full-scan survey MS experiment 
(m/z range from 375 to 1600; automatic gain control target, 1,000,000 ions; resolution at 400 
m/z, 120,000; maximum ion accumulation time, 200 ms) was performed by the Orbitrap mass 
spectrometer. CID fragmentation ion spectra were acquired in ion-trap spectrometer (automatic 
gain control target, 10,000 ions; maximum ion accumulation time, 100 ms), and Normal 
Collision Energy (NCE) of CID was set to 35. 
Circular dichroism (CD) spectroscopy 
Far-UV (190–260 nm) CD spectra were recorded on a J-810 spectropolarimeter (Jasco) at 
ambient temperature (25°C) using a 0.1-cm-pathlength quartz cuvette. The measurements of 100 
μM GlcNAc-O-GLP-1 and glycan-O-GLP-1 were carried out in 10 mM PB (pH 6.5). All spectra 
presented were averaged for at least 10 scans, and the background signal was from the buffer.  
Immunoblot 
E. coli lysates overexpressing the Crys-A protein and purified Crys-A protein in variant 
glycosylation states (O-GlcNAcylation, O-linked N-Glycan modification) were separated by 
12% SDS-PAGE and transferred onto a 0.22 µm PVDF membrane. Western blot was performed 
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against anti-His antibody (ab18184, Abcam) or anti-O-GlcNAc antibody (ab2739, Abcam). 
Chemiluminescent protein detection was performed using Immobilon™ Western 
Chemiluminescent HRP Substrate (ECL) (Millipore) and recorded on a Versadoc MP5000 (Bio-
Rad). 
2.1.3 Results and Discussion 
O-GlcNAc modification is a naturally existed protein modification which involves β-
linked GlcNAc residue to a Ser/Thr via the catalysis of O-linked GlcNAc transferase (OGT) [19-
21]. To generate peptide/proteins with O-GlcNAc modification, two approaches were employed. 
The O-GlcNAcylated peptides (GlcNAc-O-peptides) were chemically synthesized, while the O-
GlcNAcylated target protein was obtained by co-expression of OGT with the target protein, 
forming the O-GlcNAcylated protein (GlcNAc-O-protein) in vivo. Then, we moved to the stage 
to transfer the N-glycan to the GlcNAc-O-peptide/protein. The N175Q mutant of endo-β-N-
acetylglucosaminidase M (EndoM N175Q) is an enzyme that can efficiently glycosylate the 
GlcNAc-Asn-peptide/protein using N-glycan oxazolines as donor substrates [15, 22, 23]. 
However, the feasibility of the EndoM N175Q-catalyzed transglycosylation reaction on GlcNAc-
O-peptide/protein needs to be evaluated. Therefore, a series of O-GlcNAc modified peptide 
segments from natural O-GlcNAc-proteins (Table 2.1) (Database: dbOGAP) were synthesized 
and EndoM N175Q was then applied to glycosylate the GlcNAc-O-peptides using the sialylated 








Table 2. 1 N-Glycan modification of selected peptides. 
Entry Peptide Sequence Protein source 
Product 
yields (%) 
Ser-01 MVLSPADK HBA_HUMAN 61 
Ser-02 PQFSYSA AKT1_HUMAN 73 
Ser-03 PHTSGMNR FOXO1_HUMAN 30 
Ser-04 KQVSQAQT TAF4_HUMAN 32 
Ser-05 KIGSLDNI TAU_HUMAN 47 
Thr-01 TKITGGSS EMSY_HUMAN 37 
Thr-02 PKGTEITI MLL5_HUMAN 23 
Thr-03 LLPTPPLS MYC_HUMAN 21 
Thr-04 PTGTQATY EMSY_HUMAN 23 
 
Both HPLC and MALDI-TOF analysis illustrated that the remodeled products bear 
natural, full-size eukaryotic N-glycans (Figure 2.2).  
 
Figure 2. 2 HPLC chromatograph and ESI-MS spectra of glycan-O-Ser-01. 
These results indicated that the EndoM N175Q mutant can fully tolerate GlcNAc-O-
peptide although its natural substrate is GlcNAc-Asn, which will help to expand its applications 
for either natural or unnatural glycosylation of peptide/proteins to increase their stability and 
half-life. The percentage yields of the glycan-O-peptide varied from 21% to 73% for different 
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peptide substrates (Table 2.1), implying that the sequence of the substrate peptide has marked 
influence on EndoM N175Q catalyzed transglycosylation. 
To investigate whether the O-linked N-glycan would influence the structural stability of 
peptides, we chose glucagon-like peptide-1 (GLP-1) as a candidate. GLP-1 is a well-known 
peptide drug for Type 2 diabetes and has an α-helix secondary structure [24]. Liraglutide, a GLP-
1 analogue modified with fatty acid at Lys26, is a long-acting GLP-1 agonist binding to receptors 
the same as the endogenous metabolic hormone GLP-1 [25, 26]. Based on the structure of 
Liraglutide, we synthesized a GlcNAc-O-GLP-1 analogue with a GlcNAc attached to Ser26 to 
substitute the original Lys26 in natural GLP-1, and then applied EndoM N175Q to transfer a 
complex-type N-glycan onto it (Figure 2.3a). As expected, EndoM N175Q efficiently catalyzed 
the transglycosylation to form glycan-O-GLP-1 (calculated: 5517.3776, found: [M+4H]4+ = 
1380.3643, [M+5H]5+ = 1104.4921). The secondary structure of GlcNAc-O-GLP-1 and glycan-
O-GLP-1 were further examined by circular dichroism (CD) spectra in the far-UV (190–260 nm) 
range. The negligible difference of the CD spectra between GlcNAc-O-GLP-1 and glycan-O-
GLP-1 demonstrates that the N-glycan modification has no effect on the α-helix secondary 
structure of GLP-1 (Figure 2.3b). Hence, by introducing a eukaryotic N-glycan into an O-
GlcNAc site, the newly developed method, can be potentially used to make glycosylated 




Figure 2. 3 Glycosylation of GLP-1 and circular dichroism study. 
a. The scheme of glycosylation of GLP-1. b. Far-UV CD spectra of GlcNAc-O-GLP-1 and 
glycan-O-GLP-1. 
With the site-directed glycopeptides in hand, we further explored their resistance to 
GlcNAc hydrolase (OGA), the hydrolase widely distributed in mammalian cells and highly 
efficient in removing the O-GlcNAc from diverse proteins [27, 28]. OGA was recently found to 
be very sensitive to a substitution of the N-acyl group of O-GlcNAc. The extension of this group 
in a substrate can markedly decrease the hydrolyzing efficiency of OGA [29]. Several OGA 
inhibitors have been designed as GlcNAc analogues with an extended N-acyl group, such as 
PUGNAC or Thiamet-G [30]. In light of this, N-glycan could be regarded as a GlcNAc with an 
extended N-acyl group. We thus assume that the glycopeptides we produced with O-linked N-
glycans would be inert to OGA. To this end, we monitored the glycan loss on selected GlcNAc-




Figure 2. 4 HPLC and MALDI-TOF MS profiles of Ser-02-OGA. 
As expected, OGA efficiently removed GlcNAc moiety from the GlcNAc-O-peptides 
(Figure 2.4 and Table 2.2), but cannot cleave glycan from N-glycan-O-peptides. This 
demonstrates that the O-linked N-glycan modification is capable of preventing the glycan-O-
peptide or glycan-O-protein from OGA digestion in mammalian cell, which will benefit the 














Table 2. 2 OGA activity for GlcNAc-O-peptides. 






Ser-01-OGA 859.447  882.396 Yes 
Ser-02-OGA 798.354  821.314 Yes 
Ser-03-OGA 898.407 899.384  Yes 
Ser-04-OGA 888.466  911.446 Yes 
Ser-05-OGA 858.481 859.491  Yes 
Thr-01-OGA 749.391  772.389 Yes 
Thr-02-OGA 857.485  880.479 Yes 
Thr-03-OGA 836.500  859.520 Yes 
Thr-04-OGA 837.386  860.424 Yes 
GlcNAc-O-GLP-1 3312.605 3313.782  Yes 
 
In addition, N-glycan tagged at O-GlcNAc site can also resist the hydrolysis of peptide-
N-glycosidase F (PNGase F), which can exclusively remove all asparagine-linked complex, 
hybrid, or high mannose oligosaccharides. Therefore, our synthesized chimeric glycan-O-
peptides may have improved stability and increased half-life. Next, we applied the glycosylation 
strategy on a model protein, a bovine α-crystallin mutant (Crys-A) with a single O-GlcNAc 
modification site at Ser116. We have previously shown that Crys-A is prone to be modified by 
O-GlcNAc via its co-expression with OGT in E.coli BL21 (DE3) cells [17], which is a 
convenient and effective approach to produce O-GlcNAcylated proteins. In this study, milligram 
scale of GlcNAc-O-Crys-A was produced in E. coli BL21 (DE3) and purified via Ni-NTA 
affinity chromatography, and then served as a substrate for EndoM N175Q catalyzed 
transglycosylation in the presence of SCT-oxa. Both substrate GlcNAc-O-Crys-A and product 
glycan-O-Crys-A were observed and identified by immunoblot and mass spectrometry (Figure 
2.5 and 2.6). A total conversion yield of ~30% was observed as calculated by gray value 
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analysis. These findings proved that glycan-Crys-A can be successfully produced by the 
combined approach involving O-GlcNAc modification and in vitro enzymatic glycan 
remodeling. By the combined strategy, in the future much more unstable protein can be 
glycosylated for increasing the stability. 
 
Figure 2. 5 Glycosylation of bovine α-crystallin-A (Crys-A) and identification by immunoblot 
and in-gel digestion plus mass spectrometry. 
a. Immunoblot analysis of GlcNAc-O-Crys-A and and glycan-O-Crys-A. i) Anti-O-GlcNAc 
antibody is a primary antibody to detect GlcNAc. ii). Anti-His antibody is a primary antibody to 
detect His-tag in Crys-A.  b. In-gel digestion by trypsin for mass spectrometric characterization 





Figure 2. 6 ESI-MS/MS characterization of glycosylated Crys-A. 
In summary, the approach provides a general platform for producing homogenous 
peptides/glycoproteins with O-linked eukaryotic N-glycans in a site-directed manner, which may 
contribute to the enhancement of therapeutic efficiency of modified peptides/proteins. The proof-











HPLC chromatograph and MALDI-TOF spectra of GlcNAc-O-peptides. 
Ser-01       
HPLC-C18-UV: The column (4.6 mm × 250 mm) was eluted with a linear gradient of 3-30% 




MALDI-TOF MS, calculated 1062.526; found [M+Na]+ =1085.041. 
 
 


























HPLC-C18-UV: The column (4.6 mm × 250 mm) was eluted with a linear gradient of 3-30% 
ACN containing 0.1% TFA within 30 min at a flow rate of 1 mL/min. TR = 19.000 min. 
 
 
MALDI-TOF MS, calculated 1001.434; found [M+Na]+ =1024.004.  
 
 

























HPLC-C18-UV: The column (4.6 mm × 250 mm) was eluted with a linear gradient of 3-30% 
ACN containing 0.1% TFA within 30 min at a flow rate of 1 mL/min. TR = 9.349 min. 
 
 



























HPLC-C18-UV: The column (4.6 mm × 250 mm) was eluted with a linear gradient of 3-20% 




MALDI-TOF MS, calculated 1091.545; found [M+Na]+ =1113.982.  
 

























HPLC-C18-UV: The column was (4.6 mm × 250 mm) eluted with a linear gradient of 3-40% 
ACN containing 0.1% TFA within 30 min at a flow rate of 1 mL/min. TR = 17.827 min. 
 
 
MALDI-TOF MS, calculated 1061.560; found [M+Na]+ =1084.055. 
 
 




























HPLC-C18-UV: The column (4.6 mm × 250 mm) was eluted with a linear gradient of 3-20% 
ACN containing 0.1% TFA within 30 min at a flow rate of 1 mL/min. TR = 12.185 min. 
 
 
MALDI-TOF MS, calculated 952.471; found [M+Na]+ =975.085. 
 
 

























HPLC-C18-UV: The column (4.6 mm × 250 mm) was eluted with a linear gradient of 3-30% 
ACN containing 0.1% TFA within 30 min at a flow rate of 1 mL/min. TR = 21.294 min. 
 
 
MALDI-TOF MS, calculated 1060.565; found [M+Na]+ =1083.147. 
 
 
























HPLC-C18-UV: The column (4.6 mm × 250 mm) was eluted with a linear gradient of 3-40% 
ACN containing 0.1% TFA within 30 min at a flow rate of 1 mL/min. TR = 20.182 min. 
 
 
MALDI-TOF MS, calculated 1039.580; found [M+Na]+ =1063.083. 
 
 
























HPLC-C18-UV: The column (4.6 mm × 250 mm) was eluted with a linear gradient of 3-30% 
ACN containing 0.1% TFA within 30 min at a flow rate of 1 mL/min. TR = 12.320 min. 
 
 



























HPLC-C18-UV: The column (4.6 mm × 250 mm) was eluted with a linear gradient of 25-50% 
ACN containing 0.1% TFA within 40 min at a flow rate of 1 mL/min. TR = 23.115 min. 
 
 
MALDI-TOF MS, calculated 3515.684; found [M+H]+ =3516.385. 
 





























HPLC chromatograph and MALDI-TOF spectra of glycan-O-peptides 
Glycan-Ser-01 
HPLC-C18-UV: The column (4.6 mm × 250 mm) was eluted with a linear gradient of 3-30% 
ACN containing 0.1% TFA within 30 min at a flow rate of 1 mL/min. Glycan-Ser-01-TR= 
15.005 min, Ser-01-TR=17.298 min. 
 
 










S1P1 #4624-4782 RT: 19.75-20.19 AV: 19 NL: 2.66E8
T: FTMS + p NSI Full ms [400.00-1600.00]




















HPLC-C18-UV: The column (4.6 mm × 250 mm) was eluted with a linear gradient of 3-30% 
ACN containing 0.1% TFA within 30 min at a flow rate of 1 mL/min. Glycan-Ser-02-TR= 


















S2P1 #7567-7691 RT: 25.29-25.63 AV: 14 NL: 9.07E7
T: FTMS + p NSI Full ms [400.00-1600.00]




















HPLC-C18-UV: The column (4.6 mm × 250 mm) was eluted with a linear gradient of 3-30% 
ACN containing 0.1% TFA within 30 min at a flow rate of 1 mL/min. Glycan-Ser-03-TR= 8.049 
min, Ser-03-TR=9.352 min. 
 
 













S3P1 #2848-2892 RT: 9.07-9.17 AV: 4 NL: 7.44E6
T: FTMS + p NSI Full ms [400.00-1600.00]




















HPLC-C18-UV: The column (4.6 mm × 250 mm) was eluted with a linear gradient of 3-20% 
ACN containing 0.1% TFA within 30 min at a flow rate of 1 mL/min. Glycan-Ser-04-TR= 7.870 
min, Ser-04-TR=8.772 min. 
 
 













S4P1 #2802-2877 RT: 11.15-11.35 AV: 7 NL: 3.92E6
T: FTMS + p NSI Full ms [400.00-1600.00]




















HPLC-C18-UV: The column (4.6 mm × 250 mm) was eluted with a linear gradient of 3-40% 
ACN containing 0.1% TFA within 30 min at a flow rate of 1 mL/min. Glycan-Ser-05-TR= 
15.459 min, Ser-05-TR=17.777 min. 
 
 










S5P1 #6534-6593 RT: 24.07-24.21 AV: 6 NL: 1.79E8
T: FTMS + p NSI Full ms [400.00-1600.00]




















HPLC-C18-UV: The column (4.6 mm × 250 mm) was eluted with a linear gradient of 3-20% 
ACN containing 0.1% TFA within 30 min at a flow rate of 1 mL/min. Glycan-Thr-01-TR= 
10.425 min, Thr-01-TR=12.050 min. 
 
 












T1P2 #3951-4026 RT: 13.16-13.32 AV: 6 NL: 4.00E6
T: FTMS + p NSI Full ms [400.00-1600.00]




















HPLC-C18-UV: The column (4.6 mm × 250 mm) was eluted with a linear gradient of 3-20% 
ACN containing 0.1% TFA within 30 min at a flow rate of 1 mL/min. Glycan-Thr-02-TR= 
24.512 min, Thr-02-TR=29.708 min. 
 
 















T2P1 #6781-6873 RT: 22.97-23.19 AV: 8 NL: 1.99E7
T: FTMS + p NSI Full ms [400.00-1600.00]




















HPLC-C18-UV: The column (4.6 mm × 250 mm) eluted with a linear gradient of 3-40% ACN 

















T3P1 #9921-10062 RT: 31.65-32.03 AV: 15 NL: 1.04E8
T: FTMS + p NSI Full ms [400.00-1600.00]




















HPLC-C18-UV: The column (4.6 mm × 250 mm) was eluted with a linear gradient of 3-30% 
ACN containing 0.1% TFA within 30 min at a flow rate of 1 mL/min. Glycan-Thr-04-TR= 
10.298 min, Thr-04-TR=12.293 min. 
 
 










T4P1 #6065-6201 RT: 19.10-19.47 AV: 13 NL: 5.80E7
T: FTMS + p NSI Full ms [400.00-1600.00]




















HPLC-C18-UV: The column (10 mm × 250 mm)  was eluted with a linear gradient of 25-50% 
ACN containing 0.1% TFA within 35 min at a flow rate of 4 mL/min. Glycan-O-GLP-1-TR= 
21.451 min, GlcNAc-O-GLP-1-TR=23.132 min. 
 
 












G04-SCT #8982-9096 RT: 34.62-34.90 AV: 10 NL: 7.65E6
T: FTMS + p NSI Full ms [400.00-1600.00]
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1380.3643
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2.2 A novel enzymatic method for synthesis of glycopeptides carrying natural eukaryotic 
N-glycans 
2.2.1 Introduction 
N-glycosylation is one of the most prominent post-translational protein modifications and 
plays a role in various cellular functions including protein folding, sorting and stability, and cell-
cell interactions [31-33]. The majority of human proteins are glycosylated by the competitive 
actions of approximately 200 genome encoded glycosyltransferases and exhibit multiple 
glycoforms [34], which poses an enormous challenge for isolation and structure-function studies 
of single glycoform.  
In recent years, great efforts have been made to establish in vivo and in vitro glyco-
engineering technologies for preparation of well-defined glycopeptides/glycoproteins [18, 35, 
36]. Though it is still for from mature, glycosylation remodelling involving an endo-glycosidase 
(ENGase)-catalyzed transglycosylation, which transfers of a preassembled intact N-glycan en 
bloc to the GlcNAc-tagged peptide/protein, is emerging as a very promising method toward 
homogeneous glycopeptide/glycoprotein glycoforms. Besides remodelling heterogeneous 
glycoproteins, either from natural or from recombinant source [37, 38], ENGase-catalyzed 
transglycosylation was also combined with native chemical ligation (NCL) for synthesizing full 
size glycosylated proteins [39]. However, so far it is still challenging for adding first N-
acetylglucosamine (GlcNAc) onto peptides/proteins. 
In the present work, we alternatively proposed a facile approach for transferring the first 
GlcNAc onto peptide by enzymatic method and finally producing glycopeptides with natural 
eukaryotic N-glycans by three steps of enzymatic catalysis. Briefly, glucosamine (GlcN) was 
firstly installed on peptides by an engineered N-glucosyltransferase (ApNGT Q469A) derived 
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from Actinobacillus pleuropneumoniae [40], and then was acetylated by using a glucosamine N-
acetyltransferase from Clostridium acetobutylicum (GlmA) [41] to produce GlcNAc-peptides. 
The resulting GlcNAc-peptides can then be converted into glycopeptides with natural eukaryotic 
N-glycans in an ENGase-catalyzed transglycosylation reaction (Figure 2.7). 
 
Figure 2. 7 Enzymatic synthesis of glycopeptides carrying natural eukaryotic N-glycans. 
 
2.2.2 Experimental Methods 
Synthesis of UDP-GlcN, UDP-GlcN3 and UDP-GalN 
The method for synthesis of UDP-GlcN, UDP-GlcN3 and UDP-GalN were described 
previously [13, 42]. For UDP-GlcN, reaction was monitored by Thin Layer Chromatography 
(TLC) on silica gel F254 (Merck), developed by isopropanol/NH4OH=3:2(V/V), then stained 
with p-anisaldehyde solution (ethanol/sulfuric acid/p-anisaldehyde/aceticacid = 500:27:16:5.5, 
V/V/V/V). The crude products were purified by silica gel chromatography (isopropanol/ 
NH4OH=3:1) and Bio-Gel P2 size exclusion chromatography to obtain pure UDP-GlcN (500 mg, 
53%). 1H NMR (400 MHz, D2O) δ 7.88 (d, J = 8.1 Hz, 1H), 5.94–5.85 (m, 2H), 5.79 (dd, J = 
6.9, 3.4 Hz, 1H), 4.32–4.27 (m, 2H), 4.24–4.10 (m, 3H), 3.93–3.82 (m, 2H), 3.82–3.71 (m, 2H), 
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3.50 (t, J = 9.6 Hz, 1H), 3.34 (dt, J = 10.8, 3.1 Hz, 1H). HRMS (ESI): calculated for 
C15H26N3O16P2: 566.0788, found (m/z): [M+H]+ = 566.0777. 
Protein expression and purification 
The N-Glycosyltransferase ApNGT Q469A and the glucosamine/glucosaminide N-
acetyltransferase GlmA were cloned into pET22b and pET15b, respectively. The E. coli BL21 
(DE3) strains harboring the corresponding expression plasmids, were cultured in LB medium 
supplemented with ampicillin (100 μg /mL) under energetic sharking. When the optical density 
at 600 nm (OD600) reached 0.6–0.8, 0.1 mM of isopropyl-1-thio-β-D-galactopyranoside (IPTG) 
was supplied and followed by incubating at 16°C for 18 h. The cells were harvested by 
centrifugation (6,000 × g, 4°C, 20 min), and resuspended in lysis buffer (100 mM Tris-HCl, 5 
mM CaCl2, pH 8.0), and broken by ultrasonication. After centrifugation (14,000×g, 20 min) of 
the cell lysate, the supernatant was loaded onto a Ni2+-NTA affinity column (Qiagen). The 
column was pre-equilibrated with 10 column volumes of binding buffer (10 mM imidazole, 0.5 
M NaCl, 20 mM Tris-HCl, pH 8.0) before the lysate was loaded. After washing with 10 column 
volumes of binding buffer and washing buffer (30 mM imidazole, 0.5 M NaCl, 5 mM CaCl2, 20 
mM Tris-HCl, pH 8.0), the target protein was eluted with elution buffer (250 mM imidazole, 0.5 
M NaCl, 5 mM CaCl2, 20 mM Tris-HCl, pH 8.0). Elution fractions were analyzed by 12% SDS-
PAGE with Coomassie blue staining. The concentration of purified enzyme was quantified by 
the BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL) with bovine serum albumin as 
a protein standard. 
Enzymatic reactions 
(1) Synthesis of GlcN-peptides 
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Production of GlcN-peptides were carried out in the volume of 20 mL contains 20 μM 
ApNGT,10 mM UDP-GlcN (20 mM UDP-GlcN for peptide P15), 1 mM various peptides and 
with 100 mM Tris-HCl (pH 8.0) at 30°C for overnight with a slight shaker. Reactions were 
stopped by boiling 5 min and then analyzed by Shim-pack VP-ODS C18 column (5 µm, 4.6 mm 
× 250 mm) and purified through HYPERSIL GOLD C18 column (10 µm, 10 mm × 250 mm). 
The purified GlcN-peptides were further identified by HPLC and MALDI-TOF MS. 
(2) Synthesis of GlcNAc-peptides 
For synthesis of GlcNAc-peptides, 10 µM GlmA, 2 mM Ac-CoA (4 mM Ac-CoA for 
peptide P16),1 mM various GlcN-peptides with 100 mM Tris-HCl (pH7.5) were mixed at 37°C 
for 2 h. Reactions were stopped by boiling 5 min and then analyzed and purified by HPLC. The 
purified GlcNAc-peptides were further identified by MALDI-TOF MS and ESI-MS-MS 
analysis. MALDI-TOF: calculated M=1239.598; found (m/z): [M+Na]+=1262.028. The purified 
GGAN(GlcNAc)LTYTIE was identified by 1H-NMR. 1H-NMR (400 MHz, D2O, selected 
signals): δ 6.99 (d, J = 8.52 Hz, 2H, 2×Tyr Aromatic), 6.69 (d, J = 8.52 Hz, 2H, 2×Tyr 
Aromatic), 4.93 (d, J = 9.80 Hz, 1H, H-1 β-GlcNAc), 4.56 (q, J =7.55 Hz, 2H), 4.27-4.19 (m, 
4H), 4.16 (d, J = 4.96 Hz, 1H), 4.05-3.95 (m, 3H), 3.90 (d, J = 2.56 Hz, 2H), 3.7744 (s, 2H), 
3.75-3.74 (m, 2H), 3.64-3.60 (m, 1H), 3.50-3.46 (m, 1H), 3.36 (d, J = 5.64 Hz, 2H), 2.94 (dd, J = 
6.36 Hz, J = 12.24 Hz, 1H), 2.86-2.74 (m, 2H), 2.62 (dd, J = 7.56 Hz, J = 15.9 Hz, 1H), 2.36-
2.32 (m, 2H), 2.04-1.96 (m, 1H), 1.89 (s, 3H, 3×Ac GlcNAc), 1.86-1.81 (m, 1H), 1.79-1.72 (m, 
1H), 1.54-1.34 (m, 4H), 1.26 (d, J = 7.0 Hz, 3H), 1.12-1.06 (m, 1H), 1.02 (d, J = 6.32 Hz, 6H), 
0.81-0.73 (m, 12H). 
(3) Synthesis of N-Glycan-peptides 
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The reaction mixtures contained 50 mM PBS (pH 6.5), 5 nM GlcNAc-peptide as 
acceptor, 20 nM sialylated complex-type glycans oxazoline (SCT-oxa) as donor, and 20 µg 
EndoM N175Q, and was incubated at 30°C for 15 min. After optimization of reaction condition 
for EndoM N175Q, we chose to carry out 15 min incubation for peptide transglycosylation. The 
reaction was terminated by boiling 5 min and then analyzed by HPLC-C18 and ESI-MS. 
 
sMethod of Electrospray ionization tandem mass spectrometry 
GlcNAc-peptides were analyzed using Nano RP-HPLC-MS system as described 
before[43]. Briefly, samples were separated on EASY-Spray PepMap C18 Column (75 μm id × 
15 cm, 3 μm) with an LTQ-Orbitrap Elite mass spectrometer using a linear gradient from 3% to 
40% buffer B for 40 min at a flow rate of 300 nL/min (mobile phase A: 1.95% ACN, 97.95% 
H2O, 0.1% FA; mobile phase B: 79.95% ACN, 19.95% H2O, 0.1% FA). Data-dependent mode 
was applied during the acquisition. A full-scan survey MS (m/z range from 400 to 2000; 
automatic gain control target, 1,000,000 ions; resolution at 200 m/z, 60,000; maximum ion 
accumulation time, 50 ms) was acquired by the spectrometer, and ten most intense ions were 
selected for HCD fragmentation with a collision energy of 27 ev.  
Circular dichroism (CD) spectroscopy 
Far-UV (190–260 nm) CD spectra was recorded on a J-810 spectropolarimeter (Jasco) at 
ambient temperature (25°C) using a 0.1-cm-pathlength quartz cuvette. The measurements of 50 
μM mGLP-1 and GlcNAc-mGLP-1 were carried out in 10 mM PBS Buffer (pH 6.5). All spectra 
presented were averaged for 3 scans. 
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2.2.3 Results and Discussion 
ApNGT belongs to a family of cytoplasmic N-glucosyltransferases which demonstrates 
the capability of modifying polypeptides featuring sequences (Asn-Xaa-Ser/Thr, where Xaa ≠ 
Pro) of eukaryotic N-glycoproteins using nucleotide activated hexoses. Besides glucose, ApNGT 
also recognizes galactose and xylose, while the substituted glucose derivatives including 
GlcNAc, GlcN, and GlcN3 are not tolerated (Figure 2.8a). However, an engineered mutant of 
NGT (ApNGT Q469A) was recently found by our group to have more flexible acceptor and 
donor (Figure 2.8a) specificity and herein was demonstrated to be able to transfer GlcN from its 
nucleotide donor UDP-GlcN to the Asn residue of Asn-Xaa-Ser/Thr sequon (Figure 2.8b). UDP-
GlcN can be easily prepared in a one-pot two-enzyme system containing a N-acetylhexosamine 
1-kinase (Nank) from Bifidobacterium infantis and a UDP-sugar pyrophosphorylase (BLUSP) 
from Bifidobacterium longum in the presence of adenosine 5’-triphosphate (ATP) and uridine 5'-
triphosphate (UTP) [42]. Next, a bacterial glucosamine N-acetyltransferase (GlmA) was 
employed to acetylate the GlcN moiety and made GlcNAc-tagged peptide (Figure 2.8c).  
 
Figure 2. 8 Enzymatic production of GlcNAc-linked peptide. 
(a) UDP-GlcN is specifically recognized by ApNGTQ469A and (b) transferred to a given 
peptide with N-glycosylation site. (c) The resulting product was then acetylated by GlmA and (d) 
identified by MS-MS spectrum.  
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GlmA has been demonstrated to specifically catalyze the transfer of an acetyl group from acetyl 
coenzyme A to either free GlcN or GlcN residues at the non-reducing end of glycosides [41]. In 
present study, the enzyme was found to be capable of acetylating GlcN attached to natural N-
glycosylation site of peptides (Asn-Xaa-Ser/Thr) as well regardless of the amino acid sequence 
around the occupied Asn (Table 2.3).  
 
Table 2. 3 Specificity of GlmA toward glycosylated peptides. 
Entry Peptides 
Yield (%)of GlmA 
catalyzed 
acetylation 
P1 GGAN(GlcN)LTYTIER 96.6±1.7 
P2 GGSN(GlcN)LTYTIER 98.0±1.1 
P3 GGGN(GlcN)LTYTIER 97.3±2.1 
P4 GGLN(GlcN)LTYTIER 95.7±5.3 
P5 GGSN(GlcN)ITYTIER 97.0±3.3 
P6 GGSN(GlcN)VTYTIER 99.2±0.8 
P7 GGSN(GlcN)LTRTIER 88.2±2.7 
P8 GGSN(GlcN)LTATIER 94.9±3.7 
P9 GGSN(GlcN)LTSTIER 83.6±2.8 
P10 GGSN(GlcN)LTKTIER 94.8±0.2 
 
GlcNAc decorated peptides can be easily separated from GlcN-linked peptides by 
reversed-phase high-performance liquid chromatography (RP-HPLC) and were further identified 
by MALDI-TOF mass spectrometry and 1H NMR. In addition, the HCD spectrums also 
confirmed that GlcNAc-peptides were synthesized and had a series of diagnosis fragmentation 
ions for GlcNAc including 126.05, 138.05, 144.06, 168.06, 186.07 and 204.08 (Figure 2.8d), 
which has been reported in the previous study [43]. Therefore, combination of the N-
glycosylation and the acetylation reactions that are catalyzed by an evolved ApNGT Q469A and 
a bacterial N-acetyltransferase GlmA, respectively, can conveniently and efficiently prepare 
GlcNAc-N-peptides. Although GlcNAc-linked peptides can also be synthesized by solid-phase 
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peptide synthesis using GlcNAc-Asn as a building block [44] or by “Tag-and-Modify” approach 
[45] to artificially install GlcNAc onto a cysteine residue, the alternative approach that we 
developed herein can facilely add a GlcNAc moiety to a given peptide by two-step enzymatic 
reactions. 
The resulting GlcNAc-peptides are ready to be used for further glycosylation by the 
N175Q mutant of an endo-β-N-acetylglucosaminidase M (EndoM N175Q) and using the 
sialylated complex-type glycan oxazoline as a donor substrate. EndoM has a broad acceptor 
substrate specificity. Besides peptides decorated by N-linked Glc/GlcNAc [46] or O-linked 
GlcNAc [47] that were previously demonstrated to be the acceptors of EndoM, N-linked GlcN 
was also found herein to be tolerated by the catalyst. As shown in Figure 2.9, the 
transglycosylation reaction using GGAN(GlcN)LTYTIE as an acceptor gave similar yield in 
comparison with that in presence of GGAN(GlcNAc)LTYTIE, further expanding our knowledge 






Figure 2. 9 Transglycosylation of GlcN-peptide. 
a) Scheme of transglycosylation of GlcN-peptide; b) Analytical HPLC monitoring of EndoM 
N175Q catalyzed transglycosylation using the GlcN-peptide as the acceptor substrate; c) ESI-MS 
profile of desired glycan-peptide. 
Table 2. 4 Modification of N-glycoprotein derived peptides and mGLP-1. 






P11 Virus envelope glycoprotein TNITMSA 92.1 95.6 
P12 Ribosome inactivating protein RVQITNVTSKV 67.4 91.3 
P13 Hemagglutinin KYPALNVTMPN 97.2 94.3 
P14 Hydrolase inhibitor SLSYLNVTRKA 96.9 84.5 
P15 Thioester-containing protein LSVLNVTKMV 97.2 72.5 
P16 Virus neuraminidase RTFLNLTKPL 98.7 93.2 
P17 Interleukin-34 isoform X1 VLRVANITRLQ 94.3 94.4 









Finally, the approach was applied to glycosylate nine peptides. Eight of them (P11-18) 
are derived from natural N-glycoproteins (Table 2.4).  
GlcNAc-peptides from P11-P17 were prepared in high yields by our methods. For an 
adhesion-derived peptide P18 that bears two closely located N-glycosylation sites, the 
glycosylation and acetylation were also achieved in moderate yields (53.8% and 58.9%, 
respectively) (Table 2.4). All of GlcNAc-peptides were identified by MS-MS spectrum analysis, 
which demonstrated that GlcNAc-peptides were successfully synthesized by our current 
approach. Glucagon-like peptide-1 (GLP-1) is a well-known peptide candidate drug for Type 2 
diabetes. Previous research indicated that the addition of sialyl-LacNAc at Asn26/34/37 of GLP-
1 can improve its proteolytic resistance and in vivo activity [48]. Herein, a preferred N-
glycosylation sequon of ApNGT Q469A was artificially introduced at position 17 of GLP-1 
(Table 2.4).  
 
Figure 2. 10 Far-UV CD spectra of mGLP-1 and GlcNAc-mGLP-1. 
The circular dichroism (CD) analysis in the far-UV (190−260 nm) range indicated that 
the secondary structures of the modified GLP-1 (mGLP-1) mainly are α-helix. Via two-step 
reactions catalyzed by ApNGT Q469A and GlmA, GlcNAc-mGLP-1 was successfully produced 
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and maintained similar secondary structure of mGLP-1 (Figure 2.10). Afterwards, all GlcNAc-
peptides were used as the starting materials in transglycosylation reactions catalyzed by 
EndoMN175Q and made their corresponding uniform glycopeptides with complex-type N-
glycan (Table 2). Both HPLC and MS analysis illustrated that all glycopeptides bearing natural, 
full-size eukaryotic N-glycans were successfully synthesized. 
In conclusion, we developed a facile enzymatic approach for synthesis of glycopeptides 
carrying the natural eukaryotic N-glycan. Initially, the GlcN was transferred to a given peptide 
with natural N-glycosylation site, Asn-Xaa-Ser/Thr (where Xaa ≠ Pro) by an engineered N-
glycosyltransferase ApNGT Q469A to form GlcN-peptide. GlcNAc-tagged peptide was then 
produced in the reaction catalyzed by a glucosamine N-acetyltransferase GlmA and was further 
modified by EndoM N175Q to generate glycopeptides with complex-type N-glycan. Finally, the 
method was successfully applied to modify eight peptides derived from natural N-glycoproteins 
on one or two glycosylation sites and produced their corresponding glycopeptides carrying 




HPLC chromatograph and MS spectrum. 
 
MALDI-TOF MS profile of GGAN(GlcNAc)LTYTIE, calculated M=1239.598; found(m/z): 
[M+Na]+ = 1262.028. 
HCD-MS2 spectra of glycopeptides GlcNAc-P11~GlcNAc-P19 
GlcNAc-peptides were confirmed by the HCD spectrums with a series of diagnosis 













































ESI-MS spectra of glycopeptides Glycan-P11~Glycan-P19 
















Glycan-P13: Calculated M = 3452.4138; found (m/z): [M+3H]3+ = 1151.4854. 
 











Glycan-P16: Calculated M = 3406.4907; found (m/z): [M+4H]4+ = 852.6319, [M+3H]3+ = 
1136.5124, [M+2H]2+ = 1704.2498. 
 
Glycan-P17: Calculated M = 3486.5605; found (m/z): [M+4H]4+ =872.6508, [M+3H]3+ 




diGlycan-P18: Calculated M = 5616.1815; found(m/z): [M+4H]4+ = 1405.3071. 
 
 




























































































































3 GLYCAN SYNTHESIS AND DECODE BIOLOGICAL FUNCTION OF GLYCANS 
3.1 Identification of the binding roles of terminal and internal glycan epitopes using 
enzymatically synthesized N-glycans containing tandem epitopes.  
3.1.1 Introduction 
In nature, glycans are displayed universally at the surface of living cells [1] and are the 
mediators of numerous biological events, including, but not limited to protein folding and 
trafficking, cell signaling and intercellular interactions, and cell-pathogen interactions [2-4]. 
Aberrant processing of glycans may lead to malfunctions, such as the development of 
neurological diseases and cancer [5-7]. Thus, interpretation of the structures and functions of 
glycans will be crucial to better understand carbohydrate-associated biological and pathological 
processes, and to develop diagnostics and therapeutics. The diverse functions of glycans are 
directly related to their structures. Most studies, including glycan microarray studies, however, 
have been focused on the terminal glycan epitopes whose important functions are now well 
appreciated[8]. For example, the outermost sialyl-Lewis x (sLeX) sequences [Neu5Acα2–
3Galα1–4(Fucα1–3)GlcNAc-R] on human zona pellucida have been found to mediate human 
sperm-egg binding and form a zygote[9, 10]. The α-Gal (Galα1–3Galα1–4GlcNAc-R) epitope on 
the cells of non-primate mammals including pigs binds to anti-Gal antibodies naturally existed in 
humans, posing barriers of pig-human xenotransplantation [11, 12]. The presence of α-Gal as a 
terminal epitope on N-glycan of glycoprotein pharmaceuticals produced in Chinese hamster 
ovary (CHO) cells has also been shown to induce anaphylaxis reactions [13]. In N-glycans 
isolated from membrane glycoproteins of miniature pig kidneys, Galα1–3Gal and Fucα1–
3GlcNAc have been found to be presented in the same LacNAc core, generating Galα1–3-LeX 
[Galα1–3Galα1–4(Fucα1–3)GlcNAc-R] epitope [14]. In many cases, nature presents glycans 
91 
 
containing tandem epitopes as exemplified by poly-N-acetyllactosamine [poly-LacNAc, (–
3Galβ1–4GlcNAcβ1–)n] structures in glycoproteins and glycolipids in mammals [15-19] as well 
as capsular polysaccharides and lipopolysaccharides in bacteria [20-22]. Poly-LacNAc, 
composing of LacNAc repeats, exhibits critical roles in cell adhesion, immune response, and 
carcinomatosis through binding with galectins [23]. Poly-LacNAc can also be modified by α2–3-
sialylation at the terminal galactose (Gal) residue or α2–6-sialylation at the terminal and internal 
Gal residue in LacNAc repeats [24-26]. It can also be fucosylated to generate polymeric Lewis x 
(poly-LeX) structures [17, 27]. Studies on the recognition between sialylated poly-LacNAc and 
glycan-binding proteins (GBPs) indicate that, the degree of polymerization (DP) of poly-LacNAc 
with only terminal sialylation modification affects the recognition of glycans by influenza A 
virus hemagglutinins [24]. When modified by both terminal sialic acid and internal sialic acids 
(could be viewed as tandem sialylated LacNAc), more divergent binding profiles to different 
GBPs were reported [25]. Another example is polysialic acid (polySia), which is a crucial glycan 
epitope with tandem sugar residues. Its DP ranges from 2 to over 8, and polySia with different 
DPs binds differentially to different GBPs, and mainly plays an irreplaceable role in nervous 
system [28, 29]. In another study, a number of N-glycans with biantennary structure clusters 
tandemly linked together were chemoenzymatically synthesized, and the generated unnatural N-
glycans showed some unexpected strong binding affinity to some lectins, broadening our 
knowledge about the binding profile of lectins [30]. 
Several recent studies have been focusing on preparation of N-glycans with various 
structures. For instance, Boons [31] and our group [32, 33] used chemoenzymatic strategy to 
synthesize asymmetric N-glycans, most of which have only a single glycan epitope in each 
branch. Using bacterial sialyltransferases, Paulson synthesized N-glycans containing poly-
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LacNAc structures with only terminal sialylation [24] or with both terminal and internal 
sialylation [25]. Inspired by the naturally existing tandem glycan epitopes, the unnatural tandem 
N-glycan clusters, and their different binding profiles to GBPs, we describe herein the synthesis 
of a library of biantennary N-glycans with some containing tandem glycan epitopes, including 
those with a terminal sialyl LacNAc, sLeX and Siaα2–8Siaα2–3/6-R and with N-
acetylneuraminic acid (Neu5Ac) or N-glycolylneuraminic acid (Neu5Gc) sialic acid form, 
LacNAc, LeX, α-Gal, and Galα1–3-LeX; as well as those containing α-Gal, LeX, Galα1–3-LeX, 
LacNAc, and sialyl LacNAc, which is linked to an internal sialyl LacNAc or 1–2 repeats of an 
internal LacNAc or LeX as an internal glycan component.  
Since chemical synthesis of target complex glycans from scratch is usually tedious, we 
have developed a Core Synthesis/Enzymatic Extension (CSEE) strategy, in which the relatively 
simple core glycans were chemically synthesized and then the outer parts of glycans were 




Figure 3. 1 Biantennary N-glycans synthesized in this study. 
For some of the core glycans which are readily available from an abundant natural 
source, purification followed by additional processing such as trimming using exoglycosidases or 
acid hydrolysis [35-37] is a good alternative. We name the strategy Core Isolation/Enzymatic 
Extension (CIEE) and use it for the desired biantennary N-glycans. To do this, sialylated 
biantennary N-glycan with the attached asparagine (Asn) was obtained from sialylglycopeptide 
(SGP) [38] by pronase E treatment. Enzymatic desialylation then led to the formation of the core 
glycan which was enzymatically extended with a diverse array of glycosyltransferases to obtain 
the target N-glycans (Figure 3.1). One-pot multienzyme (OPME) [39] synthetic strategies were 
further adopted to make the synthesis more efficient and with lower cost. Each target glycan was 
synthesized in a milligram-scale and was purified to over 98% purity using a hydrophilic 
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interaction liquid chromatography (HILIC) column on a high-performance liquid 
chromatography (HPLC) system monitored by UV absorption. The roles of the internal glycan 
structure in affecting the binding of the glycans to GBPs and viruses were investigated using a 
glycan microarray format. The internal glycan epitopes such as LacNAc, LeX, and sialyl 
LacNAc, as well as sialylation and fucosylation of terminal glycans hindered or enhanced the 
binding of GBPs or viruses to the N-glycans. 
3.1.2 Experimental Methods 
General methods for glycan preparation 
1) Preparation of sialylglycopeptide (SGP) 
SGP was isolated from fresh chicken egg yolk by the method reported [40].  
2) Preparation of the core N-glycan 
The core N-glycan was prepared by sequential digestion of SGP with pronase E and 
sialidase.  
a). Digestion of SGP by pronase E 
SGP (5 mg) in Tris-HCl (50 mM, pH 8.8) was digested by pronase E (5 mg) at 37oC for 2 
days until no residual SGP was detected by HPLC-HILIC-ELSD. The reaction was terminated 
by boiling for 5 min. Semi-praparative Waters XBridge BEH amide column (130 Å, 5 µm, 10 
mm × 250 mm) was applied for purification. A gradient condition is solvent A: ammonium 
formate (100 mM, pH 3.4); solvent B: acetonitrile; flow rate: 4 mL/min; B%: 65–50% within 25 
min. The peak corresponding to BA-01 was pooled and lyophilized twice to remove ammonium 
formate.  BA-01 (3.5 mg) was obtained as a white powder.  
b). Sequential digestion of SGP by pronase E and sialidase 
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SGP (100 mg) in Tris-HCl (50 mM, pH 8.8) was digested by 100 mg pronase E at 37oC 
for 2 days until no SGP could be detected by HPLC-HILIC-ELSD. The pH was adjusted to 8.0 
before sialidase BiNanH2 (5 mg) was added, and reaction was incubated at 37oC overnight. 
Semi-praparative Waters XBridge BEH amide column (130 Å, 5 µm, 10 mm × 250 mm) was 
applied for purification. A gradient condition is solvent A: ammonium formate (100 mM, pH 
3.4); solvent B: acetonitrile; flow rate: 4 mL/min; B%: 65–50% within 25 min. The peak 
corresponding to BA-02 was pooled and lyophilized twice to remove ammonium formate. BA-
02 (54 mg) was obtained as a white powder. 
3) β1–3-GlcNAcylation catalyzed by NmLgtA 
Reaction mixtures contained Tris-HCl (50 mM, pH 8.0), an acceptor glycan (4 mM), 
UDP-GlcNAc (8 mM), MnCl2 (5 mM), and varying amounts of NmLgtA. FastAP (1 U/200 µL) 
was also added to digest the reaction byproduct UDP to drive reaction forward. Reactions were 
incubated at 37oC for 2 days, and were monitored by MALDI-TOF. After all acceptor was 
converted, the reaction was quenched by boiling for 5 min, followed by concentration using a 
vacufuge concentrator. HPLC-A210nm was then used to purify target glycans using a semi-
preparative amide column (130 Å, 5 µm, 10 mm × 250 mm).  
 4) β1–4-Galactosylation catalyzed by NmLgtB 
Reaction mixtures contained Tris-HCl (50 mM, pH 8.0), an acceptor glycan (4 mM), 
UDP-Gal (8 mM), MnCl2 (5 mM), and varying amounts of NmLgtB. FastAP (1 U/200 µL) was 
also added to digest the reaction byproduct UDP to drive reaction forward. Reactions were 
incubated at 37°C overnight, and were monitored by MALDI-TOF. After all acceptor was 
converted, the reaction was quenched by boiling for 5 min, followed by concentration using a 
96 
 
vacufuge concentrator. HPLC-A210nm was then used to purify target glycans using a semi-
preparative amide column (130 Å, 5 µm, 10 mm × 250 mm).  
5) α1–3-Galactosylation catalyzed by Bα1,3GalT 
Reaction mixtures contained Tris-HCl (50 mM pH 8.0), 4 mM acceptor glycans, UDP-
Gal (8 mM), MnCl2 (5 mM), and varying amounts of Bα1,3GalT. FastAP (1 U/200 µL) was also 
added to digest the reaction byproduct UDP to drive reaction forward. Reactions were incubated 
at 37°C overnight, and were monitored by MALDI-TOF. After all acceptor was converted, the 
reaction was quenched by boiling for 5 min, followed by concentration using a vacufuge 
concentrator. HPLC-A210nm was then used to purify target glycans using a semi-preparative 
amide column (130 Å, 5 µm, 10 mm × 250 mm).  
6) α1–3-Fucosylation catalyzed by Hpα1,3FT 
Reaction mixtures contained Tris-HCl (50 mM, pH 8.0), acceptor glycans (4 mM), GDP-
Fuc (8 mM), MnCl2 (5 mM), and varying amounts of Hpα1,3FT. FastAP (1 U/200 µL) was also 
added to digest the reaction byproduct GDP to drive reaction forward. Reactions incubated at 
37°C overnight, and monitored by MALDI-TOF. After all acceptor was converted, the reaction 
was quenched by boiling for 5 min, followed by concentration using a vacufuge concentrator. 
HPLC-A210nm was then used to purify target glycans using a semi-preparative amide column (130 
Å, 5 µm, 10 mm × 250 mm). 
 7) α2–3-Sialylation catalyzed by PmST1 E271F/R313Y 
Reaction mixtures contained Tris-HCl (100 mM, pH 8.0), acceptor glycans (4 mM), CTP 
(8 mM), Neu5Ac/Neu5Gc (8 mM), MgCl2 (5 mM), NmCSS (5 g/mL), and PmST1 
E271F/R313Y (2 µg/mL). Reactions were incubated at 37°C for 45 min and quenched by boiling 
for 5 min, followed by concentration using a vacufuge concentrator. HPLC-A210nm was then 
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used to purify target glycans using a semi-preparative amide column (130 Å, 5 µm, 10 mm × 250 
mm).  
8) α2–6-Sialylation catalyzed by Pd2,6ST 
Reaction mixtures contained Tris-HCl (100 mM, pH 8.0), acceptor glycans (4 mM), CTP 
(8 mM), Neu5Ac/Neu5Gc (8 mM), MgCl2 (5 mM), NmCSS (5 µg/mL), and Pd2,6ST (5 µg/mL). 
Reactions were incubated at 37°C overnight and quenched by boiling for 5 min, followed by 
concentration using a vacufuge concentrator. HPLC-A210nm was then used to purify target 
glycans using a semi-preparative amide column (130 Å, 5 µm, 10 mm × 250 mm).  
9) α2–8-Sialylation catalyzed by CjCstII 
Reaction mixtures contained Tris-HCl (100 mM, pH 8.0), acceptor glycans (4 mM), CTP 
(8 mM), Neu5Ac/Neu5Gc (8 mM), MgCl2 (5 mM), NmCSS (5 µg/mL), and CjCstII (2 µg/mL). 
Reactions were incubated at 37°C for 45 min and quenched by boiling for 5 min, followed by 
concentration using a vacufuge concentrator. HPLC-A210nm was then used to purify target 
glycans using a semi-preparative amide column (130 Å, 5 µm, 10 mm × 250 mm). 
General methods for HPLC-HILIC-UV purification of N-glycans 
1) General methods for HILIC-UV210nm purification of N-glycans 
a) BA-01, BA-02, BA-03, BA-04, BA-05, BA-06, BA-07. 
Column: Waters XBridge BEH amide column, 130 Å, 5 mm, 10 mm × 250 mm 
Solvent A: 100 mM ammonium formate, pH 3.4 






Gradient elution: Time (min) B%  Flow rate (mL/min) 
     0  65  4 
   25  50  4 
   26    0  2 
   27    0  2 
   28  65  4 
   30  65  4 
Monitor: A210nm 
b) BA-08, BA-17, BA-18, BA-24, BA-25, BA-26, BA-27, BA-28, BA-29, BA-30, BA-31, BA-
32, BA-33, BA-34. 
Column: Waters XBridge BEH amide column, 130 Å, 5 mm, 10 mm × 250 mm 
Solvent A: 100 mM ammonium formate, pH 3.4 
Solvent B: Acetonitrile 
Temperature: 40°C 
 
Gradient elution: Time (min) B%  Flow rate (mL/min) 
     0  70  4 
   35  40  4 
   36    0  2 
   37    0  2 
   38  70  4 




c) BA-09, BA-10, BA-11, BA-12, BA-13, BA-14, BA-15, BA-16. 
Column: Waters XBridge BEH amide column, 130 Å, 5 mm, 10 mm × 250 mm 
Solvent A: 100 mM ammonium formate, pH 3.4 
Solvent B: Acetonitrile 
Temperature: 40°C 
Gradient elution: Time (min) B%  Flow rate (mL/min) 
     0  60  4 
   35  45  4 
   36    0  2 
   37    0  2 
   38  60  4 
   45  60  4 
Monitor: A210nm 
d) BA-19, BA-20, BA-21, BA-22, BA-23. 
Column: Waters XBridge BEH amide column, 130 Å, 5 mm, 10 mm × 250 mm 
Solvent A: 100 mM ammonium formate, pH 3.4 









Gradient elution: Time (min) B%  Flow rate (mL/min) 
     0  57  4 
   35  47  4 
   36    0  2 
   37    0  2 
   38  57  4 
   45  57  4 
Monitor: A210nm 
e) BA-35, BA-36. 
Column: Waters XBridge BEH amide column, 130 Å, 5 mm, 10 mm × 250 mm 
Solvent A: 100 mM ammonium formate, pH 3.4 
Solvent B: Acetonitrile 
Temperature: 40°C 
Gradient elution: Time (min) B%  Flow rate (mL/min) 
     0  60  4 
   35  30  4 
   36    0  2 
   37    0  2 
   38  70  4 
   45  70  4 
Monitor: A210nm 
2) General methods for HILIC-ELSD analysis of N-glycans 
Column: Waters XBridge BEH amide column, 130 Å, 5 mm, 4.6 mm × 250 mm 
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Solvent A: 100 mM ammonium formate, pH 3.4 
Solvent B: Acetonitrile 
Temperature: 40°C 
Gradient elution: Time (min) B%  Flow rate (mL/min) 
   0  60  1 
   35  30  1 
   36    0  0.5 
   37    0  0.5 
   38  60  1 
   45  60  1 
Monitor: Evaporative light scattering detector, 60°C (Shimadzu ELSD-LTII) 
General methods for mass spectrometry analysis 
1) ESI-MS analysis of N-glycans 
In this study, HPLC-MS experiments were performed on an LTQ-Orbitrap Elite mass 
spectrometer (Thermo Fisher) equipped with EASY-spray source and nano-LC UltiMate 3000 
high performance liquid chromatography system (Thermo Fisher). Samples were transmitted into 
MS with a silica column. LTQ-Orbitrap Elite mass spectrometer was operated in the data 
dependent mode. A full-scan survey MS experiment (m/z range from 375 to 1600; automatic 
gain control target, 1,000,000 ions; resolution at 400 m/z, 240,000; maximum ion accumulation 
time, 200 ms) was acquired by the Orbitrap mass spectrometer. 
2) Method of MALDI-TOF MS analyses 
MALDI-TOF MS analyses were performed on UltrafleXtreme MALDI TOF/TOF Mass 
Spectrometer (Bruker). Scan range of MS1 was set according to the molecular weight of N-
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glycans, and reflector mode was used for N-glycan analysis. Mass spectra were obtained in both 
positive and negative extraction mode with the following voltage settings: ion source 1 (19.0 
kV), ion source 2 (15.9 kV), and lens (9.3 kV). The reflector voltage was set to 20 kV. The laser 
was pulsed at 7 Hz and the pulsed ion extraction time was set at 400 ns. The laser power was 
kept in the range of 25–40%. 
General methods for glycan microarray assay 
The glycans were printed on N-hydroxysuccinimide (NHS)-derivatized slides, each in 
replicates of 6 in a subarray, and 8 subarrays were printed on each slide. Contact printing was 
performed using 2470 Arrayer (Aushon Biosystems). All glycans were prepared at a 
concentration of 100 mM in phosphate buffer (100 mM sodium phosphate buffer, pH 8.5). The 
slides were fitted with 8-chamber adapter to separate the subarray into individual well for assay. 
Before assay, slides were rehydrated for 5 min in TSMW buffer (20 mM Tris-HCl, 150 mM 
NaCl, 0.2 mM CaCl2, and 0.2 mM MgCl2, 0.05% Tween). And then the analysis was performed 
for plant lectins, antibodies, and viruses as previously described [41]. Eight subarrays were 
assayed with Maackia amurensis lectin I (MAL-I, binds Neu5Acα2–3-Galβ1–4GlcNAc, 10 
mg/mL), Sambucus nigra lectin (SNA, binds Neu5Acα2–6Galβ1–4GlcNAc, 10 mg/mL) [42], 
Erythrina cristagalli lectin (ECL, binds Galβ1–4GlcNAc, 10 mg/mL) [43], B subunit of 
Griffonia simplicifolia lectin I (GSL-I-B4, binds α-Gal, 10 mg/mL) [44], and wheat germ 
agglutinin (WGA, binds GlcNAc and sialic acids, 0.5 mg/mL, 2 mg/mL, 5 mg/mL, and 10 
mg/mL)[45, 46]. The biotinylated lectins were detected by Cy5-streptavidin (1 mg/mL). Two 
subarrays were assayed with anti-CD15 antibody (binds LeX epitope, 5 mg/mL) and anti-CD15s 
antibody (binds sLeX epitope, 20 mg/mL), respectively. The primary antibodies were then bound 
by goat anti-mouse IgM-Alexa Fluor® 488 conjugate (5 mg/mL). Three subarrays were assayed 
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with three influenza A viruses, including swine, avian and human vaccine strains [41]. All 
viruses were labeled with Alexa Fluor 488 as previously described [41, 47], and were incubated 
on the slide at 4oC for 1 h. The slides were scanned with a microarray scanner (InnoScan 1100 
AL).  
3.1.3 Results and Discussion 
Preparation of core glycan 
Sialylglycopeptide (SGP) was obtained from egg yolks as previously described [40]. In 
order to assist immobilization of glycans for glycan microarray studies, the Asn residue to which 
the N-glycan was attached was retained by treating SGP with pronase E to provide Asn-linked 
biantennary complex-type glycan terminated with α2–6Neu5Ac (BA-01, Scheme 3.1A). The 
terminal Neu5Ac was removed by a sialidase BiNanH2 from Bifidobacterium longum subsp. 
infantis ATCC15697 [48] to expose the penultimate Gal residue in BA-02 (Scheme 3.1A) that 






Scheme 3. 1 Preparation of disialylated N-glycan BA-01, the core N-glycan (BA-02) and one-
pot enzymatic synthetic schemes for producing N-glycans with only terminal glycan 
epitopes. 
Reagents and conditions: (a) pronase E; (b) sialidase BiNanH2; (c) Neu5Gc, Neisseria 
meningitidis CMP-sialic acid synthetase (NmCSS) and Photobacterium damselae α2–6-
sialyltransferase (Pd2,6ST); (d) Neu5Ac, NmCSS and Pasteurella multocida α2–3-
sialyltransferase double mutant E271F/R313Y (PmST1 E271F/R313Y); (e) Neu5Gc, NmCSS 
and PmST1 E271F/R313Y; (f) Helicobacter pylori α1–3-fucosyltransferase (Hpα1,3FT); (g) 
bovine α1–3-galactosyltransferase (Bα1,3GalT).  
Enzymatic extension of N-glycans 
To decrease the cost and make the enzymatic glycosylation reactions more efficiently, 
one-pot multienzyme (OPME) strategy was adopted in the N-glycan synthesis whenever 
possible. For example, in all sialic acid transfer reactions, sialic acid, CTP, and Neisseria 
meningitidis CMP-sialic acid synthetase (NmCSS) [36], the enzyme responsible for the synthesis 
of the activated sugar nucleotide form of sialic acid (CMP-sialic acid), were added together with 
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a suitable sialyltransferase, allowing in situ generation and consumption of CMP-sialic acid. 
Also, in sequential extensions with several monosaccharides other than sialic acid (e.g. the 
synthesis of BA-08 in Scheme 3.1B), multiple glycosyltransferases were added successively 
once the previous reaction reached completion, and only the final products were purified. For 
elongation with sialic acids, glycan products were purified right after each OPME sialylation 
reaction. Pasteurella multocida α2–3-sialyltransferase double mutant E271F/R313Y (PmST1 
E271F/R313Y) was used to catalyze the addition of α2–3-sialic acid. Once monosialylation 
products were observed, adding more enzymes and donors into the same reaction mixtures did 
not lead to additional sialylation. Disialylation could be achieved, however, by purifying the 
monosialylated products followed by another round of sialylation reaction which led to 
sialylation on both branches of the N-glycans.  
In addition to α2–6Neu5Ac-terminated BA-01 which was readily obtained by purification 
of SGP followed by pronase E digestion (Scheme 3.1A), three sialylated N-glycans were 
prepared from BA-02 with a single sialic acid extension at each branch including BA-03 with 
terminal α2–6Neu5Gc, BA-04 with terminal α2–3Neu5Ac and BA-05 with terminal α2–
3Neu5Gc (Scheme 1B). LeX (BA-06), α-Gal (BA-07) and Galα1–3-LeX (BA-08) epitopes were 
produced by reactions catalyzed by Helicobacter pylori α1–3-fucosyltransferase (Hpα1,3FT) 
[49, 50], bovine α1–3-galactosyltransferase (Bα1,3GalT), and Bα1,3GalT followed by 
Hpα1,3FT, respectively (Scheme 3.1B). For sialyl LeX (sLeX; BA-17 and BA-18), α1–3-
fucosylation was performed after sialylation (Scheme 3.1B) [32, 51]. 
Enzymatic extension of N-glycans with tandem glycan epitopes 
To synthesize N-glycans with tandem epitopes, glycosyltransferases were added 
sequentially according to the monosaccharide sequence in the desired glycans. For example, 
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alternating utilization of Neisseria meningitidis β1–3-N-acetylglucosaminyltransferase 
(NmLgtA)[15] and N. meningitidis β1–4-galactosyltransferase (NmLgtB) [52] allowed the 
formation of glycans with tandem LacNAc sequence (–3Galβ1–4GlcNAcβ1–) (Scheme 3.2, BA-
24 as di-LacNAc and BA-25 as tri-LacNAc). These tandem LacNAc glycans were further α1–3-
galactosylated at the outermost Gal, forming an α-Gal epitope (BA-26 and BA-27). The LacNAc 
could also be fucosylated at GlcNAc with β1–3-linkage, generating LeX epitope. It is worth 
noting that, Hpα1,3FT [49, 53] could only attach α1–3Fuc to GlcNAc residue in the existing 
LacNAc unit. For instance, in BA-30, fucosylation occurred on both LacNAc because Hpα1,3FT 
was added after both LacNAc were produced, leading to tandem LeX epitope, while BA-28 was 
only internally fucosylated since the non-reducing terminal GlcNAc in GlcNAc-LacNAc was not 
an acceptable receptor for this fucosylation, resulting in LacNAc-LeX (LacNAc at the non-
reducing end) tandem epitopes. We also observed that NmLgtA could not extend the Gal residue 
in LeX epitope, therefore, during synthesis, the terminal LacNAc needed to be extended by 
GlcNAc before fucosylated into LeX. Based on this principle, we have synthesized glycans with 
di-LacNAc (BA-24), tri-LacNAc (BA-25), LacNAc-LeX (VIM-2, CD65, BA-28)[54], LacNAc-
LeX-LeX (BA-33), di-LeX (BA-30), tri-LeX (BA-34), α-Gal-LacNAc (BA-26), α-Gal-LacNAc-
LacNAc (BA-27), α-Gal-LeX (BA-31), α-Gal-LeX-LeX (BA-35), Galα1–3-LeX-LeX (BA-32) and 
Galα1–3-LeX-LeX-LeX (BA-36). In addition, the LacNAc-LeX in BA-28 was further sialylated 




Scheme 3. 2 One-pot synthetic scheme for N-glycans with tandem sugar epitopes without sialic 
acids (BA-24 to BA-36).  
Reagents and conditions: (a) NmLgtA; (b) NmLgtB; (c) Hpα1,3FT; (d) Bα1,3GalT; (e) NmCSS 
and PmST1 E271F/R313Y. 
Another group of glycans were terminally extended with sialic acids, leading to di-sialic 
acid (diSia) determinant. The diSia determinant was found abundantly existing in human brain 
(mostly in gangliosides) [29], but evidence also showed its presence in protein N-glycosylation 
[55], although the function was unknown. Therefore, we employed Campylobacter jejuni α2–
3/8-sialyltransferase (CjCstII) to accomplish the diSia modification. CjCstII worked efficiently, 
and added α2–8-linked Neu5Ac or Neu5Gc to the terminal α2–6/α2–3-linked Neu5Ac or 
Neu5Gc in sialylated LacNAc, generating a series of glycans with tandem sialic acids (Scheme 
3.3A, BA-09 to BA-16, Table 3.1). The di-LacNAc was also modified with sialyltransferases 
(Scheme 3B), and the sialyltransferases used exhibited different glycosylation profile. The α2–3-
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sialyltransferase (PmST1 E271F/R313Y) could only add terminal sialic acids (BA-19 and BA-
20), while Pd2,6ST added both terminal and internal sialic acids (BA-21 and BA-22), different 
from mammalian α2–6-sialyltransferase ST6Gal-1 that only sialylated terminal LacNAc[31]. 
 
Scheme 3. 3 One-pot synthetic scheme for N-glycans with sugar epitopes with sialic acids (BA-
09 to BA-16, BA-19 to BA-22). 
Reagents and conditions: (a) Neu5Ac, NmCSS and Campylobacter jejuni α2–3/8-
sialyltransferase CstII (CjCstII); (b) Neu5Gc, NmCSS and CjCstII; (c) Neu5Ac, NmCSS and 
PmST1 E271F/R313Y; (d) Neu5Gc, NmCSS and PmST1 E271F/R313Y; (e) Neu5Ac, NmCSS 
and Pd2,6ST; (f) Neu5Gc, NmCSS and Pd2,6ST. 
However, to produce the glycan with both terminal α2–3-Sia and internal α2–6-Sia (BA-
23), the synthetic route was strict since Pd2,6ST was capable of adding α2–6-Sia to the 
penultimate Gal to which α2–3-Sia was already linked, resulting in a mixture of glycans with 1–
3 α2–6-Sia added. To circumvent this limitation, the internal α2–6-Sia was added to the Gal of 
the inner LacNAc after the GlcNAc of the outer LacNAc was added, and then the outer LacNAc 
was completed by adding Gal and further modified by α2–3-Sia. 
Since PmST1 E271F/R313Y and CjCstII have glycosidase activity although the α2–3-
sialidase activity of wild-type PmST153 was reduced 6333-fold by E271F/R313Y mutations 




Table 3. 1 Conversion percentage of reactions catalyzed by NmCSS and CjCstII. 














BA-09   0  4 82 14 
 CMP-
Neu5Gc 
BA-10   2 22 76   0 
BA-03 CMP-
Neu5Ac 
BA-11   0 30 70   0 
 CMP-
Neu5Gc 
BA-12 19 63 18   0 
BA-04 CMP-
Neu5Ac 
BA-13   0 12 82   6 
 CMP-
Neu5Gc 
BA-14   1 19 80   0 
BA-05 CMP-
Neu5Ac 
BA-15   3 52 45   0 
 CMP-
Neu5Gc 
BA-16 11 63 25   0 
a. The percentage yield is calculated from HPLC-HILIC-ELSD data.  
During sialylation, altered activity of PmST1 E271F/R313Y was observed towards 
glycans with different structures (Table 3.2). Single LacNAc was an acceptor (BA-02) for α2–3-
sialylation, with a moderate percentage conversion (71%) during reaction within 45 min. If the 
LacNAc was modified with α1–3-Fuc to form LeX, no α2–3-sialylation was detected, consistent 
with the previous reports [32, 51]. When di-LacNAc was in the acceptor (BA-24), within 45 min, 
the percentage conversion of α2–3-sialylation was 96%, much higher compared to single 
LacNAc in BA-02. When the inner LacNAc in di-LacNAc was converted to LeX, the α2–3-
sialylation efficiency of the outer LacNAc was even higher than di-LacNAc acceptor, reaching 
99%. This indicates that longer glycans are preferred by PmST1 E271F/R313Y than shorter 
glycans (BA-24 vs. BA-02). Also, fucosylation of terminal LacNAc would hinder sialylation of 
the same LacNAc (BA-06), but fucosylation of internal LacNAc would not impede and would 
even enhance the sialylation of the terminal LacNAc (BA-28).  
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a. The percentage conversion is determined from HPLC-HILIC-ELSD data. 
b. Not detected. 
 
Glycan microarray of N-glycans 
To explore the roles of internal and terminal epitopes of these synthetic glycans in glycan-
binding events, glycan microarrays prepared from the library of N-glycans synthesized were 
screened with three classes of glycan-binding reagents, including plant lectins, antibodies, and 
viruses. 
(1) Plant lectins.  
Eight subarrays were interrogated with lectins exhibiting defined binding specificities 
including MAL-I (specific to Siaα2–3Gal-linkage) [56], SNA (specific to Siaα2–6Gal-
linkage)[42], ECL (binds terminal LacNAc)[43], GSL-I-B4 (binds Galα1–3Gal-R) [44], and 
111 
 
WGA (binds GlcNAc residue and Neu5Ac residue [45, 46]; four subarrays for four 
concentrations). The lectins were biotinylated and detected with Cy5-labeled-streptavidin. The 
results are shown as histograms in Figure 3.2. 
Glycans with terminal sLacNAc (Siaα2–3Galβ1–4GlcNAc) were bound by MAL-I [56], 
which is specific to Siaα2–3Gal-linkage. MAL-I did not distinguish between Neu5Ac and 
Neu5Gc. Even if the terminal sialic acid in sLacNAc was extended with another sialic acid in the 
C8 position (BA-13 to BA-16), the glycans were still bound by MAL-I, as reported previously 
[57, 58]. However, its binding was abolished if the sLacNAc was fucosylated to form sLeX (BA-
17 and BA-18), demonstrating the interruption of binding caused by Fuc. With regard to internal 
epitope, when terminal sLacNAc was linked with internal LacNAc (BA-19 and BA-20), stronger 
binding was observed in comparison with glycans in which sLacNAc was directly linked with 
Man in core pentasaccharide of N-glycans (BA-04 and BA-05). Nevertheless, if the internal 
LacNAc was further modified by α2–6-sialylation (as in BA-23) or α1–3-fucosylation (as in BA-
29), the enhancement in binding for MAL-I was compromised. 
Glycans terminating in s6LacNAc (Siaα2–6Galβ1–4GlcNAc) were bound by SNA [42]. 
The data for binding were consistent with the given structures in the analysis. SNA also did not 
distinguish between Neu5Ac and Neu5Gc. However, unlike MAL-I, SNA did not bind to the 
s6LacNAc determinant if α2–8-sialylation occurred to the terminal s6LacNAc, which illustrates 




Figure 3. 2 Binding profile of plant lectins with defined binding specificities. 
Five lectins were inspected including Maackia amurensis lectin I (MAL-I), Sambucus nigra 
lectin (SNA), Erythrina cristagalli lectin (ECL), B subunit of Griffonia simplicifolia lectin I 
(GSL-I-B4), and wheat germ agglutinin (WGA). 
The internal s6LacNAc does not contribute to binding with SNA, as no detectable 
binding was observed for BA-23. The comparable binding affinity for glycans with single or 
double s6LacNAc moieties (BA-01 vs. BA-21, BA-03 vs. BA-22) further indicates the 
neglectable roles the internal s6LacNAc plays in binding with SNA. 
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All tested glycans possessing a terminal LacNAc, including glycans BA-02, BA-24, BA-
25, BA-28 and BA-33, were bound by ECL [43]. Any modification to the terminal LacNAc 
epitope (sLacNAc, s6LacNAc, LeX or α-Gal as illustrated by BA-04, BA-01, BA-06 or BA-07, 
respectively) hampered the binding of ECL, demonstrating the strict glycan structural 
requirement for ECL binding. With respect to the roles of internal epitopes, internal LacNAc 
determinant is not attributable to ECL binding (as in BA-19, BA-20, BA-26 and BA-27). Nor 
does internal LacNAc or LeX determinant exhibit distinguishable effect on ECL binding, being 
exemplified by similar binding between the following groups of glycans, i.e. BA-02 vs. BA-24 
vs. BA-25, and BA-28 vs. BA-33 for internal LacNAc, and BA-24 vs. BA-28, and BA-25 vs. 
BA-33 for internal LeX. 
Glycans with Galα1–3Gal-R structures were bound by GSL-I-B4 [44], which is specific to α-Gal 
determinant. Contrast to the binding profile of MAL-I, fucosylation of the GlcNAc residue in 
terminal α-Gal epitope had no hindrance for the binding to GSL-I-B4 (BA-07 vs. BA-08), or it 
could even augment the binding (BA-32 > BA-31, BA-36 > BA-35). Internal LacNAc moiety 
did not pose apparent influence on the binding (BA-07 vs. BA-26 vs. BA-27), whereas internal 
LeX epitope generally decreased the binding (BA-35 < BA-31 < BA-07, BA-36 < BA-32), with 
the exception that no decrease was detected from BA-08 to BA-32. 
Another set of interesting observations is the binding patterns of WGA to these glycans. 
WGA is known to be specific to GlcNAc residue, including internal GlcNAc, and Neu5Ac 
residue [45, 46].According to our results, WGA only recognizes α2–3Sia epitope rather than α2–
6Sia, and is more sensitive to Neu5Ac compared to Neu5Gc. In addition, as the concentration of 
WGA increased from 0.5 to 10 µg/mL, the number of bound glycans increased. At the lowest 
concentration we tested (0.5 µg/mL), glycans with terminal sLacNAc (regardless of fucosylation, 
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BA-4, BA-17, BA-19, BA-23 and BA-29), as well as tri-LacNAc (BA-25) and α-Gal-LacNAc-
LacNAc (containing tri-LacNAc in total, BA-27) were bound by WGA. As the concentration of 
WGA increased to 2 µg/mL, besides the aforementioned glycans, single/double LacNAc (BA-02 
and BA-07) and α-Gal epitope containing single/double LacNAc (BA-24 and BA-26) were also 
bound by WGA. At the concentration of 5 µg/mL, WGA exhibited broader binding to glycans. 
Terminal Neu5Gcα2–3Galβ1–4GlcNAc (BA-05 and BA-20) was bound at this concentration. 
The Neu5Ac/Gcα2–3Galβ1–4GlcNAc epitopes were still bound by WGA even when they were 
further modified by α2–8-Neu5Ac (BA-13 and BA-15). LacNAc(-LeX)-LeX (BA-28 and BA-31) 
and α-Gal(-LeX)-LeX (BA-33 and BA-35) with non-fucosylated terminal epitopes were bound by 
WGA, while terminal single LeX (BA-06) and Galα1–3-LeX (BA-08) only displayed weak 
affinity to WGA. When the WGA concentration reached 10 µg/mL, LeX-LeX (BA-30) and 
Galα1–3-LeX-LeX (BA-32) can be additionally bound. Collectively, fucosylation of terminal 
sLacNAc, LacNAc or α-Gal epitope reduced to some extent the binding to WGA (BA-17 < BA-
04 at 0.5 µg/mL, BA-06 < BA-02, and BA-08 < BA-07 at 5 µg/mL, BA-30 < BA-28, BA-32 < 
BA-31 at 10 µg/mL). While internal LacNAc improved the binding for both sialosides and 
asialosides to WGA (BA-19 > BA-04 at 0.5 µg/mL), an effect that may be caused by WGA’s 
binding with internal GlcNAc, α2–6-sialylation or fucosylation of internal LacNAc decreased the 
binding (BA-23 < BA-19 and BA-29 < BA-19 at 0.5 µg/mL, BA-28 < BA-24, BA-31 < BA-26, 
BA-33 < BA-25, BA-35 < BA-27 at 5 µg/mL). 
(2) Antibodies. Anti-CD15 and anti-CD15s antibodies were selected to perform the binding 
study (Figure 3.3). 
Anti-CD15 antibody is an antibody that binds to LeX epitope. In our results, this antibody 
exhibited strong binding to the glycans containing di-LeX (BA-30) and tri-LeX (BA-34), but 
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failed to bind glycans with only internal LeX epitopes (BA-28 and BA-33), indicating that only 
the terminal LeX determinant participates in the binding. No binding was observed with single 
terminal LeX directly connected to the mannose in core pentasaccharide in N-glycans (BA-06), 
which is consistent with the glycan binding data published by Consortium for Functional 
Glycomics (CFG, http://www.functionalglycomics.org), highlighting the negative effect of 
internal core pentasaccharide on the binding. In addition, the terminally modified LeX, i.e. by 
sialylation as in BA-17 and BA-18 or by α-galactosylation as in BA-08, BA-32 and BA-36, were 
not binding ligand for this antibody. 
 
Figure 3. 3 Binding profile of antibodies. 
Anti-CD15s antibody binds to sLeX epitope. As consistent with the data reported by 
CFG, sLeX directly linked to the mannose in core pentasaccharide (BA-17 and BA-18) also 
failed to bind anti-CD15s antibody. However, BA-21, which has tandem s6LacNAc structure, 
unexpectedly showed considerable binding to this antibody, implying that glycan with this 
structure may mimic the sLeX that leads to the binding of anti-CD15s antibody, which means that 
binding of anti-CD15s antibody for sLeX epitope is not too strict. 
(3) Viruses.  
The binding specificity of three strains of influenza A virus, representing influenza 
viruses of swine, avian and human origin, were examined (Figure 3.4).  
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A/sw/Minnesota/02749/2009 (H1N1) isolated from swine has a known binding 
specificity towards Neu5Acα2–6Gal-linked glycans [41]. As expected, BA-01 and BA-21, both 
with terminal Neu5Acα2–6Galβ1–4GlcNAc (s6LacNAc) epitope, presented strong binding, and 
the binding to BA-21 appeared higher than BA-01. Although the internal s6LacNAc could not 
directly bind the swine virus (no binding to BA-23, which only has internal s6LacNAc), its 
presence still resulted in the higher binding of BA-21 compared to BA-01, clarifying that internal 
s6LacNAc facilitated the binding of terminal s6LacNAc. No binding was observed if the 
terminal of Neu5Acα2–6Gal-linked glycans was further modified with α2–8-linked sialic acids 
(BA-09 and BA-10), consistent with the previous report.64 Nor did Neu5Gcα2–6Gal-linked 
glycans (BA-03 and BA-22) show any binding.  
 
Figure 3. 4 Binding profile of influenza A viruses. 
The avian virus strain A/Ruddy Turnstone/DE/650625/2002, isolated from the shorebird, 
Ruddy Turnstone, was previously reported to bind Neu5Acα2–3Gal-linked glycans and 
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Neu5Acα2–6Gal-linked glycans.64 In our array, internal LacNAc improved the binding of virus 
(BA-20 > BA-05). Internal s6LacNAc significantly enhanced the binding between α2–6-
sialosides and virus (BA-21 > BA-01), but only slightly increased the binding of α2–3-sialosides 
(BA-23 > BA-04). Sialylation and fucosylation of adjacent internal LacNAc did not alter the 
binding (BA-19 vs. BA-23, BA-19 vs. BA-29). With α2–8-sialylation of terminal sLacNAc (BA-
13 and BA-14 vs. BA-04) or s6LacNAc (BA-09 and BA-10 vs. BA-01), binding with the virus 
was no longer detectable. Unlike lectins, fucosylation of terminal sLacNAc has enhanced 
binding affinity (BA-17 > BA-04, BA-18 > BA-05). The virus also showed strong binding to 
some Neu5Gcα2–3Gal-linked glycans (BA-18, fucosylated Neu5Gcα2–3LacNAc, and BA-20, 
Neu5Gcα2–3LacNAcα1–3LacNAc). However, the failure of BA-05 (Neu5Gcα2–3LacNAc) to 
bind this virus may suggest that fucosylation of terminal epitope and internal LacNAc are 
favorable factors for the binding.  
The third virus, A/Brisbane/59/2007 (H1N1), is a human vaccine strain, and can bind 
both Neu5Acα2–3Gal-linked glycans and Neu5Acα2–6Gal-linked glycans [41]. It showed 
similar binding profile to that of the Ruddy Turnstone virus we tested. The difference existed in 
that no binding to Neu5Gcα2–3Gal-linked glycans (BA-18 and BA-20) but binding to 
Neu5Gcα2–6Gal-linked glycan (BA-22) were detected with Brisbane virus. This could be 
attributed to the α2–6-sialoside preference for human virus versus α2–3-sialoside preference for 
avian virus. The binding patterns of this virus demonstrate the enhancement of binding by 
internal s6LacNAc epitope (BA-21 > BA-01, BA-22 > BA-03). 
Taken together, some general observations can be made that the influence caused by 
internal epitope or the modification of terminal epitope on the binding characteristics of plant 
lectins, antibodies, or viruses are obvious. In some cases, the internal epitope totally blocked the 
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binding. For instance, direct connection with core pentasaccharide in N-glycans completely 
abolished the binding of LeX and sLeX with the corresponding antibodies. The binding between 
glycans and specific GBPs was eliminated by fucosylation of terminal epitope, as for MAL-I and 
ECL. α2–8-Sialylation of terminal α2–3/6-sialylated LacNAc also abolished the binding, as was 
observed for the three viruses. Although α2–8-sialylation did not influence binding between α2–
3-sialylated LacNAc and MAL-I, it blocked the binding between α2–6-sialylated LacNAc and 
SNA. In some other cases, the internal epitope or modification of terminal epitope reversed the 
binding profile from no binding to binding, or even strong binding. For example, internal 
LacNAc converted the non-ligand BA-05 into a ligand BA-20 for Ruddy Turnstone virus, 
whereas fucosylation of terminal LacNAc in BA-05 generated a good ligand BA-18 for the same 
virus. Internal s6LacNAc, in the similar fashion, altered the non-bound BA-03 into a bound 
ligand BA-22 for Brisbane virus.  
Other than the abovementioned binding switch, increase or decrease of binding caused by 
internal epitope or modification of terminal epitopes was also common in our assay. The 
divergent effects led by the same epitope or modification appeared dependent on the inherent 
binding activity of the binding partners. Fucosylation of terminal epitope enhanced viral binding 
to α2–3-sialosides, reduced binding of WGA. Internal LacNAc usually strengthens the binding, 
as for MAL-I, WGA, avian and human viruses, but does not affect the binding with ECL and 
GSL-I-B4. When internal LacNAc was fucosylated, the binding was generally hampered, as for 
MAL-I, GSL-I-B4, WGA, avian and human viruses, with the exception of no influence for ECL 
binding. Sialylation of internal LacNAc, on the other hand, exhibited three different effects – no 




These results suggest that a re-examination of the binding patterns that were assigned to 
the known GBPs and viruses and their application in glycan-binding investigation is needed. For 
example, quite a few plant lectins are commonly used to define the structures of isolated glycans 
[41, 58, 59]. With our results, the expected binding could not be observed because the internal 
epitope or modification of terminal epitope caused binding decrease to an undetectable level, or 
unexpected binding could be observed by the enhancing effect. 
To sum up, by using the “Core Isolation/Enzymatic Extension (CIEE)” strategy 
combined with one-pot multienzyme synthesis, a series of N-glycans, which include those 
containing a terminal sialyl LacNAc, sLeX and Siaα2–8-Siaα2–3/6-R structures with Neu5Ac or 
Neu5Gc sialic acid form, LacNAc, LeX, α-Gal, and Galα1–3-LeX; and tandem epitopes including 
α-Gal, LeX, Galα1–3-LeX, LacNAc, and sialyl LacNAc, presented with an internal sialyl LacNAc 
or 1–2 repeats of an internal LacNAc or LeX component, were prepared in milligram-scale and 
over 98% purity by HPLC-HILIC purification monitored by UV absorption. One-pot synthesis 
has been proven as an efficient strategy for complex N-glycan preparation. All 
glycosyltransferases and sugar nucleotide synthesizing enzymes used in this study were over-
expressed by E. coli and were robust in catalyzing the synthesis of the 36 N-glycans including 
those with tandem epitopes, providing us a methodology to produce more complex structurally 
defined N-glycans. Interrogation of microarrays displaying such glycans revealed the 
participation of the internal epitopes in the binding with GBPs and viruses. In conclusion, when 
interpreting the binding between glycans and GBPs/viruses, not only the structure of the terminal 
glycan epitopes, but also the internal epitopes and/or modifications of terminal epitopes, 




HPLC profiles, MS and NMR data of purified N-glycans  
BA-01    
HILIC-ELSD, TR = 21.034 min. 
 
ESI-MS, calculated 2337.9003; found [M+3H]3+ 780.2872, [M+2H]2+ 1169.9280. 
 
1H NMR (D2O, 500 MHz): 5.14 (s, 1 H, Man4 H-1), 5.08 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 
4.96 (s, 1 H, Man4’ H-1), 4.78 (s, 1 H, Man3 H-1), 4.60-4.63 (m, 3 H, GlcNAc 2 H-1, GlcNAc5 
H-1, GlcNAc5’ H-1), 4.45 (d, J = 7.3 Hz, 2 H, Gal6 H-1, Gal6’ H-1), 4.29 (brs, 1 H, Man3 H-2), 
4.21 (brs, 1 H, Man4 H-2), 4.12 (brs, 1 H, Man4’ H-2), 3.50-4.02 (m, 66 H), 2.94 (dd, J = 17.3, 
4.2 Hz, 1 H, Asn-βCH2), 2.87 (d, J = 17.3, 6.9 Hz, 1 H, Asn-βCH2), 2.65-2.69 (m, 2 H, Neu5Ac 
H-3eq), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, 2 Ac), 2.04 (s, 6 H, 2 Ac), 2.02 (s, 3 H, Ac), 1.73 (t, J = 
12.2 Hz, 2 H, Neu5Ac H-3ax).  



































942.8500 1559.56501403.70971242.9539519.1407 593.1597 682.9200 1125.9191
121 
 
BA-02   
HILIC-ELSD, TR = 19.076 min. 
 
MALDI-MS, calculated 1755.7094; found [M+Na]+ 1777.631, [M+K]+ 1793.619. 
 
 
1H NMR (D2O, 500 MHz): 5.16 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.8 Hz, 1 H, GlcNAc1 H-1), 
4.97 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.66 (d, J = 7.8 Hz, 1 H, 
GlcNAc 2 H-1), 4.62 (d, J = 7.8 Hz, 2 H, GlcNAc5 H-1, GlcNAc5’ H-1), 4.51 (d, J = 7.8 Hz, 1 
H, Gal6 H-1), 4.50 (d, J = 7.8 Hz, 1 Gal6’ H-1), 4.29 (d, J = 1.8 Hz, 1 H, Man3 H-2), 4.23 (d, J 
= 1.7 Hz, 1 H, Man4 H-2), 4.15 (d, J = 1.8 Hz, 1 H, Man4’ H-2), 3.51-4.04 (m, 52 H), 2.98 (dd, J 
= 17.2, 4.3 Hz, 1 H, Asn-βCH2), 2.90 (d, J = 17.2, 6.8 Hz, 1 H, Asn-βCH2), 2.12 (s, 3 H, Ac), 
2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.05 (s, 3 H, Ac). 
 























BA-03   
HILIC-ELSD, TR = 22.080 min. 
 
ESI-MS, calculated 2369.8901; found [M+3H]3+ 790.9512, [M+2H]2+ 1185.9225. 
 
 
1H NMR (D2O, 500 MHz): 5.18 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 
4.99 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.46-4.66 (m, 3 H, 
GlcNAc 2 H-1, GlcNAc5 H-1, GlcNAc5’ H-1), 4.50 (d, J = 7.9 Hz, 1 H, Gal6 H-1), 4.49 (d, J = 
7.8 Hz, 1 H, Gal6’ H-1), 4.30 (s, 1 H, Man3 H-2), 4.24 (d, J = 2.2 Hz, 1 H, Man4 H-2), 4.16 (brs, 
4 H, Man4’ H-2), 3.52-4.06 (m, 70 H), 2.98 (dd, J = 17.3, 4.2 Hz, 1 H, Asn-βCH2), 2.90 (dd, J = 
17.3, 6.9 Hz, 1 H, Asn-βCH2), 2.71-2.75 (m, 2 H, Neu5Gc H-3eq), 2.16 (s, 3 H, Ac), 2.12 (s, 3 
H, Ac), 2.11 (s, 3 H, Ac), 2.06 (s, 3 H, Ac), 1.78 (t, J =12.3 Hz, 2 H, Neu5Gc H-3ax). 































1199.4117519.1406 673.2326 858.6434593.1596 1031.8743 1580.89251422.9038768.2816 1170.4205 1287.4607963.2551
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BA-04   
HILIC-ELSD, TR = 19.947 min. 
 
ESI-MS, calculated 2337.9003; found [M+3H]3+ 780.2874, [M+2H]2+ 1169.9278. 
 
 
1H NMR (D2O, 500 MHz): 5.16 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.8 Hz, 1 H, GlcNAc1 H-1), 
4.97 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.66 (d, J = 7.9 Hz, 1 H, 
GlcNAc1 H-1), 4.58-4.62 (m, 4 H, GlcNAc5 H-1, GlcNAc5’ H-1, Gal6 H-1, Gal6’ H-1), 4.29 
(brs, 1 H, Man3 H-2), 4.23 (d, J = 1.9 Hz, 1 H, Man4 H-2), 4.15-4.16 (m, 3 H), 3.51-4.04 (m, 64 
H), 2.98 (dd, J = 17.3, 4.3 Hz, 1 H, Asn-βCH2), 2.91 (dd, J = 17.3, 6.9 Hz, 1 H, Asn-βCH2), 2.80 
(dd, J = 12.4, 4.3 Hz, 2 H, Neu5Ac H-3eq), 2.12 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 
2.07 (s, 3 H, 2 Ac), 2.06 (s, 3 H, Ac), 1.84 (t, J =12.4 Hz, 2 H, Neu5Ac H-3ax).  


































445.1218 1403.7095942.8498 1559.5646519.1406 1242.9542659.2428593.1596 1125.9188
124 
 
BA-05   
HILIC-ELSD, TR = 21.148 min. 
 
 
ESI-MS, calculated 2369.8901; found [M+3H]3+ 790.9506, [M+2H]2+ 1185.9227. 
 
1H NMR (D2O, 500 MHz):5.14 (s, 1 H, Man4 H-1), 5.07 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 
4.95 (s, 1 H, Man4’ H-1), 4.78 (s, 1 H, Man3 H-1), 4.59-4.62 (m, 3 H, GlcNAc1 H-1, GlcNAc5 
H-1, GlcNAc5’ H-1), 4.45 (d, J = 7.4 Hz, 2 H, Gal6 H-1, Gal6’ H-1), 4.26 (brs, 1 H, Man3 H-2), 
4.20 (brs, 1 H, Man4 H-2), 4.12 (brs, 4 H), 3.50-4.03 (m, 67 H), 2.94 (dd, J = 17.3, 4.1 Hz, 1 H, 
Asn-βCH2), 2.87 (dd, J = 17.3, 6.8 Hz, 1 H, Asn-βCH2), 2.66-2.72 (m, 2 H, Neu5Gc H-3eq), 
2.09 (s, 3 H, Ac), 2.08 (s, 6 H, 2 Ac), 2.02 (s, 3 H, Ac), 1.75 (t, J =12.2 Hz, 2 H, Neu5Gc H-
3ax).  






































BA-06   
HILIC-ELSD, TR = 20.965 min. 
 
MALDI-MS, calculated 2047.8253; found [M+Na]+ 2069.837, [M+K]+ 2085.819. 
 
1H NMR (D2O, 500 MHz): 5.17 (d, J = 3.4 Hz, 1 H, Fuc H-1), 5.16 (d, J = 3.5 Hz, 1 H, Fuc H-
1), 5.14 (s, 1 H, Man4 H-1), 5.10 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.95 (s, 1 H, Man4’ H-1), 
4.85-4.88 (m, 2 H, Man3 H-1, GlcNAc1 H-1), 4.65 (d, J = 7.8 Hz, 1 H, GlcNAc5 H-1), 4.62 (d, 
J = 8.1 Hz, 1 H, GlcNAc5’ H-1), 4.49 (d, J = 7.7 Hz, 1 H, Gal6 H-1), 4.48 (d, J = 7.6 Hz, 1 H, 
Gal6’ H-1), 4.29 (brs, 1 H), 4.22 (d, J = 2.0 Hz, 1 H), 4.14 (d, J = 2.2 Hz, 1 H), 3.50-4.04 (m, 60 
H), 2.96 (dd, J = 17.2, 4.3 Hz, 1 H, Asn-βCH2), 2.89 (dd, J = 17.2, 6.9 Hz, 1 H, Asn-βCH2), 2.12 
(s, 3 H, Ac), 2.08 (s, 6 H, 2 Ac), 2.06 (s, 3 H, Ac), 1.22 (d, J = 6.4 Hz, 3 H, Fuc CH3), 1.21 (d, J 
= 6.4 Hz, 3 H, Fuc CH3). 
























BA-07   
HILIC-ELSD, TR = 20.877 min. 
 
MALDI-MS, calculated 2079.8151; found [M+Na]+ 2101.899, [M+K]+ 2117.880. 
 
1H NMR (D2O, 500 MHz): 5.12 (s, 1 H, Man4 H-1), 5.08 (d, J = 9.8 Hz, 1 H, GlcNAc1 H-1), 
4.93 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.69 (d, J = 8.4 Hz, 2 H, 
GlcNAc1 H-1, GlcNAc5 H-1), 4.62 (d, J = 7.9 Hz, 1 H,GlcNAc5’ H-1), 4.58 (d, J = 7.6 Hz, 2 H, 
Gal6 H-1, Gal6’ H-1), 4.47 (d, J = 7.5 Hz, 1 H, Gal7 H-1), 4.46 (d, J = 7.6 Hz, 1 H, Gal7’ H-1), 
4.26 (brs, 1 H, Man3 H-2), 4.19 (brs, 1 H, Man4 H-2), 4.16 (brs, 2 H), 4.11 (brs, 1 H), 3.46-4.00 
(m, 61 H), 2.94 (dd, J = 17.2, 4.3 Hz, 1 H, Asn-βCH2), 2.87 (dd, J = 17.2, 6.8 Hz, 1 H, Asn-
βCH2), 2.08 (s, 3 H, Ac), 2.05 (s, 6 H, 2 Ac), 2.02 (s, 3 H, Ac).  



























BA-08  HILIC-ELSD, TR = 22.716 min. 
 
MALDI-MS, calculated 2371.9309; found [M+Na]+ 2393.808, [M+K]+ 2409.785. 
 
1H NMR (D2O, 500 MHz): 5.18 (d, J = 3.5 Hz, 2 H, Fuc H-1), 5.15 (s, 1 H, Man4 H-1), 5.11 
(d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.96 (s, 1 H, Man4’ H-1), 4.85-4.87 (m, 2 H, GlcNAc2 H-1, 
GlcNAc5 H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.62-4.66 (m, 3 H, GlcNAc5’ H-1, 
Gal6 H-1, Gal6’ H-1), 4.56 (d, J = 7.7 Hz, 1 H, Gal7 H-1), 4.55 (d, J = 7.7 Hz, 1 H, Gal7 H-1), 
4.29 (brs, 1 H, Man3 H-2), 4.20-4.24 (m, 5 H), 4.14 (d, J = 2.3 Hz, 1 H), 3.50-4.06 (m, 68 H), 
2.98 (dd, J = 17.2, 4.4 Hz, 1 H, Asn-βCH2), 2.91 (dd, J = 17.2, 6.8 Hz, 1 H, Asn-βCH2), 2.12 (s, 
3 H, Ac), 2.09 (s, 6 H, 2 Ac), 2.08 (s, 3 H, Ac), 2.05 (s, 3 H, Ac), 1.23 (d, J = 6.3 Hz, 3 H, Fuc 
CH3), 1.22 (d, J = 6.3 Hz, 3 H, Fuc CH3).  

























BA-09   
HILIC-ELSD, TR = 22.309 min. 
 
ESI-MS, calculated 2920.0911; found [M+3H]3+ 974.3523, [M+2H]2+ 1461.0229. 
 
1H NMR (D2O, 500 MHz): 5.17 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 
5.00 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.64-4.67 (m, 3 H, 
GlcNAc2 H-1, GlcNAc5 H-1, GlcNAc5’ H-1), 4.48 (d, J = 7.6 Hz, 2 H, Gal6 H-1, Gla6’ H-1), 
4.30 (brs, 1 H, Man3 H-2), 4.20-4.24 (m, 3 H), 4.14-4.16 (m, 3 H), 3.54-4.03 (m, 76 H), 2.98 
(dd, J = 17.3, 4.2 Hz, 1 H, Asn-βCH2), 2.90 (dd, J = 17.3, 7.0 Hz, 1 H, Asn-βCH2), 2.82 (dd, J = 
12.3, 4.4 Hz, 2 H, Neu5Ac H-3eq), 2.60-2.63 (m, 2 H, Neu5Ac H-3eq), 2.12 (s, 6 H, 2 Ac), 2.11 
(s, 3 H, Ac), 2.10 (s, 6 H, 2 Ac), 2.07 (s, 6 H, 2 Ac), 2.05 (s, 3 H, Ac), 1.79 (t, J = 12.3 Hz, 2 H, 
Neu5Ac H-3ax), 1.69 (t, J = 12.1 Hz, 2 H, Neu5Ac H-3ax).  







































BA-10   
HILIC-ELSD, TR = 23.342 min. 
 
ESI-MS, calculated 2952.0809; found [M+3H]3+ 985.0117, [M+2H]2+ 1477.0123. 
 
1H NMR (D2O, 500 MHz): 5.17 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 
5.00 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.64-4.67 (m, 3 H, 
GlcNAc2 H-1, GlcNAc5 H-1, GlcNAc5’ H-1), 4.48 (d, J = 6.8 Hz, 2 H, Gal6 H-1, Gla6’ H-1), 
4.30 (brs, 1 H, Man3 H-2), 4.22-4.24 (m, 3 H), 4.14-4.16 (m, 3 H), 3.54-4.04 (m, 80 H), 2.98 
(dd, J = 17.2, 4.1 Hz, 1 H, Asn-βCH2), 2.93 (dd, J = 17.2, 7.0 Hz, 1 H, Asn-βCH2), 2.84 (dd, J = 
12.4, 4.5 Hz, 2 H, Neu5Ac H-3eq), 2.60-2.63 (m, 2 H, Neu5Gc H-3eq), 2.12 (s, 6 H, 2 Ac), 2.11 
(s, 3 H, Ac), 2.10 (s, 6 H, 2 Ac), 2.05 (s, 3 H, Ac), 1.80 (t, J = 12.4 Hz, 2 H, Neu5Ac H-3ax), 
1.69 (t, J = 12.1 Hz, 2 H, Neu5Gc H-3ax).  

































480.6090 1491.0026582.3186 653.3619 955.8905751.8108 1190.4075874.8497 1062.0341 1323.4653 1400.2385
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BA-11   
HILIC-ELSD, TR = 22.883 min. 
 
ESI-MS, calculated 2952.0809; found [M+3H]3+ 985.0118, [M+2H]2+ 1477.0130. 
 
1H NMR (D2O, 500 MHz): 5.17 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 
5.00 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.63-4.66 (m, 3 H, 
GlcNAc2 H-1, GlcNAc5 H-1, GlcNAc5’ H-1), 4.48 (d, J = 7.6 Hz, 2 H, Gal6 H-1, Gla6’ H-1), 
4.31 (brs, 1 H, Man3 H-2), 4.22-4.25 (m, 4 H), 4.13-4.16 (m, 4 H), 3.54-4.04 (m, 78 H), 2.98 
(dd, J = 17.3, 4.2 Hz, 1 H, Asn-βCH2), 2.90 (dd, J = 17.3, 7.1 Hz, 1 H, Asn-βCH2), 2.81 (dd, J = 
12.5, 4.4 Hz, 2 H, Neu5Ac H-3eq), 2.61-2.64 (m, 2 H, Neu5Gc H-3eq), 2.13 (s, 6 H, 2 Ac), 2.12 
(s, 3 H, Ac), 2.07 (s, 6 H, 2 Ac), 2.06 (s, 3 H, Ac), 1.78 (t, J = 12.1 Hz, 2 H, Neu5Ac H-3ax), 
1.71 (t, J = 12.3 Hz, 2 H, Neu5Gc H-3ax).  

































617.2034519.1384 955.8914 1528.02781190.40751104.3538 1331.4642887.9789 1404.4887681.8726 741.1951
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BA-12   
HILIC-ELSD, TR = 23.883 min. 
 
ESI-MS, calculated 2984.0708; found [M+3H]3+ 995.6749, [M+2H]2+ 1493.0063. 
 
1H NMR (D2O, 500 MHz): 5.17 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 
5.00 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.64-4.67 (m, 3 H, 
GlcNAc2 H-1, GlcNAc5 H-1, GlcNAc5’ H-1), 4.48 (d, J = 7.6 Hz, 2 H, Gal6 H-1, Gla6’ H-1), 
4.30 (brs, 1 H, Man3 H-2), 4.22-4.26 (m, 5 H), 4.12-4.16 (m, 5 H), 3.54-4.04 (m, 80 H), 2.98 
(dd, J = 17.3, 4.0 Hz, 1 H, Asn-βCH2), 2.90 (dd, J = 17.4, 7.1 Hz, 1 H, Asn-βCH2), 2.83 (dd, J = 
12.4, 4.5 Hz, 2 H, Neu5Gc H-3eq), 2.61-2.64 (m, 2 H, Neu5Gc H-3eq), 2.13 (s, 6 H, 2 Ac), 2.12 
(s, 3 H, Ac), 2.05 (s, 3 H, Ac), 1.80 (t, J = 12.4 Hz, 2 H, Neu5Gc H-3ax), 1.71 (t, J = 12.1 Hz, 2 
H, Neu5Gc H-3ax). 
 
































445.1198 1477.0146 1503.9937519.1383 1063.3663633.1983 1185.9160 1339.4614893.3105722.3243 766.2303
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BA-13   
HILIC-ELSD, TR = 20.851 min. 
 
ESI-MS, calculated 2920.0911; found [M+3H]3+ 974.3483, [M+2H]2+ 1461.0177. 
 
1H NMR (D2O, 500 MHz): 5.15 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.6 Hz, 1 H, GlcNAc1 H-1), 
4.96 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.65 (d, J = 7.8 Hz, 1 H, 
GlcNAc2 H-1), 4.48 (m, 4 H, , GlcNAc5 H-1, GlcNAc5’ H-1, Gal6 H-1, Gla6’ H-1), 4.29 (brs, 1 
H, Man3 H-2), 4.13-4.23 (m, 8 H), 3.54-4.04 (m, 74 H), 2.98 (dd, J = 17.4, 3.7 Hz, 1 H, Asn-
βCH2), 2.90 (dd, J = 17.4, 6.8 Hz, 1 H, Asn-βCH2), 2.81-2.83 (m, 2 H, Neu5Ac H-3eq), 2.71-
2.73 (m, 2 H, Neu5Ac H-3eq), 2.12 (s, 3 H, Ac), 2.11 (s, 6 H, 2 Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 
H, Ac), 2.07 (s, 6 H, 2 Ac), 2.05 (s, 3 H, Ac), 1.78 (t, J = 11.5 Hz, 4 H, Neu5Ac H-3ax). 


































519.1382 1493.0033948.3302593.1569 1049.3656667.1760 1169.4183741.1944 1315.4678815.2132 1388.2415
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BA-14   
HILIC-ELSD, TR = 21.858 min. 
 
ESI-MS, calculated 2952.0809; found [M+3H]3+ 985.0113, [M+2H]2+ 1477.0131. 
 
1H NMR (D2O, 500 MHz): 5.15 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 
4.96 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.65 (d, J = 7.8 Hz, 1 H, 
GlcNAc2 H-1), 4.57-4.62 (m, 4 H, GlcNAc5 H-1, GlcNAc5’ H-1, Gal6 H-1, Gla6’ H-1), 4.29 
(brs, 1 H, Man3 H-2), 4.12-4.23 (m, 10 H), 3.54-4.04 (m, 76 H), 2.98 (dd, J = 17.3, 4.0 Hz, 1 H, 
Asn-βCH2), 2.90 (dd, J = 17.3, 6.8 Hz, 1 H, Asn-βCH2), 2.83 (dd, J = 12.0, 3.9 Hz, 2 H, Neu5Ac 
H-3eq), 2.71-2.73 (m, 2 H, Neu5Gc H-3eq), 2.12 (s, 3 H, Ac), 2.11 (s, 6 H, 2 Ac), 2.09 (s, 3 H, 
Ac), 2.08 (s, 3 H, Ac), 2.05 (s, 3 H, Ac), 1.75-1.82 (m, 4 H, Neu5Ac H-3ax, Neu5Gc H-3ax). 


































445.1198 974.3506 1528.0296519.1383 1461.0186617.2031 1060.3630667.1761 1177.4175 1323.4662882.6468741.1948
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BA-15   
HILIC-ELSD, TR = 21.895 min. 
 
ESI-MS, calculated 2952.0809; found [M+3H]3+ 985.0113, [M+2H]2+ 1477.0136. 
 
1H NMR (D2O, 500 MHz): 5.15 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 
4.96 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.65 (d, J = 7.9 Hz, 1 H, 
GlcNAc2 H-1), 4.57-4.62 (m, 4 H, GlcNAc5 H-1, GlcNAc5’ H-1, Gal6 H-1, Gla6’ H-1), 4.29 
(brs, 1 H, Man3 H-2), 4.26 (brs, 1 H), 4.13-4.23 (m, 9 H), 3.54-4.06 (m, 76 H), 2.98 (dd, J = 
17.3, 3.9 Hz, 1 H, Asn-βCH2), 2.90 (dd, J = 17.3, 6.9 Hz, 1 H, Asn-βCH2), 2.79-2.83 (m, 2 H, 
Neu5Ac H-3eq), 2.72-2.76 (m, 2 H, Neu5Gc H-3eq), 2.12 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 
3 H, Ac), 2.07 (s, 6 H, 2 Ac), 2.05 (s, 3 H, Ac), 1.75-1.80 (m, 4 H, Neu5Ac H-3ax, Neu5Gc H-
3ax). 
  
































990.6841445.1198 964.3265519.1383 1528.0291593.1569 1177.9192667.1762 1331.46401126.3776887.9791741.1948 1404.2380
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BA-16   
HILIC-ELSD, TR = 22.941 min. 
 
ESI-MS, calculated 2984.0708; found [M+3H]3+ 995.6746, [M+2H]2+ 1493.0075. 
 
1H NMR (D2O, 500 MHz): 5.15 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 
4.96 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.65 (d, J = 7.9 Hz, 1 H, 
GlcNAc2 H-1), 4.57-4.62 (m, 4 H, GlcNAc5 H-1, GlcNAc5’ H-1, Gal6 H-1, Gla6’ H-1), 4.29 
(brs, 1 H, Man3 H-2), 4.26 (brs, 1 H), 4.13-4.23 (m, 11 H), 3.54-4.06 (m, 78 H), 2.98 (dd, J = 
17.3, 4.3 Hz, 1 H, Asn-βCH2), 2.90 (dd, J = 17.3, 7.1 Hz, 1 H, Asn-βCH2), 2.83 (dd, J = 12.3, 4.4 
Hz, 2 H, Neu5Gc H-3eq), 2.74 (dd, J = 12.8, 4.7 Hz, 2 H, Neu5Gc H-3eq), 2.12 (s, 3 H, Ac), 
2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.05 (s, 3 H, Ac), 1.79 (t, J = 12.3 Hz, 4 H, Neu5Gc H-3ax). 
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BA-17   
HILIC-ELSD, TR = 21.476 min. 
 
ESI-MS, calculated 2630.0161; found [M+3H]3+ 877.6557, [M+2H]2+ 1315.9793. 
 
1H NMR (D2O, 500 MHz): 5.17 (d, J = 3.7 Hz, 1 H, Fuc H-1), 5.16 (d, J = 3.9 Hz, 1 H, Fuc H-
1), 5.15 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.8 Hz, 1 H, GlcNAc1 H-1), 4.96 (s, 1 H, Man4’ H-1), 
4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.65 (d, J = 7.8 Hz, 1 H, GlcNAc2 H-1), 4.62 (d, J = 
8.2 Hz, 2 H, GlcNAc5 H-1, GlcNAc5’ H-1), 4.56 (d, J = 7.5 Hz, 1 H, Gal6 H-1), 4.55 (d, J = 7.5 
Hz, 1 H, Gal6’ H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (brs, 1 H), 4.11-4.14 (m, 4 H), 3.50-4.04 
(m, 71 H), 2.98 (dd, J = 17.3, 4.3 Hz, 1 H, Asn-βCH2), 2.90 (dd, J = 17.3, 6.9 Hz, 1 H, Asn-
βCH2), 2.80 (dd, J = 12.3, 4.2 Hz, 2 H, Neu5Ac H-3eq), 2.12 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 
(s, 3 H, Ac), 2.07 (s, 6 H, 2 Ac), 2.05 (s, 3 H, Ac), 1.84 (t, J = 12.0 Hz, 2 H, Neu5Ac H-3ax), 
1.21 (d, J = 6.1 Hz, 3 H, Fuc CH3), 1.20 (d, J = 6.2 Hz, 3 H, Fuc CH3). 




































BA-18   
HILIC-ELSD, TR = 22.572 min. 
 
ESI-MS, calculated 2662.0059; found [M+3H]3+ 888.3190, [M+2H]2+ 1331.9748. 
 
1H NMR (D2O, 500 MHz): 5.16 (d, J = 3.6 Hz, 1 H, Fuc H-1), 5.15 (d, J = 3.8 Hz, 1 H, Fuc H-
1), 5.14 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.96 (s, 1 H, Man4’ H-1), 
4.86 (t, J = 6.0 Hz, 1 H), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.65 (d, J = 7.6 Hz, 1 H, 
GlcNAc2 H-1), 4.62 (d, J = 7.8 Hz, 2 H, GlcNAc5 H-1, GlcNAc5’ H-1), 4.56 (d, J = 7.7 Hz, 1 
H, Gal6 H-1), 4.55 (d, J = 7.6 Hz, 1 H, Gal6’ H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (d, J = 2.1 
Hz, 1 H), 4.12-4.16 (m, 5 H), 3.49-4.06 (m, 73 H), 2.98 (dd, J = 17.3, 4.3 Hz, 1 H, Asn-βCH2), 
2.90 (dd, J = 17.3, 6.9 Hz, 1 H, Asn-βCH2), 2.82 (dd, J = 12.3, 4.3 Hz, 2 H, Neu5Gc H-3eq), 
2.12 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 3 H, Ac), 2.05 (s, 6 H, 2 Ac), 1.85 (t, J = 12.1 Hz, 2 
H, Neu5Gc H-3ax), 1.21 (d, J = 6.2 Hz, 3 H, Fuc CH3), 1.20 (d, J = 6.2 Hz, 3 H, Fuc CH3). 








































BA-19   
HILIC-ELSD, TR = 21.703 min. 
 
ESI-MS, calculated 3068.1647; found [M+3H]3+ 1023.7105, [M+2H]2+ 1535.0579. 
 
1H NMR (D2O, 500 MHz):5.16 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.8 Hz, 1 H, GlcNAc1 H-1), 
4.97 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.74 (d, J = 8.2 Hz, 2 H, 
GlcNAc 2 H-1, GlcNAc5 H-1), 4.66 (d, J = 7.9 Hz, 1 H, GlcNAc5’ H-1), 4.59-4.62 (m, 4 H, 
GlcNAc7 H-1, GlcNAc7’ H-1, Gal6 H-1, Gal6’ H-1), 4.50 (d, J = 7.6 Hz, 1 H, Gal8 H-1), 4.49 
(d, J = 7.6 Hz, 1 H, Gal8’ H-1), 4.29 (brs, 1 H, Man3 H-2), 4.23 (brs, 1 H), 4.20 (brs, 2 H), 4.16 
(d, J =2.7 Hz, 1 H), 4.14 (d, J = 2.5 Hz, 2 H), 3.51-4.03 (m, 86 H), 2.98 (dd, J = 17.2, 4.3 Hz, 1 
H, Asn-βCH2), 2.91 (dd, J = 17.3, 6.9 Hz, 1 H, Asn-βCH2), 2.80 (dd, J = 12.4, 4.5 Hz, 2 H, 
Neu5Ac H-3eq), 2.11 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 12 H, 4 Ac), 2.05 
(s, 3 H, Ac), 1.84 (t, J = 12.4 Hz, 2 H, Neu5Ac H-3ax). 
  





































BA-20   
HILIC-ELSD, TR = 22.661 min. 
 
ESI-MS, calculated 3100.1545; found [M+3H]3+ 1034.3748, [M+2H]2+ 1551.0538. 
1H NMR (D2O, 500 MHz): 5.15 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 
4.97 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.74 (d, J = 8.1 Hz, 2 H, 
GlcNAc 2 H-1, GlcNAc5 H-1), 4.65 (d, J = 7.8 Hz, 1 H, GlcNAc5’ H-1), 4.59-4.62 (m, 4 H, 
GlcNAc7 H-1, GlcNAc7’ H-1, Gal6 H-1, Gal6’ H-1), 4.50 (d, J = 7.6 Hz, 1 H, Gal8 H-1), 4.49 
(d, J = 7.6 Hz, 1 H, Gal8’ H-1), 4.29 (brs, 1 H, Man3 H-2), 4.23 (brs, 1 H), 4.20 (brs, 2 H), 4.13-
4.18 (m, 5 H), 3.51-4.03 (m, 88 H), 2.98 (dd, J = 17.2, 4.3 Hz, 1 H, Asn-βCH2), 2.91 (dd, J = 
17.3, 6.8 Hz, 1 H, Asn-βCH2), 2.81 (dd, J = 12.4, 4.5 Hz, 2 H, Neu5Ac H-3eq), 2.12 (s, 3 H, Ac), 
2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 12 H, 4 Ac), 2.05 (s, 3 H, Ac), 1.85 (t, J = 12.4 Hz, 2 
H, Neu5Ac H-3ax).





































BA-21   
HILIC-ELSD, TR = 23.996 min. 
 
ESI-MS, calculated 3650.3555; found [M+4H]4+ 913.5821, [M+3H]3+ 1217.7748. 
1H NMR (D2O, 500 MHz): 5.16 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.6 Hz, 1 H, GlcNAc1 H-1), 
4.98 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.74 (d, J = 7.3 Hz, 2 H, 
GlcNAc 2 H-1, GlcNAc5 H-1), 4.63-4.66 (m, 3 H, GlcNAc5’ H-1, GlcNAc7 H-1, GlcNAc7’ H-
1), 4.45-4.50 (m, 4 H, Gal6 H-1, Gal6’ H-1, Gal8 H-1, Gal8’ H-1), 4.29 (brs, 1 H, Man3 H-2), 
4.22 (brs, 1 H), 4.20 (brs, 2 H), 4.15 (m, 2 H), 3.51-4.05 (m, 101 H), 2.98 (dd, J = 17.2, 3.6 Hz, 1 
H, Asn-βCH2), 2.90 (dd, J = 17.3, 6.5 Hz, 1 H, Asn-βCH2), 2.68-2.71 (dd, 4 H, Neu5Ac H-3eq), 
2.11 (s, 3 H, Ac), 2.09 (s, 6 H, 2 Ac), 2.08 (s, 3 H, Ac), 2.06 (s, 12 H, 4 Ac), 2.04 (s, 3 H, Ac), 
1.71-1.77 (m, 4 H, Neu5Ac H-3ax). 
  





































BA-22   
HILIC-ELSD, TR = 25.652 min. 
 
ESI-MS, calculated 3714.3352; found [M+4H]4+ 929.5767, [M+3H]3+ 1239.1026. 
 
1H NMR (D2O, 500 MHz): 5.17 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.8 Hz, 1 H, GlcNAc1 H-1), 
4.98 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.75 (d, J = 7.6 Hz, 2 H, 
GlcNAc 2 H-1, GlcNAc5 H-1), 4.63-4.66 (m, 3 H, GlcNAc5’ H-1, GlcNAc7 H-1, GlcNAc7’ H-
1), 4.47-4.51 (m, 4 H, Gal6 H-1, Gal6’ H-1, Gal8 H-1, Gal8’ H-1), 4.30 (brs, 1 H, Man3 H-2), 
4.21-4.23 (m, 4 H), 4.15-4.17 (m, 4 H), 3.54-4.03 (m, 106 H), 2.98 (dd, J = 17.3, 4.3 Hz, 1 H, 
Asn-βCH2), 2.90 (dd, J = 17.3, 7.0 Hz, 1 H, Asn-βCH2), 2.73 (dd, J =12.3, 4.3 Hz, 4 H, Neu5Gc 
H-3eq), 2.12 (s, 3 H, Ac), 2.11 (s, 3 H, Ac), 2.10 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, 
Ac), 2.05 (s, 3 H, Ac), 1.74-1.80 (m, 4 H, Neu5Gc H-3ax). 
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BA-23   
HILIC-ELSD, TR = 23.283 min. 
 
ESI-MS, calculated 3650.3555; found [M+4H]4+ 913.5816, [M+3H]3+ 1217.7743. 
 
1H NMR (D2O, 500 MHz): 5.17 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 
4.99 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.72 (d, J = 8.2 Hz, 2 H, 
GlcNAc 2 H-1, GlcNAc5 H-1), 4.63-4.66 (m, 3 H, GlcNAc5’ H-1, GlcNAc7 H-1, GlcNAc7’ H-
1), 4.59 (d, J = 7.8 Hz, 2 H, Gal6 H-1, Gal6’ H-1), 4.46-4.48 (m, 2 H, Gal8 H-1, Gal8’ H-1), 
4.30 (brs, 1 H, Man3 H-2), 4.23 (d, J = 1.9 Hz, 1 H), 4.21 (brs, 2 H), 4.14-4.17 (m, 3 H), 3.51-
4.04 (m, 100 H), 2.98 (dd, J = 17.2, 4.2 Hz, 1 H, Asn-βCH2), 2.90 (dd, J = 17.3, 7.0 Hz, 1 H, 
Asn-βCH2), 2.80 (dd, J =12.5, 4.5 Hz, 2 H, Neu5Ac H-3eq), 2.68-2.72 (m, 2 H, Neu5Ac H-3eq), 
2.12 (s, 3 H, Ac), 2.11 (s, 3 H, Ac), 2.10 (s, 3 H, Ac), 2.07 (s, 18 H, 6 Ac), 2.05 (s, 3 H, Ac), 1.84 
(t, J = 12.5 Hz, 2 H, Neu5Ac H-3ax), 1.75 (t, J = 12.1 Hz, 2 H, Neu5Ac H-3ax).  






































BA-24   
HILIC-ELSD, TR = 21.225 min. 
 
MALDI-MS, calculated 2485.9738; found [M+Na]+ 2507.573, [M+K]+ 2523.541.   
 
1H NMR (D2O, 500 MHz): 5.16 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 
4.97 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.74 (d, J = 8.3 Hz, 2 H, 
GlcNAc 2 H-1, GlcNAc5 H-1), 4.65 (d, J = 7.8 Hz, 1 H, GlcNAc5’ H-1), 4.61 (d, J = 7.7 Hz, 2 
H, GlcNAc7 H-1, GlcNAc7’ H-1), 4.49-4.53 (m, 4 H, Gal6 H-1, Gal6’ H-1, Gal8 H-1, Gal8’ H-
1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (d, J = 2.1 Hz, 1 H), 4.20 (brs, 2 H), 4.14 (d, J = 2.3 Hz, 1 
H), 3.51-4.03 (m, 74 H), 2.98 (dd, J = 17.3, 4.3 Hz, 1 H, Asn-βCH2), 2.90 (dd, J = 17.3, 6.8 Hz, 
1 H, Asn-βCH2), 2.80 (dd, J =12.5, 4.5 Hz, 2 H, Neu5Ac H-3eq), 2.68-2.72 (m, 2 H, Neu5Ac H-
3eq), 2.12 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 3 H, Ac), 2.06 (s, 3 H, Ac), 
2.05 (s, 3 H, Ac).  























BA-25   
HILIC-ELSD, TR = 22.644 min. 
 
MALDI-MS, calculated 3216.2382; found [M+Na]+ 3238.343, [M+K]+ 3254.335. 
 
1H NMR (D2O, 500 MHz): 5.15 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 
4.96 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.74 (d, J = 8.2 Hz, 3 H, 
GlcNAc 2 H-1, GlcNAc5 H-1, GlcNAc5’ H-1), 4.65 (d, J = 7.8 Hz, 1 H, GlcNAc7 H-1), 4.62 (d, 
J = 7.6 Hz, 2 H, GlcNAc7’ H-1, GlcNAc8 H-1), 4.47-4.53 (m, 7 H, GlcNAc8’ H-1, Gal6 H-1, 
Gal6’ H-1, Gal8 H-1, Gal8’ H-1, Gal10 H-1, Gal10’ H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (brs, 
1 H), 4.19 (brs, 4 H), 4.14 (d, J = 1.8 Hz, 1 H), 3.51-4.04 (m, 96 H), 2.97 (dd, J = 17.2, 4.3 Hz, 1 
H, Asn-βCH2), 2.90 (dd, J = 17.3, 6.8 Hz, 1 H, Asn-βCH2), 2.11 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 
2.08 (s, 3 H, Ac), 2.07 (s, 12 H, 4 Ac), 2.05 (s, 3 H, Ac).  



























BA-26   
HILIC-ELSD, TR = 22.564 min. 
 
MALDI-MS, calculated 2810.0795; found [M+Na]+ 2831.924, [M+K]+ 2847.912. 
 
1H NMR (D2O, 500 MHz): 5.19 (d, J = 3.7 Hz, Gal-9 H-1, Gal9’ H-1), 5.16 (s, 1 H, Man4 H-
1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.97 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with 
D2O, Man3 H-1), 4.74 (d, J = 8.2 Hz, 2 H, GlcNAc 2 H-1, GlcNAc5 H-1), 4.65 (d, J = 7.8 Hz, 1 
H, GlcNAc5’ H-1), 4.58-4.63 (m, 4 H, GlcNAc7 H-1, GlcNAc7’ H-1, Gal6 H-1, Gal6’ H-1), 
4.50 (d, J = 7.6 Hz, 1 H, Gal8 H-1), 4.49 (d, J = 7.5 Hz, 1 H, Gal8’ H-1), 4.29 (brs, 1 H, Man3 
H-2), 4.20-4.24(m, 7 H), 4.14 (brs, 1 H), 4.05-4.06 (m, 2 H), 3.97-4.04 (m, 8 H), 3.69-3.91 (m, 
60 H), 3.51-3.56 (m, 2 H), 2.98 (dd, J = 17.2, 4.3 Hz, 1 H, Asn-βCH2), 2.91 (dd, J = 17.3, 6.8 
Hz, 1 H, Asn-βCH2), 2.12 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 6 H, 2 Ac), 
2.05 (s, 3 H, Ac). 
























BA-27   
HILIC-ELSD, TR = 23.654 min. 
 
MALDI-MS, calculated 3540.3439; found [M+Na]+ 3562.375, [M+K]+ 3578.362. 
 
1H NMR (D2O, 500 MHz): 5.18 (d, J = 3.7 Hz, Gal-11 H-1, Gal11’ H-1), 5.16 (s, 1 H, Man4 
H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.97 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap 
with D2O, Man3 H-1), 4.74-4.76 (m, 3 H, GlcNAc 2 H-1, GlcNAc5 H-1, GlcNAc5’ H-1), 4.65 
(d, J = 7.8 Hz, 1 H, GlcNAc7 H-1), 4.58-4.62 (m, 5 H, , GlcNAc7’ H-1, GlcNAc9 H-1, 
GlcNAc9’ H-1, Gal6 H-1, Gal6’ H-1), 4.48-4.52 (m, 4 H, Gal8 H-1, Gal8’ H-1, Gal10 H-1, 
Gal10’ H-1), 4.29 (brs, 1 H, Man3 H-2), 4.20-4.24(m, 8 H), 4.14 (d, J = 2.2 Hz, 1 H), 4.05-4.06 
(m, 2 H), 3.50-4.03 (m, 103 H), 2.98 (dd, J = 17.3, 4.3 Hz, 1 H, Asn-βCH2), 2.90 (dd, J = 17.3, 
6.8 Hz, 1 H, Asn-βCH2), 2.12 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 12 H, 4 
Ac), 2.05 (s, 3 H, Ac). 

























BA-28    
HILIC-ELSD, TR = 22.891 min. 
MALDI-MS, calculated 2778.0897; found [M+Na]+ 2799.728, [M+K]+ 2815.709. 
 
1H NMR (D2O, 500 MHz): 5.14-5.16 (m, 3 H, Fuc H-1, Man4 H-1), 5.10 (d, J = 9.7 Hz, 1 H, 
GlcNAc1 H-1), 4.95 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.74 (d, J 
= 8.0 Hz, GlcNAc 2 H-1), 4.62-4.66 (m, 3 H, GlcNAc5 H-1, GlcNAc5’ H-1, GlcNAc7 H-1), 
4.51-4.53 (m, 3 H, GlcNAc7’ H-1, Gal6 H-1, Gal6’ H-1), 4.47 (d, J = 7.6 Hz, 1 H, Gal8 H-1), 
4.46 (d, J = 7.6 Hz, 1 H, Gal8’ H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (d, J = 2.3 Hz, 1 H), 4.14 
(brs, 3 H), 3.50-4.04 (m, 81 H), 2.98 (dd, J = 17.2, 4.3 Hz, 1 H, Asn-βCH2), 2.90 (dd, J = 17.2, 
6.8 Hz, 1 H, Asn-βCH2), 2.12 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.06 (s, 9 H, 3 Ac), 2.05 (s, 3 H, 
Ac), 1.19 (d, J = 6.2 Hz, 3 H, Fuc CH3), 1.18 (d, J = 6.2 Hz, 3 H, Fuc CH3).  
























BA-29       
HILIC-ELSD, TR = 23.063 min. 
 
ESI-MS, calculated 3360.2805; found [M+3H]3+ 1121.0820. 
 
1H NMR (D2O, 500 MHz): 5.14-5.16 (m, 3 H, Fuc5 H-1, Fuc5’ H-1, Man4 H-1), 5.11 (d, J = 
9.7 Hz, 1 H, GlcNAc1 H-1), 4.95 (s, 1 H, Man4’ H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-
1), 4.74 (d, J = 7.7 Hz, 1 H, GlcNAc 2 H-1), 4.59-4.66 (m, 5 H, , GlcNAc5 H-1, GlcNAc5’ H-1, 
GlcNAc7 H-1, GlcNAc7’ H-1, Gal6 H-1), 4.51 (d, J = 7.8 Hz, 1 H, Gal6’ H-1), 4.47 (d, J = 7.3 
Hz, 1 H, , Gal8 H-1), 4.46 (d, 1 H, Gal8’ H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (brs, 1 H), 4.16 
(d, J = 2.6 Hz, 1 H), 4.14 (brs, 4 H), 3.50-4.06 (m, 94 H), 2.97 (dd, J = 17.3, 4.3 Hz, 1 H, Asn-
βCH2), 2.90 (dd, J = 17.3, 6.8 Hz, 1 H, Asn-βCH2), 2.79 (dd, J = 12.4, 4.5 Hz, 2 H, Neu5Ac H-
3eq), 2.11 (s, 3 H, Ac), 2.07 (s, 6 H, 2 Ac), 2.06 (s, 12 H, 4 Ac), 2.05 (s, 3 H, Ac), 1.83 (t, J = 
12.4 Hz, 1 H, Neu5Ac H-3ax), 1.19 (d, J = 5.9 Hz, 3 H, Fuc CH3), 1.18 (d, J = 5.9 Hz, 3 H, Fuc 
CH3). 
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BA-30   
HILIC-ELSD, TR = 24.067 min. 
 
MALDI-MS, calculated 3070.2055; found [M+Na]+ 3091.861, [M+K]+ 3107.847. 
 
1H NMR (D2O, 500 MHz): 5.18 (d, J = 3.7 Hz, 2 H, Fuc H-1), 5.16 (s, 1 H, Man4 H-1), 5.15 
(d, J = 3.9 Hz, 2 H, Fuc H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.95 (s, 1 H, Man4’ H-1), 
4.87 (d, J = 6.7 Hz, 1 H, GlcNAc 2 H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.74 (d, J 
= 8.0 Hz, GlcNAc5 H-1), 4.62-4.66 (m, 3 H, GlcNAc5’ H-1, GlcNAc7 H-1, GlcNAc7’ H-1), 
4.50 (d, J = 7.8 Hz, 2 H, Gal6 H-1, Gal6’ H-1), 4.47 (d, J = 7.5 Hz, 1 H, Gal8 H-1), 4.46 (d, J = 
7.1 Hz, 1 H, Gal8’ H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (d, J = 1.9 Hz, 1 H), 4.14 (brs, 4 H), 
3.50-4.04 (m, 80 H), 2.98 (dd, J = 17.3, 4.4 Hz, 1 H, Asn-CH2), 2.91 (dd, J = 17.2, 6.8 Hz, 1 H, 
Asn-CH2), 2.12 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.06 (s, 6 H, 2 Ac), 2.05 (s, 6 H, 2 Ac), 1.21 (d, 
J = 6.6 Hz, 6 H, 2 Fuc CH3), 1.19 (d, J = 6.3 Hz, 3 H, Fuc CH3), 1.18 (d, J = 6.1 Hz, 3 H, Fuc 
CH3).






















BA-31   
HILIC-ELSD, TR = 24.016 min. 
MALDI-MS, calculated 3102.1953; found [M+Na]+ 3123.988, [M+K]+ 3139.978. 
 
1H NMR (D2O, 500 MHz): 5.18 (d, J = 3.7 Hz, 2 H, Gal9 H-1, Gal9’ H-1), 5.15 (s, 1 H, Man4 
H-1), 5.14 (d, J = 3.7 Hz, 2 H, Fuc H-1), 5.10 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.95 (s, 1 H, 
Man4’ H-1), 4.84 (d, J = 6.8 Hz, 1 H, GlcNAc 2 H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-
1), 4.74 (d, J = 7.6 Hz, 1 H, GlcNAc5 H-1), 4.58-4.66 (m, 5 H, GlcNAc5’ H-1, GlcNAc7 H-1, 
GlcNAc7’ H-1, Gal6 H-1, Gal6’ H-1), 4.47 (d, J = 7.2 Hz, 1 H, Gal8 H-1), 4.46 (d, J = 7.0 Hz, 1 
H, Gal8’ H-1), 4.29 (brs, 1 H, Man3 H-2), 4.21-4.24 (m, 5 H), 4.13 (m, 3 H), 3.51-4.06 (m, 80 
H), 2.98 (dd, J = 17.4, 4.1 Hz, 1 H, Asn-βCH2), 2.90 (dd, J = 17.4, 7.0 Hz, 1 H, Asn-βCH2), 2.11 
(s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 6 H, 2 Ac), 2.06(s, 6 H, 2 Ac), 2.05 (s, 3 H, Ac), 1.19 (d, J 
= 5.9 Hz, 3 H, Fuc CH3), 1.18 (d, J = 6.0 Hz, 3 H, Fuc CH3).  























BA-32  HILIC-ELSD, TR = 25.127 min. 
 
MALDI-MS, calculated 3394.3111; found [M+Na]+ 3416.201, [M+K]+ 3432.191. 
1H 
NMR (D2O, 500 MHz): 5.19 (d, J = 3.6 Hz, 4 H, Gal9 H-1, Gal9’ H-1, Fuc7 H-1, Fuc7’ H-1), 
5.16 (s, 1 H, Man4 H-1), 5.15 (d, J = 3.7 Hz, 2 H, Fuc5 H-1, Fuc5’ H-1), 5.11 (d, J = 9.8 Hz, 1 
H, GlcNAc1 H-1), 4.95 (s, 1 H, Man4’ H-1), 4.87 (d, J = 6.8 Hz, 1 H, GlcNAc 2 H-1), 4.81 (s, 1 
H, overlap with D2O, Man3 H-1), 4.75 (d, J = 8.2 Hz, 1 H, GlcNAc5 H-1), 4.62-4.66 (m, 3 H, 
GlcNAc5’ H-1, GlcNAc7 H-1, GlcNAc7’ H-1), 4.58 (d, J = 7.7 Hz, 2 H, , Gal6 H-1, Gal6’ H-1), 
4.45-4.48 (m, 2 H, Gal8 H-1, Gal8’ H-1), 4.29 (brs, 1 H, Man3 H-2), 4.20-4.25 (m, 5 H), 4.13 
(brs, 3 H), 3.50-4.06 (m, 88 H), 2.98 (dd, J = 17.4, 4.4 Hz, 1 H, Asn-βCH2), 2.91 (dd, J = 17.4, 
6.8 Hz, 1 H, Asn-βCH2), 2.12 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.06 (s, 12 H, 4 Ac), 1.22 (d, J = 
6.5 Hz, 6 H, 6 H, Fuc CH3), 1.20 (d, J = 5.9 Hz, 3 H, Fuc CH3), 1.19 (d, J = 5.8 Hz, 3 H, Fuc 
CH3). 





















BA-33   
HILIC-ELSD, TR = 25.084 min. 
 
MALDI-MS, calculated 3800.4699; found [M+Na]+ 3822.483, [M+K]+ 3838.475.
 
1H NMR (D2O, 500 MHz): 5.16 (brs, 5 H, Fuc7 H-1, Fuc7’ H-1, Fuc5 H-1, Fuc5’ H-1, Man4 
H-1), 5.11 (d, J = 9.8 Hz, 1 H, GlcNAc1 H-1), 4.95 (s, 1 H, Man4’ H-1), 4.85 (d, J = 6.8 Hz, 1 
H, GlcNAc 2 H-1), 4.81 (s, 1 H, overlap with D2O, Man3 H-1), 4.74 (d, J = 8.0 Hz, 2 H, 
GlcNAc5 H-1, GlcNAc5’ H-1), 4.62-4.66 (m, 3 H, GlcNAc7 H-1, GlcNAc7’ H-1, GlcNAc9 H-
1), 4.46-4.53 (m, 7 H, GlcNAc9’ H-1, Gal6 H-1, Gal6’ H-1, Gal8 H-1, Gal8’ H-1, Gal10 H-1, 
Gal10’ H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (brs, 1 H), 4.13 (m, 8 H), 3.50-4.04 (m, 109 H), 
2.97 (dd, J = 17.2, 3.3 Hz, 1 H, Asn-βCH2), 2.91 (dd, J = 17.2, 6.6 Hz, 1 H, Asn-βCH2), 2.12 (s, 
3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 9 H, 3 Ac), 2.05 (s, 9 H, Ac), 1.19 (d, J = 5.3 Hz, 12 H, 4 
Fuc CH3).  
























BA-34  HILIC-ELSD, TR = 26.016 min. 
 
MALDI-MS, calculated 4092.5857; found [M+Na]+ 4114.752, [M+K]+ 4130.760.  
 
1H NMR (D2O, 500 MHz): 5.15-5.18 (m, 7 H, Fuc5 H-1, Fuc5’ H-1, Fuc7 H-1, Fuc7’ H-1, 
Fuc9 H-1, Fuc9’ H-1, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.95 (s, 1 H, Man4’ 
H-1), 4.84-4.88 (m, 2 H, GlcNAc 2 H-1, GlcNAc5 H-1), 4.81 (s, 1 H, overlap with D2O, Man3 
H-1), 4.74 (d, J = 8.2 Hz, 2 H, GlcNAc5’ H-1, GlcNAc7 H-1), 4.62-4.66 (m, 3 H, GlcNAc7’ H-
1, GlcNAc9 H-1, GlcNAc9’ H-1), 4.45-4.51 (m, 6 H, Gal6 H-1, Gal6’ H-1, Gal8 H-1, Gal8’ H-
1, Gal10 H-1, Gal10’ H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (brs, 1 H), 4.14 (m, 7 H), 3.50-4.04 
(m, 118 H), 2.98 (dd, J = 17.2, 4.3 Hz, 1 H, Asn-βCH2), 2.91 (dd, J = 17.2, 6.7 Hz, 1 H, Asn-
βCH2), 2.12 (s, 3 H, Ac), 2.08 (s, 6 H, 2 Ac), 2.06 (s, 15 H, 5 Ac), 1.21 (d, J = 6.6 Hz, 6 H, 2 Fuc 
CH3), 1.19 (d, J = 6.1 Hz, 12 H, 4 Fuc CH3).  


























BA-35  HILIC-ELSD, TR = 25.860 min. 
 
MALDI-MS, calculated 4124.5755; found [M+Na]+ 4147.558, [M+K]+ 4163.586.  
1H 
NMR (D2O, 500 MHz): 5.18 (d, J = 3.8 Hz, 2 H, Gal11 H-1, Gal11’ H-1), 5.12-5.16 (m, 5 H, 
Fuc5 H-1, Fuc5’ H-1, Fuc7 H-1, Fuc7’ H-1, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-
1), 4.95 (s, 1 H, Man4’ H-1), 4.85 (d, J = 6.2 Hz, 2 H, GlcNAc 2 H-1, GlcNAc5 H-1), 4.81 (s, 1 
H, overlap with D2O, Man3 H-1), 4.74 (d, J = 8.1 Hz, 2 H, GlcNAc5’ H-1, GlcNAc7 H-1), 4.65 
(d, J = 7.9 Hz, 1 H, GlcNAc7’ H-1), 4.63 (d, J = 8.1 Hz, 1 H, GlcNAc9 H-1), 4.59 (d, J = 7.8 Hz, 
1 H, GlcNAc9’ H-1), 4.45-4.50 (m, 6 H, Gal6 H-1, Gal6’ H-1, Gal8 H-1, Gal8’ H-1, Gal10 H-1, 
Gal10’ H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22-4.24 (m, 5 H), 4.14 (brs, 5 H), 3.50-4.06 (m, 120 
H), 2.98 (dd, J = 17.3, 4.3 Hz, 1 H, Asn-βCH2), 2.90 (dd, J = 17.3, 6.8 Hz, 1 H, Asn-βCH2), 2.12 
(s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 9 H, 3 Ac), 2.05 (s, 9 H, 3 Ac), 1.19 (d, J = 6.1 Hz, 12 H, 
4 Fuc CH3).  





















BA-36  HILIC-ELSD, TR = 26.784 min. 
 
MALDI-MS, calculated 4416.6913; found [M+Na]+ 4439.416, [M+K]+ 4455.475. 
1H NMR (D2O, 500 MHz): 5.15-5.19 (m, 9 H, Gal11 H-1, Gal11’ H-1, Fuc5 H-1, Fuc5’ H-1, 
Fuc7 H-1, Fuc7’ H-1, Fuc9 H-1, Fuc9’ H-1, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-
1), 4.95 (s, 1 H, Man4’ H-1), 4.84-4.87 (m, 2 H, GlcNAc 2 H-1, GlcNAc5 H-1), 4.81 (s, 1 H, 
overlap with D2O, Man3 H-1), 4.75 (d, J = 8.0 Hz, 2 H, GlcNAc5’ H-1, GlcNAc7 H-1), 4.62-
4.66 (m, 2 H, GlcNAc7’ H-1, GlcNAc9 H-1), 4.57 (d, J = 7.7 Hz, 2 H, GlcNAc9’ H-1, Gal6 H-
1), 4.46-4.49 (m, 5 H, Gal6’ H-1, Gal8 H-1, Gal8’ H-1, Gal10 H-1, Gal10’ H-1), 4.29 (brs, 1 H, 
Man3 H-2), 4.22-4.25 (m, 5 H), 4.14 (brs, 5 H), 3.50-4.06 (m, 128 H), 2.98 (dd, J = 17.4, 4.2 Hz, 
1 H, Asn-βCH2), 2.91 (dd, J = 17.4, 6.8 Hz, 1 H, Asn-βCH2), 2.12 (s, 3 H, Ac), 2.08 (s, 6 H, 2 
Ac), 2.06 (s, 15 H, 5 Ac), 1.19 (d, J = 6.0 Hz, 18 H, 6 Fuc CH3). 





















3.2 Decoding glycan protein interactions by a new class of asymmetric N-glycans.  
3.2.1 Introduction 
N-linked glycans are the sugar chains bonded to a peptide and a protein through the side 
chain of asparagine residue, which is a predominant protein modification in eukaryotes, also 
widely exists in archaea, but is very rare in eubacteria [60-62]. N-glycans are involved in many 
crucial biological functions such as protein folding, degradation [63-65], cell differentiation, cell 
adhesion, host-pathogen interaction and cancer metastasis[66-68]. In nature, N-glycans possess 
an inherited complexity and diversity. In mammalian cells, N-glycans have numerous structures 
which usually contain different glycan epitopes (sugar residues linked to each other in a specific 
sequence) in different branches [31]. Since glycan epitopes are usually the binding partners of 
specific antibodies or glycan-binding proteins (e.g. lectins), the study of binding pattern of a 
glycan epitope in an asymmetric N-glycan will deepen our understanding of the roles of context 
in glycan-binding events involving asymmetric N-glycans. 
Owing to the structural microheterogeneity, it is difficult to acquire homogeneous and 
structurally defined N-glycans from natural source. Although synthetic efforts on symmetric N-
glycans are prominent [37, 69-73], unfortunately, due to structural complexity, strategies for 
chemically or chemoenzymatically synthesis of asymmetrically branched N-glycans are very 
limited. By chemical synthesis of core structure and enzymatic extension of terminal epitopes, a 
group of asymmetric single- or bi-antennary N-glycans was synthesized with terminal glycan 
epitopes reported by our gourp [32]. With the aid of orthogonal protection groups, Boons group 
achieved synthesis of tri-antennary N-glycans with distinctive appendages to different branches 
[32]. Later, they further developed the strategy by incorporation of unnatural glycosyl linkages to 
fulfil selective installation of distinct appendages at different branching points [74]. Based on the 
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limited accessibility of asymmetrically branched N-glycans, glycan-binding studies involving 
asymmetric N-glycans [32] are rare, although glycan microarray studies has burst over the past 
two decades [8]. To find out more about the binding pattern of glycan epitopes in asymmetric N-
glycans, herein, we produced a new class of asymmetric single- or bi-antennary N-glycans in 
which one branch is terminated by a tetrasaccharide motif (Man2GlcNAc2) in the core 
pentasaccharide of mammalian N-glycans, and investigated the binding pattern. 
The synthesis was achieved by employing a mutant of EndoM, an endo-β-N-
acetylglucosaminidases (ENGases) from Mucor hiemali that can hydrolyze the N,N'-
diacetylchitobiose moiety in the core pentasacharide of mammalian N-glycans. The mutant EndoM 
N175Q, which has a decreased hydrolytic activity, can transfer natural N-glycans or oxazoline N-
glycans to any peptide or protein with a GlcNAc residue to form a β1–4-glycosidic linkage, hence 
becoming a useful tool in the synthesis of homogeneous glycopeptides and glycoproteins [75-77]. 
Lai-Xi Wang and co-workers found that ENGase-based glycosynthases can synthesize a class of 
symmetric N-glycan clusters with isolated glycan as donor and acceptor [30]. We herein report a 
strategy to chemoenzymatically synthesize a new class of homogeneous and structurally well-
defined asymmetric N-glycans to investigate the influence of context on the binding to terminal 
glycan epitope. This class of asymmetric N-glycans contains core glycan motifs at both core 
position and terminal position (red rectangles in Groups A and B in Scheme 3.4, blue rectangles 
in Groups C and D in Scheme 3.5), and may serve as a good candidate for deep exploration of the 




Scheme 3. 4 Groups A and B glycans were synthesized by EndoM N175Q with α1-3Man branch 
glycan oxazoline as donor. 
 (**: Conversion rate was not calculated because the peak of starting material 7 is overlapped 




Scheme 3. 5 Groups C and D glycans were synthesized by EndoM N175Q with α1-6Man branch 
glycan oxazoline as donor. 
(N/A: No product isolated, hence yield is not applicable; **: Conversion rate was not calculated 
because the peak of starting material 7 is overlapped with peak of impurity). 
 
3.2.2 Experimental Methods 
General methods for HPLC analysis and purification of N-glycans 
1) General methods for HILIC-ELSD analysis of N-glycans 
Column: Waters XBridge BEH amide column, 130 Å, 5 µm, 4.6 mm × 250 mm 
Solvent A: 100 mM ammonium formate, pH 3.4 





Gradient elution: Time  B%  Flow rate (mL/min) 
   0  65  1 
   25  50  1 
   26  0  0.5 
   27  0  0.5 
   28  65  1 
   30  65  1 
Monitor: Evaporative light scattering detector, 60°C (Shimadzu ELSD-LTII) 
2) General methods for HILIC-UV210nm purification of N-glycans (1a-9a, 2b, 6b, 7b) 
Column: Waters XBridge BEH amide column, 130 Å, 5 µm, 4.6 mm × 250 mm 
Solvent A: 100 mM ammonium formate, pH 3.4 
Solvent B: Acetonitrile 
Temperature: 40°C 
Gradient elution: Time  B%  Flow rate (mL/min) 
   0  65  1 
   25  50  1 
   26  0  0.5 
   27  0  0.5 
   28  65  1 
   30  65  1 
Monitor: A210nm 
3) Methods for HILIC-UV210nm purification of N-glycans (10b) 
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Column: Waters XBridge BEH amide column, 130 Å, 5 µm, 10 mm × 250 mm 
Solvent A: 100 mM ammonium formate, pH 3.4 
Solvent B: Acetonitrile 
Temperature: 40°C 
Gradient elution: Time  B%  Flow rate (mL/min) 
   0  65  4 
   25  50  4 
   26  0  2 
   27  0  2 
   28  65  4 
   30  65  4 
Monitor: A210nm 
General methods for mass spectrometry analyses 
1) Method of ESI-MS analyses 
ESI-MS experiments were performed on an LTQ-Orbitrap Elite mass spectrometer 
(Thermo Fisher) equipped with EASY-spray source and nano-LC UltiMate 3000 high performance 
liquid chromatography system (Thermo Fisher). Samples were transmitted into MS with a silica 
column. LTQ-Orbitrap Elite mass spectrometer was operated in the data dependent mode. A full-
scan survey MS experiment (m/z range from 375 to 1600; automatic gain control target, 1,000,000 
ions; resolution at 400 m/z, 240,000; maximum ion accumulation time, 200 ms) was acquired by 
the Orbitrap mass spectrometer. 
2) Method of MALDI-TOF MS analyses 
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MALDI-TOF MS analyses were performed on UltrafleXtreme MALDI TOF/TOF Mass 
Spectrometer (Bruker). Scan range of MS1 was set according to the molecular weight of N-glycans, 
and reflector mode was used for N-glycan analysis. Mass spectra were obtained in both positive 
and negative extraction mode with the following voltage settings: ion source 1 (19.0 kV), ion 
source 2 (15.9 kV), and lens (9.3 kV). The reflector voltage was set to 20 kV. The laser was pulsed 
at 7 Hz and the pulsed ion extraction time was set at 400 ns. The laser power was kept in the range 
of 25–40%. 
Synthesis of acceptor N-glycans, N-glycan oxazolines (as donor) and deacetylation of 
asymmetric N-glycan products 
1) Synthesis of acceptor N-glycans 
The acceptor N-glycans were prepared as previously described [32].  
2) Synthesis of N-glycan oxazolines 
Materials: All chemicals were purchased as reagent grade and used without further 
purification. Anhydrous dichloromethane (CH2Cl2), acetonitrile (CH3CN), tetrahydrofuran 
(THF), N,N-dimethyl formamide (DMF), toluene, and methanol (MeOH) were purchased from a 
commercial source without further distillation. Pulverized Molecular Sieves MS-4 Å (Aldrich) 
for glycosylation was activated by heating at 350oC for 3 h. Reactions were monitored by 
analytical thin-layer chromatography (TLC) in EM silica gel 60 F254 plates and visualized under 
UV (254 nm) and/or by staining with acidic ceric ammonium molybdate or p-anisadehyde. Flash 
chromatography was performed on silica gel (Merck) of 40–63μm particle size and P2 gel 
(Biorad). 1H NMR spectra were recorded on a Bruker AVANCE 400 (400 MHz), and Bruker 
AVANCE 500 (500 MHz) spectrometer at 25oC. All 1H Chemical shifts (in ppm) were assigned 
according to CDCl3 (δ= 7.24 ppm) and D2O (δ = 4.79 ppm). 13C NMR spectra were obtained 
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with Bruker AVANCE 600 spectrometer and calibrated with CDCl3 (δ = 77.00 ppm). Coupling 
constants (J) are reported in hertz (Hz). Splitting patterns are described using the following 
abbreviations: s, singlet; brs, broad singlet; d, doublet; t, triplet; q, quartet; dd, doublet of 
doublet; m, multiplet. 1H NMR spectra are reported in the following order: chemical shift, 
multiplicity, coupling constant(s), and number(s) of protons. All NMR signals were assigned on 
the basis of 1H NMR, COSY, HSQC, HMQC, and 13C NMR experiments. High resolution 






Synthesis of N-glycan oxazolines. 
Reagents and conditions: a: DDQ, phosphate buffer (pH 7.0), DCM, 89%; b: BnBr, NaH, 
DMF, 90%; c: PhBCl2, Et3SiH, DCM, -78oC, 92%; d: NIS, AgOTf, 4 Å MS, DCM, 0oC, 16: 
95%; 19: 88%; e: (i) ethylenediamine, n-butanol, 90oC, 10 h; (ii): Py, Ac2O, over two steps, 17: 
65%; 20: 63%; f: Pd(OH)2, H2, MeOH, 90%; g: 2-chloro-1,3-dimethylimidazolinium chloride 
(DMC), Et3N, H2O, quantitative; h: (i): MeONa, MeOH; (ii): Pd(OH)2, H2, MeOH, over two 
steps, 85%. 
For the synthesis of N-glycan oxazolines (a and b), we adopted the same synthetic 
strategy to install the mannose residue at the 3- and 6-positions of the β-mannose moiety 
(Scheme S1). We envisaged that disaccharide 11 containing a crucial β-mannoside would be a 
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versatile precursor for the synthesis of N-glycan oxazolines, which can transform to disaccharide 
acceptors 12 and 14 by sequential introducing and removal of the protecting groups. The 
versatile precursor disaccharide 11 and donor fragment 15 were prepared as previously reported. 
To synthesize oxazoline a, thioether donor 15 was stereoselectively installed onto C3-hydroxyl 
of disaccharide 12 in the presence of N-iodosuccinimide (NIS)/AgOTf with a yield of 95%. The 
two phthalimides of 16 were then converted into acetamides in two steps by treatment with 
hydrazine hydrate followed by acetylation with Ac2O/pyridine to afford 17, which was subject to 
the removal of acetyl group by MeONa/MeOH and the global deprotection of Bn and 
benzylidene acetal by catalytic hydrogenolysis with Pd(OH)2/H2 in MeOH/H2O (10:1) to give 
the trisaccharide 36. Following Wang’s method, treatment of 18 with an excess of 2-chloro-1,3-
dimethylimidazolinium chloride (DMC) and Et3N in water afforded the desired sugar oxazoline 
a in quantitative yield, which was readily purified by gel filtration on a Sephadex G-15 column. 
Similarly, sugar oxazoline b was synthesized by installing 15 onto C6-hydroxyl of β-man of 14, 






deoxy-phthalimido-β-D-glucopyranoside (12): The compound 11 (1.67 g, 1.61 mmol) was 
dissolved in CH2Cl2 (30 mL) and phosphate buffer (6 mL, pH 7), and DDQ (729 mg, 3.21 mmol) 
was added at 0°C. The reaction mixture was allowed to warm to room temperature for 3 h before 
it was quenched with saturated aqueous NaHCO3, washed with brine, dried over Na2SO4, and 
concentrated. The residue was purified by chromatography on a silica gel column to afford the 
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desired product 31 (1.36 g, 89%). [α]D20 5.68 (c 1, CH2Cl2); 1H NMR (CDCl3, 400 MHz):  7.68-
7.71 (m, 2 H), 7.52-7.54 (m, 2 H), 7.35-7.46 (m, 14 H), 7.22-7.24 (m, 1 H), 7.09-7.15 (m, 5 H), 
6.98-7.01 (m, 2 H), 6.89-6.93 (m, 3 H), 5.50 (s, 1 H), 5.20-5.22 (m, 1 H), 5.06 (d, J = 11.6 Hz, 1 
H), 4.93 (d, J = 12.4 Hz, 1 H), 4.85 (d, J = 12.4 Hz, 1 H), 4.84 (d, J = 12.1 Hz, 1 H), 4.75 (d, J = 
11.6 Hz, 1 H), 4.70 (s, 1 H), 4.58 (d, J = 12.4 Hz, 1 H), 4.56 (d, J = 12.0 Hz, 1 H), 4.49 (d, J = 
12.3 Hz, 1 H), 4.31-4.33 (m, 2 H), 4.27 (dd, J = 10.6, 5.0 Hz, 1 H), 4.14-4.20 (m, 1 H), 3.78-3.80 
(m, 2 H), 3.74-3.75 (m, 2 H), 3.56-3.61 (m, 3 H), 3.18-3.23 (m, 1 H); 13C NMR (CDCl3, 100 
MHz): d 167.8, 138.8, 138.3, 137.8, 137.4, 137.2, 133.7, 129.2, 129.1, 128.7, 128.6, 128.3, 
128.2, 128.1, 128.0 (2 C), 127.9, 127.8, 127.7 (2 C), 127.0, 126.4, 125.4, 123.3, 102.1, 102.0, 
97.5, 79.6, 79.2, 78.9, 77.5, 77.2, 77.1, 76.9, 75.7, 74.8, 74.6, 73.8, 71.0, 70.8, 68.6, 68.5, 67.0, 
55.8. MALDI-MS: [M+Na]+ C55H53NO12Na calcd for 942.3465, found 942.4147. 
 
Benzyl 2,3-O-di-benzyl-4,6-O-benzylidene-β-D-Mannopyranosyl-(1→4)-3,6-O-di-
benzyl-2-deoxy-phthalimido-β-D-glucopyranoside (13): Compound 12 (1 g, 1.09 mmol) was 
dissolved in dry DMF (15 mL). NaH (78 mg, 1.96 mmol), Bu4NI (36 mg, 0.1 mmol), followed 
by BnBr (194 μL, 1.64 mmol) were added at 0°C, the reaction mixture was stirred under argon 
for 4 h. The solvent was evaporated, and the residue was diluted with ethyl acetate and washed 
with water and a brine solution. After dried over Na2SO4, the organic layer was evaporated. The 
residue was purified on a silica gel column (Hexanes: EtOAc = 5:1) to afford the desired product 
13 (989 mg, 90%) as colorless oil.  [α]D20 10.7 (c 1, CH2Cl2); 1H NMR (CDCl3, 400 MHz):  
7.70 (brs, 2 H), 7.52-7.59 (m, 4 H), 7.35-7.43 (m, 18 H), 7.11-7.16 (m, 5 H), 6.98-6.99 (m, 2 H), 
6.87-6.91 (m, 3 H), 7.98 (s, 1 H), 5.20 (d, J = 7.8 Hz, 1 H), 4.91-4.95 (m, 3 H), 4.87 (d, J = 12.3 
Hz, 1 H), 4.81 (d, J = 12.4 Hz, 1 H), 4.75 (d, J = 12.0 Hz, 1 H), 4.66 (d, J = 12.4 Hz, 1 H), 4.63 
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(d, J = 8.8 Hz, 1 H), 4.57 (d, J = 12.4 Hz, 1 H), 4.50 (d, J = 12.4 Hz, 1 H), 4.48 (d, J = 12.1 Hz, 1 
H), 4.29-4.32 (m, 2 H), 4.26 (dd, J = 10.4, 4.6 Hz, 1 H), 4.17 (dd, J = 7.1, 4.3 Hz, 1 H), 4.11 (dd, 
J = 9.2, 2.8 Hz, 1 H), 3.82 (d, J = 2.8 Hz, 1 H), 3.75 (dd, J = 10.6, 0.8 Hz, 1 H), 3.62-3.66 (m, 2 
H), 3.53-3.56 (m, 1 H), 3.49 (dd, J = 9.8, 2.9 Hz, 1 H), 3.18-3.24 (m, 1 H); 13C NMR (CDCl3, 
100 MHz): d 167.8, 138.8, 138.7 (2 C), 137.9, 137.7, 137.3, 133.7, 131.7, 129.1, 128.9, 128.6, 
128.4 (2 C), 128.3 (2 C), 128.2 (3 C), 128.0, 127.9, 127.8, 127.7, 127.6 (2 C), 127.5, 127.0, 
126.2, 123.3, 102.0, 101.4, 97.5, 79.5, 78.8, 78.4, 77.1, 77.0, 75.1, 74.8, 74.7, 73.7, 72.6, 70.8, 





phthalimido-β-D-glucopyranoside (14): A mixture of compound 13 (300 mg, 0.297 mmol) and 4 
Å molecular sieves in dry CH2Cl2 (20 mL) was stirred at room temperature under argon for 2 h. 
Et3SiH (142 μL, 0.892 mmol) and PhBCl2 (116 μL, 0.892 mmol) were added at -78°C. The 
reaction mixture was stirred at -78oC for 1 h and quenched upon addition of solid NaHCO3 and 
MeOH. The resulting mixture was filtered. The filtrate was diluted with CH2Cl2 and washed with 
aqueous NaHCO3, brine, dried over Na2SO4, and concentrated. The residue was purified on a 
silica gel column (EA: Hex =1:3) to afford the product 14 (276 mg, 92%). [α]D20 -4.68 (c 1, 
CH2Cl2); 1H NMR (CDCl3, 400 MHz):  7.70 (brs, 2 H), 7.50-7.52 (m, 2 H), 7.28-7.41 (m, 20 
H), 7.09-7.11 (m, 5 H), 6.92-6.98 (m, 5 H), 5.23 (d, J = 7.9 Hz, 1 H, GlcNAc-H-1), 4.94-4.99 
(m, 4 H), 4.88 (d, J = 12.4 Hz, 1 H), 4.76 (d, J = 12.1 Hz, 1 H), 4.48-4.66 (m, 7 H), 4.30-4.37 (m, 
2 H), 4.10 (t, J = 9.4 Hz, 1 H), 3.80-3.89 (m, 4 H), 3.74 (dd, J = 11.0, 3.3 Hz, 1 H), 3.63-3.67 (m, 
1 H), 3.54 (dd, J = 11.7, 5.7 Hz, 1 H), 3.44 (dd, J = 9.4, 2.7 Hz, 1 H), 3.27-3.31 (m, 1 H); 13C 
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NMR (CDCl3, 100 MHz): d 167.9, 138.8, 138.6, 138.4, 137.9, 137.3, 133.8, 131.7, 128.6, 128.5, 
128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7 (3 C), 127.6 (2 C), 127.5, 127.1, 123.3, 101.0, 
97.5, 82.6, 78.9, 77.0, 75.8, 75.2, 75.1, 74.9, 74.8, 74.5 (2 C), 73.7, 71.8, 70.8, 68.7, 62.4, 55.8; 





glucopyranoside (16): A mixture of donor 15 (90 mg, 0.167 mmol), acceptor  12 (130 mg, 0.129 
mmol) and 4 Å molecular sieves in dry CH2Cl2 was stirred at room temperature under argon for 
1 h. NIS (49 mg, 0.219 mmol) and AgOTf (5 mg, 0.019 mmol) were added at 0°C. The reaction 
mixture was stirred at 0°C for 0.5 h before it was quenched with a few drops of triethylamine. 
The resulting mixture was filtered. The filtrate was diluted with CH2Cl2 and washed with 5% 
Na2S2O3, aqueous NaHCO3, brine, dried over Na2SO4, and concentrated. The residue was 
purified on a silica gel column to get the desired title compound 16 (181 mg, 95%) as white 
foam. [α]D20 6.38 (c 1, CH2Cl2); 1H NMR (CDCl3, 400 MHz):  7.70-7.73 (m, 2 H), 7.55-7.60 
(m, 4 H), 7.32-7.50 (m, 28 H), 7.14-7.23 (m, 5 H), 7.05-7.07 (m, 2 H), 6.96-6.99 (m, 3 H), 5.77 
(brs, 1 H), 5.64 (s, 1 H), 5.48 (d, J = 0.8 Hz, 1 H), 5.28 (d, J = 7.8 Hz, 1 H), 4.92-5.05 (m, 5 H), 
4.83 (d, J = 11.2 Hz, 1 H), 4.79 (d, J = 11.9 Hz, 1 H), 4.76 (d, J = 11.8 Hz, 1 H), 4.74 (d, J = 8.9 
Hz, 1 H), 4.51-4.66 (m, 6 H), 4.40 (t, J = 4.4 Hz, 2 H), 4.32 (dd, J = 10.4, 4.7 Hz, 1 H), 4.19-4.23 
(m, 2 H), 4.12-4.15 (m, 1 H). 3.99-4.00 (m, 2 H), 3.94-3.97 (m, 2 H), 3.88-3.91 (m, 1 H), 3.80 (t, 
J = 10.5 Hz, 2 H), 3.65-3.69 (m, 2 H), 3.58-3.61 (m, 2 H), 3.19-3.25 (m, 1 H), 2.22 (s, 3 H, Ac); 
13C NMR (CDCl3, 100 MHz):  170.1, 138.9, 138.7, 138.5, 138.3, 138.0, 137.9, 137.5, 137.3, 
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133.8, 131.8, 128.9, 128.8, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0 (2 C), 127.9, 127.8 (3 
C), 127.1, 126.2, 123.3, 101.7, 101.2, 98.9, 97.6, 79.1, 78.8, 78.4, 78.1, 77.6, 75.7, 75.5, 75.2, 
75.0, 74.6, 74.4, 73.7, 73.6, 72.5, 71.7, 70.9 (2 C), 69.3, 68.5, 68.3, 67.1, 55.9, 21.1; MALDI-





glucopyranoside (17): The compound 16 (150 mg, 0.101 mmol) was dissolved in nBuOH at 
room temperature, followed by addition of ethylenediamine (nBuOH: ethylenediamine = 2:1). 
After being stirred at 90°C for 12 h, the mixture was evaporated in vacuo to give a residue for the 
next step without further purification. To a solution of the residue in pyridine was added Ac2O. 
After being stirred at room temperature for 12 h, the solution was diluted with EtOAc and 
washed with aqueous HCl (1 M), saturated aqueous NaHCO3, and brine solution. The organic 
layer was dried over Na2SO4, filtered, and evaporated in vacuo to give a residue, which was 
purified by silica gel column chromatography to give compound 17 (85 mg, 65% over two 
steps). [α]D20 1.60 (c 1, CH2Cl2); 1H NMR (CDCl3, 400 MHz):  7.53-7.54 (m, 2 H), 7.26-7.46 
(m, 40 H), 5.99 (d, J = 8.0 Hz, 1 H, NH), 5.70 (brs, 1 H), 5.61 (s, 1 H), 5.42 (s, 1 H), 5.03 (d, J = 
6.7 Hz, 1 H), 4.99 (brs, 1 H), 4.96 (t, J = 5.0 Hz, 2 H), 4.87 (d, J = 12.2 Hz, 1 H), 4.84 (d, J = 
12.5 Hz, 1 H), 4.77 (d, J = 11.2 Hz, 1 H), 4.72 (d, J = 12.5 Hz, 1 H), 4.66-4.69 (m, 3 H), 4.64 (d, 
J = 7.6 Hz, 1 H), 4.55-4.58 (m, 2 H), 4.51 (d, J = 11.0 Hz, 1 H), 4.49 (d, J = 11.9 Hz, 1 H), 4.12-
4.20 (m, 3 H), 4.00-4.06 (m, 2 H), 3.88-3.97 (m, 4 H), 3.78-3.86 (m, 3 H), 3.62-3.75 (m, 4 H), 
3.15-3.19 (m, 1 H), 2.18 (s, 3 H, Ac), 1.79 (s, 3 H, Ac); 13C NMR (CDCl3, 100 MHz):  170.4, 
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170.1, 138.9, 138.6, 138.3, 138.1, 137.9, 137.7, 137.3, 128.9, 128.6, 128.5 (2 C), 128.4, 128.3, 
128.2 (2 C), 128.1, 128.0, 127.9 (2 C), 127.8 (2 C), 127.7, 127.6, 126.1, 101.5, 101.2, 99.3, 98.8, 
78.8, 78.5, 78.0, 77.8, 77.5, 75.7, 75.4, 75.3, 75.2, 74.3, 73.7, 73.6, 72.4, 71.7, 70.8, 69.2, 69.1, 





glucopyranoside (18): Pd(OH)2 on carbon was added to a solution of compound 17 (70 mg, 
0.054 mmol) in MeOH/H2O (10/1). The mixture was stirred under 1 atmosphere of hydrogen. 
After being stirred for 24 h, the mixture was filtered through a PTFE syringe filter and 
concentrated in vacuo. The residue was purified by Bio-Gel P-2 (BIO-RAD) column 
chromatography using water as eluent. The product was then lyophilized to get compound 18 (28 
mg, 90%) as white powder. [α]D20 6.78 (c 0.5, H2O); 1H NMR (D2O, 400 MHz):  5.15-5.17 (m, 
1 H), 5.12 (s, 1 H), 5.06 (s, 0.5 H), 4.74 (s, 1 H), 4.18-4.21 (m, 1 H), 4.03-3.06 (m, 1 H), 3.78-
3.90 (m, 6 H), 3.56-3.75 (m, 9 H), 3.40-3.43 (m, 1 H), 2.12 (s, 1.5 H, Ac), 2.00 (s, 3 H, Ac); 13C 
NMR (D2O, 100 MHz):  174.4, 173.2, 102.4, 99.9, 99.4, 94.9, 90.5, 80.5 (2 C), 79.3, 78.9, 76.1, 
74.6, 73.4, 72.3, 72.2, 70.3, 70.2, 70.1, 70.0 (4 C), 69.1, 68.7, 66.9 (2 C), 65.8 (2 C), 61.1, 60.8, 






Synthesis of the α 2, 6 oxazoline (a) 
Compound 18 (10 mg, 0.018 mmol) and 2-chloro-1,3-dimethylimidazolinium chloride 
(DMC, 45 mg, 0.264 mmol) were dissolved in 0.2 mL of water at 4 oC. Then Et3N (108 μL, 
0.774 mmol) was added and the mixture was shaken at 4oC for 30 min. The residue was subject 
to gel filtration on a Sephadex G-15 column. The column was eluted by water containing 0.05% 
Et3N. The fractions containing the glycan-oxazoline were combined. The fractions were mixed 
with an aqueous solution of NaOH (0.1 M, 10 µL) and were then lyophilized to give the glycan-
oxazoline (a) as a white powder (9.5 mg, quantitative yield). The inclusion of a catalytic amount 
of NaOH ensures an alkaline situation for the oxazoline for its stability after freeze-dry. 1H NMR 
(D2O, 400 MHz):  6.07 (d, J = 7.4 Hz, 1 H, H-1 of oxazoline), 5.08 (s, 1 H, H-1 of α-Man), 4.72 
(s, 1 H, H-1 of β-Man), 4.37 (s, 1 H), 4.17 (d, J = 6.7 Hz, 1 H), 4.12 (s, 1 H), 4.04 (s, 1 H), 3.86-
3.95 (m, 3 H), 3.59-3.75 (m, 9 H), 3.36-3.43 (m, 2 H), 2.05 (s, 3 H, CH3 of oxazoline); 13C NMR 
(D2O, 100 MHz):  168.6, 102.4, 100.9, 99.8, 80.3, 77.3, 76.2, 73.3, 70.9, 70.2, 70.1, 70.0, 69.1, 





Mannopyranosyl-(1→4)-3,6-O-di-benzyl-2-deoxy-phthalimido-β-D-glucopyranoside (19): A 
mixture of donor 15 (103 mg, 0.192 mmol), acceptor 14 (150 mg, 0.148 mmol) and 4 Å 
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molecular sieves in dry CH2Cl2 was stirred at room temperature under argon for 1 h. NIS (56 mg, 
0.252 mmol) and AgOTf (8 mg, 0.030 mmol) were added at 0°C. The reaction mixture was 
stirred at 0°C for 0.5 h before it was quenched with a few drops of triethylamine. The resulting 
mixture was filtered. The filtrate was diluted with CH2Cl2 and washed with 5% Na2S2O3, 
aqueous NaHCO3, brine, dried over Na2SO4, and concentrated. The residue was purified on a 
silica gel column to get the desired title compound 19 (193 mg, 88%) as white foam. [α]D20 -5.92 
(c 1, CH2Cl2); 1H NMR (CDCl3, 500 MHz):  7.68 (brs, 2 H), 7.55-7.57 (m, 2 H), 7.19-7.42 (m, 
36 H), 7.08-7.12 (m, 4 H), 6.97-7.00 (m, 2 H), 6.71-6.75 (m, 3 H), 5.46 (brs, 1 H), 5.20 (d, J = 
7.8 Hz, 1 H), 4.99-5.03 (m, 3 H), 4.96 (t, J = 4.0 Hz, 1 H), 4.89 (d, J = 11.3 Hz, 1 H), 4.85 (d, J = 
12.6 Hz, 1 H), 4.75 (d, J = 12.1 Hz, 1 H), 4.64-4.70 (m, 3 H), 4.50-4.59 (m, 7 H), 4.46 (d, J = 
12.1 Hz, 1 H), 4.29-4.33 (m, 3 H), 4.19 (dd, J = 14.3, 7.2 Hz, 1 H), 4.14 (t, J = 8.0 Hz, 1 H), 
3.87-4.03 (m, 5 H), 3.73-3.84 (m, 5 H), 3.60-3.63 (m, 2 H), 3.40-3.47 (m, 2 H), 1.98 (s, 3 H, Ac); 
13C NMR (CDCl3, 100 MHz):  171.2, 170.0, 139.0, 138.9, 138.7, 138.6, 138.5, 138.3, 138.1 (2 
C), 137.3, 133.5, 131.8, 128.6, 128.5 (2 C), 128.4 (2 C), 128.3 (2 C), 128.2 (2 C), 127.9 (2 C), 
127.8 (4 C), 127.7 (3 C), 127.6, 127.5 (3 C), 127.4, 127.0, 123.1, 102.0, 98.4, 97.5, 82.8, 79.9, 
77.9, 76.7, 75.0, 74.9, 74.8, 74.4, 74.2, 74.0, 73.6, 73.4, 71.8, 71.7, 71.3, 70.8, 68.9, 68.4, 67.1, 




Mannopyranosyl-(1→4)-3,6-O-di-benzyl-2-deoxy-acetamido-β-D-glucopyranoside (20): The 
compound 19 (160 mg, 0.108 mmol) was dissolved in nBuOH at room temperature, followed by 
172 
 
addition of ethylenediamine (nBuOH: ethylenediamine = 2:1). After being stirred at 90°C for 12 
h, the mixture was evaporated in vacuo to give a residue for the next step without further 
purification. To a solution of the residue in pyridine was added Ac2O. After being stirred at room 
temperature for 12 h, the solution was diluted with EtOAc and washed with aqueous HCl (1 M), 
saturated aqueous NaHCO3, and brine solution. The organic layer was dried over Na2SO4, 
filtered, and evaporated in vacuo to give a residue, which was purified by silica gel column 
chromatography to give compound 20 (95 mg, 63% over two steps). [α]D20 -3.60 (c 1, CH2Cl2); 
1H NMR (CDCl3, 400 MHz):  7.47-7.48 (m, 2 H), 7.32-7.40 (m, 41 H), 7.18-7.19 (m, 2 H), 5.46 
(s, 1 H), 5.45 (d, J = 9.4 Hz, 1 H), 5.06 (d, J = 7.0 Hz, 1 H), 4.92-5.01 (m, 5 H), 4.86 (d, J = 10.9 
Hz, 1 H), 4.59-4.69 (m, 6 H), 4.53-4.56 (m, 3 H), 4.52 (d, J = 12.1 Hz, 1 H), 4.47 (d, J = 10.9 
Hz, 1 H), 4.40 (d, J = 12.1 Hz, 1 H), 3.37 (d, J = 12.7 Hz, 1 H), 4.17-4.21 (m, 1 H), 4.11 (t, J = 
7.8 Hz, 1 H), 3.97-3.99 (m, 2 H), 3.90-3.92 (m, 1 H), 3.80-3.88 (m, 5 H), 3.73-3.76 (m, 2 H), 
3.62 (dd, J = 10.9, 2.3 Hz, 1 H), 3.45-3.54 (m, 3 H), 3.28 (d, J = 10.8 Hz, 1 H), 2.13 (s, 3 H, Ac), 
1.60 (s, 3 H, Ac); 13C NMR (CDCl3, 100 MHz):  170.5, 170.3, 139.3, 138.9, 138.7, 138.5, 
138.4, 138.2 (2 C), 138.1, 138.0, 128.6, 128.5, 128.4 (2 C), 128.3 (3 C), 128.2, 128.1 (2 C), 
127.9, 127.8 (2 C), 127.7 (2 C), 127.6 (2 C), 127.5 (2 C), 127.3, 100.7, 99.4, 97.8, 82.9, 78.5, 
77.0, 75.3, 75.0, 74.9, 74.7, 74.5, 73.6, 73.3, 71.8, 71.7, 71.5, 70.9, 69.5, 69.0, 68.7, 67.1, 60.5, 




glucopyranoside (21): Compound 20 (80 mg, 0.057 mmol) was dissolved in MeOH, and NaOMe 
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in MeOH was added until pH was 10. After stirring at room temperature for 2 h, the solution was 
neutralized with ion-exchange resin (H+), and then filtered. The residue was dissolved in 
MeOH/H2O (10/1), and Pd(OH)2 on carbon was added to the solution. The mixture was stirred 
under 1 atmosphere of hydrogen. After being stirred for 24 h, the mixture was filtered through a 
PTFE syringe filter and concentrated in vacuo. The residue was purified by Bio-Gel P-2 (BIO-
RAD) column chromatography using water as eluent. The product was then lyophilized to get 
compound 21 (31 mg, 85% over two steps) as white powder. [α]D20 -2.78 (c 0.5, H2O); 1H NMR 
(D2O, 400 MHz):  5.16 (s, 0.6 H), 4.86 (s, 1 H), 4.72 (s, 1 H), 4.67 (d, 1 H, J = 5.0 Hz, 1 H), 
4.03 (s, 1 H), 3.80-3.90 (m, 6 H), 3.75-3.77 (m, 2 H), 3.54-3.59 (m, 9 H), 2.00 (s, 3 H, Ac); 13C 
NMR (D2O, 100 MHz):  174.6, 100.5, 100.4, 99.6, 94.8, 90.4, 80.1, 79.8, 74.4, 74.3, 72.7, 72.3, 
70.4 (2 C), 70.3, 70.2, 69.8 (2 C), 69.1, 66.8, 66.2, 66.1, 60.9, 60.2, 60.1, 56.0, 53.6, 22.2, 21.9; 
ESI-MS: [M+Na]+ C20H35NO16Na calcd for 568.1854, found 568.1790. 
 
 
Synthesis of the α 2,6 oxazoline (b) 
Compound 21 (10 mg, 0.018 mmol) and 2-chloro-1,3-dimethylimidazolinium chloride 
(DMC, 45 mg, 0.264 mmol) were dissolved in 0.2 mL of water at 4oC. Then Et3N (108 μL, 0.774 
mmol) was added and the mixture was shaken at 4oC for 30 min. The residue was subject to gel 
filtration on a Sephadex G-15 column. The column was eluted by water containing 0.05% Et3N. 
The fractions containing the glycan-oxazoline were combined. The fractions were mixed with an 
aqueous solution of NaOH (0.1 M, 10 μL) and were then lyophilized to give the glycan-
oxazoline (b) as a white powder (9.5 mg, quantitative yield). The inclusion of a catalytic amount 
174 
 
of NaOH ensures an alkaline situation for the oxazoline for its stability after freeze-dry. 1H NMR 
(D2O, 400 MHz):  6.10 (d, J = 7.3 Hz, 1 H, H-1 of oxazoline), 4.95 (s, 1 H, H-1 of a-Man), 4.73 
(s, 1 H, H-1 of b-Man), 4.38 (dd, J = 2.9, 1.9 Hz, 1 H), 4.18-4.21 (m, 1 H), 4.01 (dd, J = 3.4, 1.7 
Hz, 1 H), 3.99 (d, J = 1.2 Hz, 1 H), 3.93-3.95 (m, 1 H), 3.90-3.92 (m, 1 H), 3.85-3.89 (m, 2 H), 
3.76-3.79 (m, 2 H), 3.73-3.74 (m, 1 H), 3.68-3.70 (m, 2 H), 3.62-3.66 (m, 3 H), 3.53-3.57 (m, 1 
H), 3.41-3.45 (m, 1 H), 2.07 (s, 3 H, CH3 of oxazoline); 13C NMR (D2O, 100 MHz):  168.6, 
101.5, 99.9, 99.6, 77.8, 74.5, 72.8, 72.7, 70.9, 70.4, 69.9, 69.2, 66.8, 66.7, 66.0, 65.1, 61.7, 60.9, 
13.0. ); ESI-MS: [M+Na]+ C20H33NO15Na calcd for 550.1748, found 550.1790. 
3) Deacetylation of asymmetric N-glycan products 
Glycan was dissolved in a mixture of H2O and 28%-30% NH4OH (10% in volume) to 
achieve a 341 μM final concentration of glycan. The reaction mixture was shaken at room 
temperature for 2 h. Upon completion, as indicated by MALDI-TOF MS, the reaction mixture 
was lyophilized and the residue was reconstituted in water and subjected to gel filtration over 
Sephadex G-25 (eluent 0.1 M NH4HCO3). Fractions containing product were combined and 
lyophilized to give the respective products as an amorphous white solid. 
Labeling of N-glycans with AEAB 
AEAB (N-(aminoethyl)-2-amino benzamide) was used to label compounds 1-10, 1a-9a, 
2b, 6b, 7b, and 10b to assist their printing onto slides. The AEAB labeling reactions were 
performed[78]5 using the following conditions: Dissolve 8 mg of AEAB in 100 μL solution of 
DMSO/AcOH (7:3 v/v) (labelling solution A), and dissolve 6 mg of NaCNBH3 in another 100 μL 
solution of DMSO/AcOH (7:3 v/v) (labelling solution B). To every 100 μg glycan sample, 25 μL 
of labelling solution A and 25 μL of labelling solution B were added, mixed well and incubated in 
a water bath for 2 h at 65°C.  Labeled glycans were precipitated with acetonitrile (10 volumes) and 
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incubated at -20°C for 1 h. After centrifugation (13,000 g for 10 min), the supernatant was 
removed. The pellet was dried in a vacufuge for 15 min. Labeled glycan was dissolved in 100 μL 
of water and purified using a Waters XBridge BEH amide column (130 Å, 5 µm, 4.6 mm × 250 
mm) as described. Sample concentration was determined using the peak area and comparing to 10 
nmol of known standard (AEAB labelled lactose).  
General methods for glycan microarray 
1) Customized glycan array preparation 
Customized glycan arrays were printed in an 8-subarray format by Z Biotech (Aurora, CO, 
USA). The AEAB-tagged glycans were printed onto microarray substrates coated with NHS 
surface chemistry. Within each subarray, the glycans were printed in 6 replicates at 100 µM 
concentration in print buffer (300 mM sodium phosphate, pH 8.5, 0.005% Tween-20), 0.6 nL for 
each replicate, and print buffer or AEAB alone was printed as a negative binding control. A 
biotinylated PEG amine was printed within each subarray to serve as a positive control. Covalent 
coupling was processed at 80% humidity for 30 min. Then, the unreacted NHS groups were 
blocked with blocking buffer (50 mM ethanolamine in 50 mM sodium borate, pH 9.2) for 1 h and 
the slide was rinsed with water, dried and stored at -20oC until use. 
2) Methods of glycan microarray analysis 
Binding studies using plant lectins were performed as previously described [79].  
Glycan microarray involving viral lectins was analyzed as follows: Recombinant HA 
proteins (1 mg/mL, 15 μL) were pre-mixed with Penta-His Alexa Fluor 647 Conjugate (0.2 
mg/mL, 35 μL) and Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody Alexa 
Fluor 647 (2 mg/mL, 2.3 μL) in a molar ratio of 4:2:1 and were incubated on ice for 15 min, 
followed by dilution to 200 μL with TSMTB buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 
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mM CaCl2, 2 mM MgCl2, 0.05 Tween-20, and 1% BSA). The array slide was mounted with a 
ProPlate 8 Well Module, and 200 μL of TSMTB buffer was added to each well and the slide was 
shaken for 30 min. Then the buffer was removed and 200 μL of HA-antibody pre-mixed complexes 
was added to each well, and the slide was sealed and incubated at room temperature for 2 h. The 
slide was then washed by TSMT buffer, TSM buffer and deionized water. After dried by brief 
centrifuge, the slide was scanned with a GenePix 4000B microarray scanner by recording the 
fluorescent signal of Cy5. The average relative fluorescence units (RFUs) and standard error 
measurement (SEM) were calculated and shown in bar graphs (SEM value as error bars). 
3.2.3 Results and Discussion 
Sialylglycopeptide (SGP) was obtained from egg yolks as previously described [40]. In 
order to assist immobilization of glycans for glycan microarray studies, the Asn residue to which 
the N-glycan was attached was retained by treating SGP.  
The synthesis of the asymmetric N-glycans were performed (Schemes 3.4-3.5, Groups A-
D) by using two N-glycan oxazolines (a and b) that were chemically synthesized as donors, and 
ten asymmetric N-glycans with only one terminal β1-2GlcNAc residue (1-10) that were 
chemoenzymatically synthesized as acceptor. Group A or B glycans contain double α1–3Man 
branch core glycan motifs (i.e. core pentasaccharide minus α1–6Man), and the terminal α1–3Man 
branch core glycan motif located in α1–3Man branch or α1–6Man branch, respectively. Similarly, 
Group C or D glycans contain double α1–6Man branch core glycan motifs (i.e. core 
pentasaccharide minus α1–3Man) and the terminal α1–6Man branch core glycan motif located in 
α1–3Man branch or α1–6Man branch, respectively.  
Incubation of glycan oxazolines and asymmetric N-glycans (1-10) (the molar ratio of donor 
to acceptor was 5:1) with EndoM N175Q at 30°C for 1 h produced all asymmetric N-glycans. 
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Generally speaking, the conversion rate was higher for transglycosylation reaction to α1–6Man 
branch than to α1–3Man branch (Group B vs. Group A, Group D vs. Group C, respectively), 
regardless of which donor was used. However, when b was donor, out of 9 structures we designed, 
only 4 glycans were synthesized. The failure of producing the corresponding xb glycans can be a 
result of space hindrance caused by the appendage on the non-acceptor branch (i.e. the branch 
without terminal β1–2GlcNAc residue). However, the length of the non-acceptor branch is not the 
only factor that determines the conversion rate of this transglycosylation reaction, which can be 
illustrated by the highest conversion rates for 4a and 8a comparing to those for other glycans in 
each group, respectively.  
To achieve selective transglycosylation, 7 was partially protected by peracetylation of 
GlcNAc residue on the 1,3Man branch for the synthesis of asymmetric N-glycans. After 7a0 and 
7b0 were synthesized by EndoM-N175Q, deacetylation was performed to provide 7a and 7b 
(Scheme 3.6). The product of each reaction was analyzed by HPLC-ELSD with HILIC column 
and then was purified under the monitor of A210nm according to the retention time from the 
analytical run, as previously reported [32, 34, 79]. The collected substance was lyophilized and 
analyzed by MS.  
 
Scheme 3.6. Selective transglycosylation achieved by using acetylated glycan as acceptor. 
Next, we labelled all asymmetric N-glycans (both acceptors and products for comparison) 
with AEAB (N-(aminoethyl)-2-amino benzamide), generated customized glycan arrays via Z 
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Biotech (Aurora, CO, USA; the slide is available from Z biotech and Chemily LLC.) and examined 
the recognition of 5 plant lectins (SNA, ECL, PHA-E, GNA, and WGA) as well as 2  
hemoagglutinin proteins (HAs) [NNR19941 (HA of A/New York/18/2009 H1N1) and NR42486 
(HA of A/Czech Republic/32/2011 H1N1; A/Czech Republic/32/2011 (H1N1) is an influenza A 
virus isolated from the seasonal outbreaks of 2009 H1N1 virus and after the viruses have been 
adapted to the human population for two influenza seasons); BEI Resources Repository] of 2009 
H1N1 influenza A viruses to the asymmetric N-glycans. The results are illustrated as histograms 
in Figure 3.5 and Figure 3.6. 
SNA[42] and HAs of 2009 H1N1 influenza A viruses [80] are known to bind Siaα2–6Gal. 
It is interesting that results from our experiments suggested that they exhibited different 
preferences to the two branches in the asymmetric N-glycans. Specifically, SNA preferred to bind 
α1–3Man branch (9>5), while both HAs showed higher binding to α1–6Man branch (5>9). 
Nevertheless, the binding of all three proteins to their favorite branch was hampered slightly (for 
SNA, 5a<5, 9a<9) or significantly (for HAs, almost no detectable binding for 5a and 9a) when the 
other branch was extended with a or b by the transglycosylation reaction, demonstrating the 
extended glycans in the other antennary could have impaired glycan epitope binding between 
glycans and HA proteins of the 2009 H1N1 virus.  
 
Figure 3. 5 Glycan microarray analyses [binding profiles with two viral hemoagglutinin (HA)]. 
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ECL can bind Galβ1–4GlcNAc [43], and it demonstrated preferential binding to the epitope 
in α1–3Man branch (8>4). PHA-E, another lectin that recognizes outer Gal [30], favors the Gal 
located in α1–6Man branch (4>8). When the other branch was elongated by transglycosylation, 
the binding to Gal of both lectins decreased (8a<8, 4a<4). PHA-E also binds terminal GlcNAc 
[30], but preferred GlcNAc in α1–3Man branch (1>10, 2>6). Likewise, bulky groups on the other 
branch (branched Man3 or sialylated LacNAc) hindered the binding of PHA-E to GlcNAc 
regardless of which branch this GlcNAc is in (3, 5, and 9).  
  
Figure 3. 6 Glycan microarray analyses (binding profiles with five plant lectins). 
WGA, which is reported to bind chitin oligomers (GlcNAcn) [30], also liked GlcNAc in 
α1–3Man branch (1>10), and displayed substantial increases in binding when the glycans were 
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extended with α1–3Man branch core glycan motif, no matter the extension located in α1–3Man 
branch or α1–6Man branch (2a-9a vs. 2-9). In contrast, elongation with α1–6Man branch core 
glycan motif did not show this effect (2b vs. 2), indicating that WGA favors binding to GlcNAc 
oligomers linked with α1–3Man branch. In addition, no binding to Siaα2–6Gal was detected 
further confirmed that WGA only binds to Sia in Siaα2–3Gal, consistent with our previous 
observation. 
GNA is a lectin that binds high-mannose glycans especially Manα1-3Man epitope [30]. 
Before transglycosylation, it exhibited higher binding to glycans exposing only Manα1-3Man at 
the terminal than those exposing only Manα1-6Man (2 vs. 6) or exposing both Manα1-3Man and 
Manα1-6Man (3 vs. 6). The binding also decreased as the branches extended, due to the masking 
effect of the extension on Man in glycan core. After transglycosylation, the glycans containing 
terminal Manα1-3Man epitope displayed higher binding to the original glycans (xa vs. x) and to 
those containing terminal Manα1-6Man epitope (xa vs. xb).  
To sum up, we have synthesized a class of asymmetric N-glycans with a facile 
transglycosylation approach and applied them for the binding study of lectins to glycan epitopes 
locating in different branches. Also, donor and acceptor substrate specificity of EndoM N175Q 
was investigated. The binding study revealed that lectins selectively bind to their recognizable 
epitopes on different branches in asymmetric N-glycans. Meanwhile, the elongation of glycans on 




HPLC analyses of N-glycan synthesizing mixtures and MS data of purified N-glycans 














































































































ESI-MS, calculated 2296.8198; found [M-2H]2- 1147.4038, [M+HCOOH-2H]2- 1170.4063. 
 
  



















    z=2
1170.4063
















































































































ESI-MS, calculated 2296.8198; found [M-2H]2- 1147.4046, [M+HCOOH-2H]2- 1170.4059. 
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4 LARGE-SCALE SYNTHESIS OF OLIGOSACCHARIDES 
4.1 Biochemical characterization of Helicobacter pylori α1–3/4FT and synthesis of 
fucosylated human milk oligosaccharides 
4.1.1 Introduction 
Lactose, lipid and human milk oligosaccharides (HMOs), construct the three major 
components within human milk [1, 2]. HMOs are a group of oligosaccharides that are found 
uniquely in human milk, and can provide pivotal beneficial effects to the health of breast-fed 
infants [3, 4]. In typical human milk oligosaccharides, 70 percent of HMOs are fucosylated [5]. 
Fucosylation of HMOs plays crucial roles in the function of HMOs, such as prebiotic effects and 
constructing the host epithelial cell surface glycans [6, 7]. 3-fucosyllactose [3-FL, Galβ1–
4(Fucα1–3)Glc] and LNFP III [Galβ1–4(Fucα1–3)GlcNAcβ1–3Galβ1–4Glc)] can provide 
protection to infants as prebiotics for specific gut bifidobacterial strains[8] and prevent 
cytotoxicity of protozoan parasites and binding to host intestinal cell [9]. Fucosylated HMOs can 
resemble cell surface glycans of the host epithelium and are functional as competitive soluble 
receptor analogs that can prevent adhesion of intestinal pathogen to epithelial surfaces and their 
translocation as well as the bacterial binding against the intestinal mucosa [10]. Besides above 
function, some fucosylated HMOs have potential applications in pharmaceuticals. LNFP III can 
improves glucose tolerance and insulin sensitivity [11] and reduce experimental allergic 
encephalomyelitis (EAE) severity and central nervous system (CNS) inflammation [12]. 
Therefore, synthesis of fucosylted HMOs is crucial for functional study of HMOs. Compared 
with chemical synthesis, enzymatic fucosylation is an efficient and environmentally friendly 
approach to obtain the desired fucosylated HMOs.  
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α1,3/4-fucosyltransferase from H. pylori (Hp3/4FT) and α1,3-fucosyltransferase from H. 
pylori (Hp3FTα66) which is H. pylori (Hp3/4FT) lacking the C-terminal 66 amino acid residues  
can transfer fucose from the donor GDP-fucose to the acceptor N-acetyllactosamine to form 
Lewis X (LeX) antigen. The enzyme was firstly reported by Lin group [13] and already applied 
for oligosaccharide synthesis by Wang group [14, 15], Boons group [16]] and Cao group [17]. 
However, whether or not lactose can be recognized as an acceptor by the enzyme remains 
unclear, since Lin group found enzyme cannot recognize lactose as an acceptor whereas Boons 
group reported that it can transfer two fucoses on Siaα2–3Galβ1–4GlcNAcβ1–3Galβ1–4Glc 
which contained lactose group to form Siaα2–3Galβ1–4(Fucα1–3)GlcNAcβ1–3Galβ1–4(Fucα1–
3)Glc. Also, Cao group did not mention that it could transfer fucose to lactose group when they 
synthesized LNFPIII with Galβ1–4GlcNAcβ1–3Galβ1–4Glc as an acceptor. In addition, no 
biochemical characterization of the enzyme was reported so far. Based on its extensive 
application in the enzymatic synthesis of LeX antigen and fucosylated HMOs, here we 
systematically and biochemically characterized the enzyme in detail, especially focusing on its 
acceptor specificity and its application in efficient synthesis of fucosylated HMOs. 
4.1.2 Experimental Methods 
Cloning of His6-Hp3FT66 
Truncated N-His6-tagged Hp3FT (His6-Hp3FT66) was cloned into pET15b vector. 
Primers used were: forward 5’-GATCCATATGTTTCAGCCGCTGCTG-3’ (NdeI restriction site 
is underlined) and reverse 5’-CGCGGATCCTTATTAGTAGTTAACACGCAGATC-3’ (BamHI 
restriction site is underlined).  
Polymerase chain reaction (PCR) were performed in a total volume of 50 µL containing a 
template DNA (10 ng of synthetic gene for Hp3FT), 0.2 µM of each of forward and reverse 
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primers, 1 × Herculase buffer, dNTP mixture (1 mM), and 5 U of Herculase-enhanced DNA 
polymerase. The reaction was subjected to 30 cycles of amplification with an annealing 
temperature of 53C for Hp3FT. The resulting PCR products were digested with NdeI and BamHI 
restriction enzymes, purified, and ligated with pET15b vector predigested with NdeI and BamHI 
at 16C for overnight. The ligated product was transformed into electro-competent DH5α cells. 
Selected colonies were grown for overnight in Luria Bertaine media (10 g tryptone, 5 g yeast 
extract, and 10 g NaCl per liter) supplemented with ampicilin (100 µg mL-1). Plasmids were 
purified and positive clones were verified by restriction mapping and DNA sequencing performed 
by the Sequencing Facility at the Georgia State University.  
Expression of His6-Hp3FT66 
Plasmids containing the target gene were transformed into E. coli BL21 (DE3) chemically 
competent cells for protein expression. E. coli cells were cultured in Terrific Broth (TB) (12 g L−1 
tryptone, 24 g L−1 yeast extract, 0.4% glycerol, 2.3 g L−1 KH2PO4 and 12.5 g L−1 K2HPO4) 
containing 100 µg mL−1 of ampicillin at 37°C with rigorous shaking at 250 rpm in a C25KC 
incubator shaker (New Brunswick Scientific, Edison, NJ, USA) until the OD600nm reached 0.8–1.0. 
The flask was chilled in an ice-water bath for 20 min. Overexpression of the target protein was 
achieved by adding 0.1 mM of isopropyl-1-thio-β-D-galactopyranoside (IPTG) to the E. coli 
culture followed by incubation of the induced culture at 20C for 20 h with vigorous shaking at 
250 rpm. 
Purification of His6-Hp3FT66 
His6-tagged recombinant proteins were purified from cell lysate. To obtain cell lysate, cells 
were harvested by centrifugation at 4,000 rpm (Sorvall) at 4C for 2 h. The cell pellet was 
resuspended in lysis buffer (pH 8.0, 100 mM Tris-HCl containing 0.1% Triton X-100) (20 mL per 
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liter cell culture) and the mixture went through two freeze-thaw cycles. Lysozyme (50 µg mL-1) 
and DNase I (3 µg mL-1) were added to the cell suspension. The mixture was incubated at 37C 
for 1 h with gentle shaking (125 rpm). Cell lysate was obtained as the supernatant by centrifugation 
at 11,000 rpm (Sorvall) for 20 min at 4C. Purification was performed by loading the supernatant 
onto a 10 cm × 1.5 cm nickel-nitrilotriacetic acid (Ni2+-NTA) column pre-equilibrated with 10 
column volumes of binding buffer (5 mM imidazole, 0.5 M NaCl, 50 mM Tris-HCl, pH 7.5). The 
column was wash with 8 column volumes of binding buffer and 8 column volumes of washing 
buffer (30 mM imidazole, 0.5 M NaCl, 50 mM Tris-HCl, pH 7.5). Protein of interest was eluted 
with an elute buffer (200 mM imidazole, 0.5 M NaCl, 50 mM Tris-HCl, pH 7.5). The fractions 
containing purified recombinant protein were dialyzed against Tris-HCl buffer (pH 8.0, 20 mM) 
containing 10% glycerol and NaCl (100 mM). Dialyzed proteins were stored at 4C.  
Quantification of purified protein 
The concentration of purified protein was determined using a bicinchoninic acid (BCA 
Protein Assay Kit (Pierce Biotechnology, Rockford, IL)) with bovine serum albumin (BSA) as a 
protein standard. The absorbance of the samples was measured in a 96-well microplate at 562 nm 
using a BioTek Synery HT Multi-Mode Microplate reader.  
pH profiles of His6-Hp3FT66 
All assays were carried out in duplicate. Each reaction in a total volume of 10 µL contains 
a buffer (200 mM) with pH varying from 4.0 to 11.0, MnCl2 (20 mM), GDP-Fucose (1 mM), 
LacNAcβPro2AA (1 mM), and 1.2 µg His6-Hp3FT66. The buffers used were sodium acetate, pH 
4.0–4.5; MES, pH 5.0–6.5; HEPES, pH 7.0; Tris-HCl, pH 7.5–9.0; and CAPSO, pH 9.5; CAPS, 
pH 10.0–11.0. Reactions were carried out at 37°C for 15 min before being quenched by adding 
pre-chilled 20% acetonitrile (20 µL). The samples were kept on ice until aliquots of 8 µL were 
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injected and analyzed by a Shimadzu LC-2010A HPLC system equipped with a membrane online 
degasser, a temperature control unit, and a fluorescence detector. A reverse-phase Waters 
Spherisorb C18 column (250 × 4.6 mm i.d., 5 µm particle size) protected with a C18 guard column 
cartridge was used. The mobile phase was 18% acetonitrile. Fluorescently labeled compounds 
LacNAcβPro2AA and LeXβPro2AA were detected by excitation at 315 nm and emission at 400 
nm.  
Ethylenediaminetetraacetic acid (EDTA) and metal effects on the α1–3-fucosyltransferase 
activities of His6-Hp3FT66  
The reactions were carried out in duplicates in a total volume of 10 µL in Tris-HCl buffer 
(100 mM, pH 7.5) containing GDP-fucose (1 mM), LacNAcβPro2AA (1 mM), and recombinant 
enzyme (1.2 µg) in the presence of EDTA (5 mM) or a divalent metal salt (MgCl2 or MnCl2) (5 
mM, 10 mM, or 20 mM). Reactions without EDTA or a metal ion were used as controls. Reactions 
were in carried out in duplicate at 37°C for 15 min, quenched and assayed using the same method 
as described above for pH profile.  
General procedure of HMOs synthesis by Hp3FT66. 
(1) β1–3-GlcNAcylation catalyzed by NmLgtA 
Reaction mixtures contained Tris-HCl (100 mM, pH 8.0), acceptor glycans (lactose or LNnT (3), 
3-8 mg, 10 mM), UDP-GlcNAc (1: 1.3 equiv.), MnCl2 (10 mM), and varying amounts of 
NmLgtA. FastAP (1 U/200 µL) was also added to digest the reaction byproduct UDP to drive 
reaction forward. Reactions were incubated at 37C for overnight, and were monitored by 
MALDI-TOF. After all acceptor was converted, the reaction was quenched by boiling for 5 min, 
followed by NmLgtB for galactose extension or by Hp1,3FT66 for fucose extension. No 
purification for this step of enzymatic extension. 
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(2) β1–4-Galactosylation catalyzed by NmLgtB 
Reaction mixtures contained Tris-HCl (100 mM, pH 8.0), acceptor glycans (reaction 
from NmLgtA or Hp1,3FT66, 5-12 mg, 10 mM), UDP-Gal (1: 1.3 equiv.), MnCl2 (10 mM), 
and varying amounts of NmLgtB. FastAP (1 U/200 µL) was also added to digest the reaction 
byproduct UDP to drive reaction forward. Reactions were incubated at 37°C overnight, and were 
monitored by MALDI-TOF. After all acceptor was converted, the reaction was quenched by 
boiling for 5 min, followed by Hp3FT66 for fucose extension. No purification for this step of 
enzymatic extension except compounds 7 and 8. Compounds 7 and 8 were purified by HPLC-
HILIC column (130 Å, 5 µm, 10 mm × 250 mm). Mobile phase A: 100 mM ammonium formate, 
pH 3.4; Mobile phase B: acetonitrile; Gradient: 80% to 60% B over 35 min, 60% to 0% B over 1 
min, 0% B for 2 min, 0% to 80% B over 2 min, 80% B for 5 min. HPLC eluent was monitored 
by absorption at 210 nm, and glycan-containing fractions were analyzed by MS. 
(3) α1–3-Fucosylation catalyzed by Hp3FT66 
Reaction mixtures contained Tris-HCl (100 mM, pH 8.0), acceptor glycans (compound 8, 
4 mg or reaction from NmLgtA or NmLgtB, 4-10 mg, 10 mM), GDP-Fuc (1: 1.3—1:4 equiv, 
depending on how many fucoses were transferred), MnCl2 (10 mM), and varying amounts of 
Hp1,3FT66. FastAP (1 U/200 µL) was also added to digest the reaction byproduct GDP to 
drive reaction forward. Reactions incubated at 37°C overnight, and monitored by MALDI-TOF. 
After all acceptor was converted, the reaction was quenched by boiling for 5 min, followed by 
concentration using a vacufuge concentrator. HPLC-A210nm was then used to purify target 
glycans using a semi-preparative amide column (130 Å, 5 µm, 10 mm × 250 mm). Mobile phase 
A: 100 mM ammonium formate, pH 3.4; Mobile phase B: acetonitrile; Gradient: 80% to 60% B 
over 35 min, 60% to 0% B over 1 min, 0% B for 2 min, 0% to 80% B over 2 min, 80% B for 5 
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min. HPLC eluent was monitored by absorption at 210 nm, and glycan-containing fractions were 
analyzed by MS. 
 Gal1–4(Fuc1–3)Glc (1). 5 mg, 88%; 1H NMR (600 MHz, D2O) δ 5.34 (d, J = 4.2, 
0.5H), 5.28 (d, J = 4.2 Hz, 0.4H), 5.08 (d, J = 3.6 Hz, 0.4H), 4.80-4.72 (m, 1H), 4.55 (d, J =  7.8 
Hz, 0.6H), 4.33 (d, J = 7.8 Hz, 1H), 3.84-3.35 (m, 16 H), 1.09-1.07 (m, 3H); 13C NMR (150 
MHz, D2O) δ 101.77, 101.74, 98.48, 98.34, 95.79, 92.05, 76.97, 75.50, 75.33, 74.91, 74.68, 
72.64, 72.58, 72.38, 71.93, 71.11, 70.88, 69.25, 69.20, 68.29, 68.09, 68.01, 66.47, 66.43, 61.51, 
61.48, 59.74, 59.66, 15.22. MALDI-TOF m/z calculated for C18H32NaO15 (M+Na): 511.16, 
found 511.36. 
Gal1–4(Fuc1–3)GlcNAc1–3Gal1–4Glc (4). 10 mg, 80%; 1H NMR (600 MHz, D2O)  
δ 5.14 (d, J = 3.6 Hz, 0.4H), 5.05 (d, J = 4.2 Hz, 1H), 4.76 (d, J = 6.6 Hz, 1H), 4.63 (d, J = 8.4 
Hz, 1H), 4.58 (d, J = 8.4 Hz, 0.6H), 4.38 (d, J = 10.8 Hz, 1 H), 4.36 (d, J = 7.8 Hz, 1H), 4.08 (d, 
J = 3.0 Hz, 1H), 3.90-3.48 (m, 26.4H), 3.43-3.40 (m, 1H), 3.21-3.18 (m, 0.6H), 1.94 (s, 3H), 
1.09 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, D2O) δ 174.71, 102.93, 102.90, 102.54, 101.78, 
98.59, 05.74, 91.81, 82.08, 78.27, 75.12, 74.92, 74.80, 74.74, 74.36, 73.80, 73.06, 72.48, 71.92, 
71.40, 71.14, 71.05, 70.12, 69.98, 69.20, 68.35, 67.70, 66.69, 61.51, 60.96, 60.08, 59.95, 59.63, 
55.96, 22.26, 15.31. MALDI-TOF m/z calculated for C32H55NNaO25(M+Na): 876.31, found 
876.71. 
 Gal1–4(Fuc1–3)GlcNAc1–3Gal1–4(Fuc1–3)Glc (5). 8 mg, 68%; 1H NMR 
(600 MHz, D2O) δ 5.28 (s, 0.7HO, 5.22 (s, 0.7 H), 5.03-4.98 (m, 2.6H), 4.56-4.49 (m, 5.4 H), 
4.31 (d, J = 7.2 Hz, 1.4H), 4.26 (d, J = 7.8 Hz, 1.3H), 3.94 (s, 1H), 3.80-3.33 (m, 30H), 1.86 (s, 
3H), 1.02-1.01 (m, 6H); 13C NMR (150 MHz, D2O) δ 174.72, 102.48, 101.73, 98.56, 98.42, 
95.82, 92.11, 81.55, 81.49, 76.98, 75.53, 75.35, 75.06, 74.90, 74.73, 74.67, 74.47, 73.02, 72.66, 
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72.46, 72.35, 72.26, 71.90, 71.03, 70.93, 70.67, 70.63, 69.26, 69.18, 68.33, 68.25, 68.22, 68.00, 
67.68, 66.66, 66.46, 61.49, 59.78, 59.62, 55.93, 22.22, 15.28, 15.19. MALDI-TOF m/z 
calculated for C38H68NNaO29 (M+Na): 1022.36, found 1022.46. 
 GlcNAc1–3Gal1–4(Fuc1–3)Glc (6). 12 mg, 84%; 1H NMR (600 MHz, D2O)  
5.33 (d, J = 4.2 Hz, 0.6H), 5.27 (d, J = 4.2 Hz, 0.5H), 5.08 (d, J = 4.2 Hz, 0.5H), 4.74-4.73 (m, 
1H), 4.58 (dd, J = 2.4 and 8.4 Hz, 1H), 4.55 (d, J = 8.4 Hz, 0.5H), 4.32 (d, J = 7.8 Hz, 1H), 3.99 
(d, J = 3.6 Hz, 1H), 3.87-3.33 (m, 22H), 1.93 (s, 3H), 1.07-1.06 (m, 3H); 13C NMR (150 MHz, 
D2O) 174.90, 102.76, 101.70, 98.51, 98.40, 95.81, 92.09, 81.44, 81.39, 76.97, 75.58, 75.32, 
74.65, 74.46, 73.44, 72.65, 72.35, 72.27, 71.90, 70.90, 70.70, 70.65, 69.67, 69.23, 69.18, 68.23, 
68.01, 67.98, 66.44, 61.43, 60.42, 59.76, 59.69, 55.60, 22.14, 15.20. MALDI-TOF m/z 
calculated for C26H45NNaO20 (M+Na): 714.25, found 714.67. 
 Gal1–4GlcNAc1–3Gal1–4(Fuc1–3)Glc (7). 6 mg, 80%; 1H NMR (600 MHz, 
D2O) δ 5.27 (d, J = 4.2 Hz, 0.5 H), 5.21 (d, J = 3.6 Hz, 0.5 H), 5.02 (d, J = 4.2 Hz, 0.5 H), 4.67-
4.65 (m, 2H), 4.53 (d, J = 8.4 Hz, 1H), 4.49 (d, J = 7.8 Hz, 0.5 Hz), 4.32 (d, J = 7.8 Hz, 1H), 
4.25 (d, J = 7.8 Hz, 1H), 3.94 (d, J = 3.0 Hz, 1H), 3.80-3.28 (m, 28H), 1.87 (s, 3H), 1.09-0.99 
(m, 3H); 13C DEPT 135 NMR (150 MHz, D2O) δ 102.83, 102.67, 101.70, 98.52, 98.41, 95.81, 
92.09, 81.54, 81.49, 78.12, 76.97, 75.52, 75.32, 74.66, 74.49, 74.46, 72.65, 72.47, 72.35, 72.26, 
72.09, 71.90, 70.94, 70.64, 70.60, 69.24, 69.19, 68.22, 68.01, 67.98, 66.46, 66.41, 61.43, 59.81, 
59.75, 59.68, 55.14, 22.14, 15.19. MALDI-TOF m/z calculated for C32H55NNaO25 (M+Na): 
876.31, found 876.06. 
Gal1–4(Fuc1–3)GlcNAc1–3Gal1–4(Fuc1–3)GlcNAc1–3Gal1–4Glc (9). 4 mg, 
80%; 1H NMR (600 MHz, D2O) δ 5.15 (d, J = 4.2 Hz, 0.4H), 5.06 (d, J = 3.6 Hz, 1H), 5.04 (d, J 
= 4.2 Hz, 1H), 4.65-4.63 (m, 2.6H), 4.59 (d, J = 8.4 Hz, 1H), 4.40-4.36 (m, 3H), 4.08 (d, J = 3.6 
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Hz, 1H), 4.02 (d, J = 3.0 Hz, 1H), 3.90-3.41 (m, 48H), 1.95 (s, 3H), 1.95 (s, 3H), 1.10 (d, J = 6.6 
Hz, 3H), 1.07 (d, J = 6.6 Hz, 3H). 13C DEPT 135 NMR (150 MHz, D2O) δ 102.84, 102.47, 
101.67, 98.65, 98.54, 95.66, 91.76, 81.99, 81.52, 78.09, 74.98, 74.84, 74.67, 74.37, 73.70, 72.90, 
72.64, 72.37, 71.83, 70.96, 70.45, 69.89, 69.09, 68.27, 67.60, 66.62, 61.46, 60.90, 59.96, 59.52, 
59.27, 55.87, 22.16, 15.24. MALDI-TOF m/z calculated for C52H88N2NaO39 (M+Na) 1387.50, 
found 1387.45. 
 Gal1–4(Fuc1–3)GlcNAc1–3Gal1–4(Fuc1–3)GlcNAc1–3Gal1–4(Fuc1–
3)Glc (10). 4.8 mg, 94%; 1H NMR (600 MHz, D2O) δ 5.35 (d, J = 4.2 Hz, 1H), 5.29 (d, J = 3.6 
Hz, 1H), 5.10 (d, J = 4.2 Hz, 1H), 5.05 (dd, J = 3.6, 8.4 Hz, 3H), 4.63 (d, J = 8.4 Hz, 3H), 4.57 
(d, J = 7.8 Hz, 1H), 4.39-4.36 (m, 2H), 4.33 (d, J = 7.8 Hz, 1H), 4.02 (bs, 2H), 3.90-4.40 (m, 
60H), 1.94 (s, 6H), 1.10-1.07 (m, 9H). 13C DEPT 135 NMR (150 MHz, D2O) δ 102.47, 101.72, 
98.56, 95.82, 92.18, 81.60, 75.53, 75.35, 75.05, 74.90, 74.74, 74.43, 73.01, 72.75, 72.46, 71.90, 
71.04, 70.52, 69.17, 68.34, 68.22, 68.00, 67.69, 66.67, 66.47, 61.45, 59.62, 55.94, 22.23, 15.29, 
15.26, 15.20. MALDI-TOF m/z calculated for C58H98N2NaO43 (M+Na) 1533.55, found 1533.54. 
4.1.3 Results and Discussion 
Ultra-performance liquid chromatography (UPLC)-based pH profile studies were carried 
out using fluorophore 2-anthranilic acid (2AA)-labelled disaccharide LacNAcβPro2AA as 
acceptor substrate.  
His6-Hp3FT66 was active in a broader pH range and the optimal activity was found in the pH 




Figure 4. 1 pH profile of His6-Hp3FT∆66. 
The effects of metal cations Mg2+ and Mn2+ on the activities of His6-Hp3FTα66 were 
examined at pH 7.5. A metal cation is not required for the fucosyltransferases (Figure 4.2) which 





Figure 4. 2 Metal cation effects on Hp3FT∆66. 
 Black columns, reactions with Mn2+, EDTA, or no metal; grey column, reactions with Mg2+. 
  As shown in Table 4.1, among three 2AA-labelled acceptor substrates, Hp3/4FT 
showed the highest catalytic efficiency for LacNAcβ2AA (kcat/KM = 10.87 s-1 mM-1) due to 
the lowest KM value (0.46±0.07 mM) and a medium range kcat (5.00±0.18 s-1). Galβ1–
3GlcNAcβ2AA has a medium catalytic efficiency (5.89 s-1 mM-1) with the worst KM 
(1.32±0.24 mM) and the highest kcat (7.77±0.45 s-1). Lacβ2AA has the lowest catalytic 
efficiency (kcat/KM = 0.55 s-1 mM-1) with a medium KM value (kcat/KM = 0.99±0.18 mM) and 
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the lowest kcat value (0.54±0.03 s-1, more than 9-folder lower than the other two). Hp3/4FT 
also showed different catalytic efficiencies for guanosine 5’-diphosphate fucose (GDP-Fuc) 
when different acceptors were used. The catalytic efficiencies were 0.80 s-1 mM-1, 7.01 s-1 
mM-1, and 11.19 s-1 mM-1 when LacNAcβ2AA, LacNAcβ2AA, and Galβ1–3GlcNAcβ2AA 
were used as the acceptors, respectively. 
Table 4. 1 Kinetic parameters of Hp3/4FT. 
Substrate KM (mM) VM (mM s-1) kcat (s-1) kcat/KM (s-1 mM-1) 
LacβPro2AA 0.99±0.18 (1.03±0.06)×10-3 0.54±0.03 0.55 
GDP-Fuc 0.38±0.07 (0.57±0.03)×10-3 0.30±0.14 0.80 
LacNAcβPro2AA 0.46±0.07 (1.18±0.04)×10-3 5.00±0.18 10.87 
GDP-Fuc 0.86±0.13 (1.42±0.06)×10-3 6.02±0.26 7.01 
Galβ1–
3GlcNAcβPro2AA 
1.32±0.24 (1.83±0.11)×10-3 7.77±0.45 5.89 
GDP-Fuc 0.35±0.06 (0.92±0.04)×10-3 3.92±0.16 11.19 
 
Based on kinetic parameters of Hp3/4FT, Hp3FT66 specificity study was approached 
and fucosylated HMOs were synthesized. (Scheme 4.1) 
 
Scheme 4. 1 Fucosylated HMOs were synthesized by Hp3FT∆66 according its acceptor 
specificity. 





We found that it can efficiently transfer fucose from GDP-Fuc to lactose or LacNAc. 3-
FL (1) can be efficiently synthesized by the enzyme. However, when synthesizing LNFP III (4) 
from lacto-N-neotetraose (LNnT, 3), it preferentially transfers fucose onto LacNAc rather than 
lactose, the structure of which was identified by tandem MS and 2D NMR (Figure 4.3) 
indicating its higher catalytic efficiency on LacNAc than lactose, consistent with the kinetic 
study. If the ratio of GDP-Fuc to LNnT was 2:1, two fucoses can be added and lacto-N-
neodifucohexaose II (LNnDFH II, 5) [18] was acquired and identified by tandem MS (Figure 
4.4b). According to tandem MS results, specific fragment of Gal1–4(Fuc1–3)GlcNAc can be 
found in LNFP III (4), whereas Gal1–4(Fuc1–3)Glc was not (Figure 4.4a). In comparison, 
specific fragments of both Gal1–4(Fuc1–3)GlcNAc and Gal1–4(Fuc1–3)Glc can be found 










Figure 4. 3 LNFP III (4) characterization by MALDI-TOF tandem mass spectrometry and 2D 
NMR. 
In addition, we found that the preferences of Hp3FT66 to LacNAc and lactose in para-
lacto-N-neohexaose (paraLNnH, 8) [19] is similar to those in LNnT, firstly transferring two 
fucose to two LacNAcs to obtain difuco-para-lacto-N-neohexaose (DF-paraLNnH, 9) [19], and 
then transferring the third fucose on lactose to synthesize trifuco- para-lacto-N-neohexaose (TF-






Figure 4. 4 Specificity of Hp3FT∆66 was identified by tandem MS. 
 (a) LNFP III (4); (b) LNnDFH II (5); (c) LNnFP V (7); (d) DF-paraLNnH (9); (e) TF-paraLNnH 
(10). 
If we change the sequence of glycosyltransferases used (first LgtB and then Hp3FT66), 
lacto-N-neofucopentaose (LNnFP V or LNFP VI, 7) [20], an isomer of LNFP III (4) can be 
obtained from lacto-N-triose II (LNT II, 2). LNnFP V (7) was identified by tandem MS (Figure 
4.4c) and 2D NMR. Hp3FT66 was facile and efficient for the reason that no acceptors can be 
detected by MALDI-TOF MS when 7 fucosylated HMOs were efficiently synthesized.  
In conclusion, recombinant Hp3FT66 readily expressed in E. coli was systematically and 
biochemically characterized. Hp3FT66 can recognize both lactose and LacNAc as acceptors, but 
preferentially transfers fucose onto LacNAc rather than lactose when both lactose and LacNAc 
groups exist in one glycan because Hp3FT66 showed higher catalytic efficiencies for LacNAc 
than lactose based on kinetic study. According to acceptor specificity study, 7 fucosylated HMOs 
were successfully synthesized, which are important probes for their biological studies. 
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4.2 Fucosylated human milk oligosaccharide (HMOs) production in large scale by 
combined engineered E.coli. 
4.2.1 Introduction 
  Generally, three strategies are employed so far for large-scale oligosaccharide 
production: (1) chemical synthesis, (2) enzymatic synthesis, and (3) whole-cell 
synthesis/living cell factory. Every strategy has its advantages, however, each strategy has 
distinct challenges for synthesis of complex oligosaccharides: 
  (1) Chemical synthesis: for large-scale synthesis of more complex 
oligosaccharides, lengthy synthetic steps and relatively low overall yield impair the 
practicality of pure chemical synthesis. 
  (2) Enzymatic synthesis: a large number of purified enzymes are still and likely to 
hinder scale-up production of oligosaccharides. 
  (3) “Living cell factory” strategy: Two major restrictions exist for production of 
oligosaccharides larger than trisaccharides: (a) larger oligosaccharide substrates can not 
be transported into living E. coli for additional extensions; (b) several intermediates were 
formed along the biosynthetic pathway when multiple GTs are coexpressed with mono- 
or disaccharide substrates, leading to difficulty in purifying the intended product [21, 22]. 
  To solve this limitation, we set up a platform which combines two strategies: (1) 
fermentation of “living cell factory” enabled production of lactose derived trisaccharides; 
(2) single- or multi-step whole-cell catalyzed production of more complex 
oligosaccharides. For trisaccharide production with lactose as starting material, an 
engineered E. coli strain containing the essential enzymes for the sugar chain extension is 
used. By supplying the E. coli culture with lactose, multi-gram of trisaccharide can be 
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produced from 1 L of E. coli culture by simple fermentation. For oligosaccharides which 
are derived from starting materials other than lactose, step-wise whole-cell catalysis with 
engineered E. coli strains are used. By this combined technology, we have adopted the 
simplicity of “living cell factory” for lactose-derived trisaccharide production, and 
expanded the possibility of synthesis of more complex oligosaccharides by multi-step 
whole-cell catalysis (Scheme 4.2) 
  
Scheme 4. 2 Fucosylated HMOs were synthesized by Hp3FT∆66 according its acceptor 
specificity. 
 
  Besides affecting host resistance and parasite homing as HMOs [23, 24], LNFP III, 
Gal1–4(Fuc1–3)GlcNAc1–3Gal1–4Glc) can also reduce experimental allergic 
encephalomyelitis (EAE) severity and central nervous system (CNS) inflammation[12] 
and improves glucose tolerance and insulin sensitivity [11]. In addition, α1–3-fucosylated 
HMOs were found to be protective against mortality for HIV-exposed uninfected (HEU) 
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children during breastfeeding [25]. Lewis antigen-type HMOs structures were also shown 
to reduce selectin-mediated cell-cell interactions [26, 27]. Therefore, herein we choose 
two fucosylated HMOs, LNFP III and lacto-N-neofucopentaose V [LNnFP V, Gal1–
4GlcNAc1–3Gal1–4(Fuc1–3)Glc)] that are isomers, as targets to demonstrate our 
strategy.  
4.2.2 Experimental Methods 
Construction of Strain 1, Strain 2, Strain 3, and Strain LacZ. 
Strain 1: lgtA-pET15b plasmid was used and stored in our lab [15]. One microgram of 
plasmid was transformed into JM109 (DE3) competent cell. Selected colonies were grown for 
overnight in Luria Bertaine media (10 g tryptone, 5 g yeast extract, and 10 g NaCl per liter) 
supplemented with ampicilin (100 µg mL-1). Plasmids were purified and positive clones were 
verified by restriction mapping and DNA sequencing performed by the Sequencing Facility at 
the Georgia State University.  
Strain 2: galE and lgtB were cloned into pETDuet-1 vector. Primers used were: galE-
pET-F1: ACA CATATG ATGAGAGTTCTGGTTACCGGT (NdeI) and galE-pET-R1: GCC 
GGTACC ATCGGGATAT CCCTGTGGAT G (KpnI); lgtB-pET-F1: ACA GGATCC 
GATGCAAAACCACGTTATCAGC (BamHI) and lgtB-pET-R1: GGC GAGCTC 
GATTGGAAAGGC ACAATGAACTG (SacI). 
Polymerase chain reaction (PCR) were performed in a total volume of 50 µL containing a 
template DNA (galE and lgtB gene were stored in our lab), 0.2 µM of each of forward and 
reverse primers, 1 × Herculase buffer, dNTP mixture (1 mM), and 5 U of Herculase-enhanced 
DNA polymerase. The reaction was subjected to 30 cycles of amplification with an annealing 
temperature of 55C for galE and lgtB. The resulting PCR products were digested with NdeI and 
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KpnI restriction enzymes for galE and with BamHI and SacI restriction enzymes for lgtB, 
purified, and ligated with predigested pETDuet-1 vector at 16C for overnight. The ligated 
product was transformed into electro-competent DH5α cells. Selected colonies were grown 
overnight in Luria Bertaine media (10 g tryptone, 5 g yeast extract, and 10 g NaCl per liter) 
supplemented with ampicilin (100 µg mL-1). Plasmids were purified and positive clones were 
verified by restriction mapping and DNA sequencing performed by Sequencing Facility at the 
Georgia State University. The constructed galE-lgtB-pETDuet-1 was transformed into E.coli 
BL21 (DE3) competent cell. Strain 3: The strain was used and stored in our lab [15].  
Medium preparation in Fed-Batch fermentation. 
Table 4. 2 ECAM medium (1 L) 
Ingredients Amount 
KH2PO4    (Potassium Phosphate monobasic- 
JT3246-05) 
7.8 g 
Citric acid    (monohydrate- JT0115) 1g 
(NH4)2SO4    (Ammonium Sulfate- 4702-3) 2.33 g 
Trace metal solution   1ml 
Thiamine HCl    10 mg 
Glycerol   22 g 
MgSO4  1 g 
CaCl2  40 mg 
Ampicillin 100 mg 
Filter sterilize into autoclaved bottle. 
Table 4. 3 Batch medium (10 L) 
Ingredients Amount 
Antifoam 204 750 µL 
KH2PO4    (Potassium Phosphate monobasic- JT3246-05) 22 g 
Citric acid    (monohydrate- JT0115) 10 g 
(NH4)2SO4    (Ammonium Sulfate- 4702-3) 45 g 
Trace metal solution 10 mL 
Thiamine HCl 0.1 g 
Glycerol 220 g 
MgSO4 10 g 
CaCl2 0.4 g 
Ampicillin 1 g 
Filter sterilize into autoclaved bottle. 
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Table 4. 4 Feed medium (5 L) 
Ingredients Amount 
Glycerol 1000 g 
KH2PO4    (Potassium Phosphate monobasic- JT3246-05) 7.5 g 
(NH4)2HPO4 (Ammonium phosphate dibasic) 50 g 
NaH2PO4 (sodium phosphate monobasic, monohydrate) 20 g 
(NH4)2SO4    (Ammonium Sulfate- 4702-3) 25 g 
Citric acid    (monohydrate- JT0115) 20 g 
MgSO4 23.4 g 
Trace metal solution 30 mL 
CaCl2 10 g 
Thiamine HCl 0.5 g 
FeSO4 2.5 g 
Adjust pH to 5.2 with 4N sulfuric acid. Filter sterilize into autoclaved bottle. 
 
Table 4. 5 Trace metal solution (1 L) 
Name Amount 
EDTA 5 g 
FeSO4 ·7H2O 10 g 
ZnSO4 ·7H2O 2 g 
MnSO4 ·H2O 2 g 
CoCl2 ·6H2O 0.2 g 
CuSO4 ·H2O 0.1 g 
Na2MoO4 ZnSO4 ·2H2O 0.2 g 
H3BO3 0.1 g 
Filter sterilize into autoclaved bottle. 
Expression of Strain 2, Strain 3 and LacZ and whole cell catalyzed oligosaccharide production. 
Strain 2 or Strain 3 was cultured in LB medium containing 100 µg mL−1 of ampicillin or 
50 µg mL−1 kanamycin at 37°C with rigorous shaking at 200 rpm in a C25KC incubator shaker 
(New Brunswick Scientific, Edison, NJ, USA) until the OD600 reached 0.6–0.8. The flask was 
chilled in an ice-water bath for 30 min. Overexpression of the target protein was achieved by 
adding 0.1 mM of isopropyl-1-thio-β-D-galactopyranoside (IPTG) to the E. coli culture followed 
by incubation of the induced culture at 16C for 20 h with vigorous shaking at 200 rpm. Cells were 
harvested from 2 L culture by centrifugation at 4,000 rpm (Sorvall) at 4C for 40 min. The cell 
pellet from 2 L culture was resuspended in 20 mL Tris-HCl buffer (pH 7.5) containing 100 mM 
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NaCl, 1% Triton X-100 (v/v). Then cells were subject to freeze at -20°C and thaw at 25°C to 
increase the permeability of substrate.  
Mixture of LNT-II and lactose from cyotosol in Strain 1 fermentation was mixed with 
different amount of frozen and thawed Strain LacZ in 100 mM Tris-HCl (pH 7.5) buffer, and was 
shaken at 120 rpm, 25°C overnight for lactose hydrolysis.  
LNT-II or LNT-3FT [Gal1–4GlcNAc1–3Gal1–4(Fuc1–3)Glc)] and UDP-Glc were 
mixed with different amount of frozen-and-thawed Strain 2 in 100 mM Tris-HCl (pH 7.5) buffer, 
and were shaken at 120 rpm, 25°C overnight for LNnT or LNnFPV synthesis.  
LNT-II or LNnT and unpurified GDP-Fuc which was synthesized by previous method[28] 
were mixed with different amount of frozen-and-thawed Strain 3 in 100 mM Tris-HCl (pH 7.5) 
buffer, and were shaken at 120 rpm, 25°C overnight for LNT-II-3FT or LNFP III synthesis.  
Standard curve of oligosaccharides. 
Different amounts (5 µg, 10 µg, 20 µg, 40 µg, 100 µg, 150 µg and 200 µg) of 
oligosaccharide samples (lactose, LNT-II, LNnT and LNT-II-3FT) were analyzed in triplicates by 
HPLC-HILIC-ELSD column to generate standard curve of oligossacharides.  
General methods for HILIC-ELSD analysis of oligosaccharides. 
Column: Waters XBridge BEH amide column, 130 Å, 5 µm, 4.6 mm × 250 mm 
Solvent A: 100 mM ammonium formate, pH 3.4 







Gradient elution: Time  B%  Flow rate (mL/min) 
   0  80  1 
   35  60  1 
   36  0  1 
   40  0  1 
   41  80  1 
   48  80  1 
Monitor: Shimadzu ELSD-LTII, 60°C. 
4.2.3 Results and Discussion 
By this combined technology, we have adopted the simplicity of “living cell factory” for 
lactose-derived trisaccharide production, and expanded the possibility of synthesis of more 
complex oligosaccharides by multi-step whole-cell catalysis (compared to previous reports). Our 
practice also showed the successful uptake of complex oligosaccharide (up to pentasaccharide) 
by cells in whole-cell catalysis (Scheme 4.2). In addition, an outstanding advantage of whole-
cell catalysis is the low requirement for the purity of starting materials used by whole cell. For 
example, sugar nucleotides from enzymatic preparation mixture can be directly added to the 
whole-cell glycosyltransfer reaction system without purification to serve as sugar donor for GT’s 
reaction, and the oligosaccharide product from a fermentation process or a previous whole-cell 
catalysis can be directly used for the next step whole-cell catalysis. The tolerance toward high 
concentration of sugar nucleotide or nucleotide and salts by the engineered E. coli strains allows 
us to skip the purification step of intermediate oligosaccharide and only purify the final 




Fed-batch fermentation of LNT-II. 
Lactose and LNT-II concentration were identified by standard curve of oligosaccharides 
(5 µg, 10 µg, 20 µg, 40 µg, 100 µg, 150 µg and 200 µg. From 5 µg to 200 µg, the curve was 
linear.). The E.coli JM109 (DE3) which is lacY+ and lacZ- harboring lgtA-pET22b plasmid was 
used for LNT-II production in vivo. In order to produce LNT-II in large scale, a fed-batch 
strategy was employed. Glycerol was used as carbon source and lactose was used as substrate 
rather than carbon source because LacZ, an enzyme to hydrolyze lactose, was deficient in E.coli 
JM109 (DE3). LNT-II was produced with a batch volume of 10 L mineral salt medium and 5 L 
feed medium. Fed-batch cultivation was set at 37°C, adjusting pH 7.0 with 2 M NaOH. The 
oxygen concentration (pO2) was maintained at 30% by adjusting stirrer speed and aeration rate. 
Firstly, Strain 1 was cultivated with 50 mL ECAM medium overnight at 37C. Then the resulting 
50 mL ECAM culture was transferred to 500 mL ECAM medium for another 8 h cultivation at 
37C and this was used as seed when OD600 reached 1. Then, the 500 mL seed medium 
(OD600=1.06) was transferred into 10 L batch medium and cultivated at 37C. When glycerol in 
the batch medium was completely consumed, lactose was supplemented at a final concentration 
of 5 g/L and 0.5 mM IPTG were added in the medium. In addition, feed medium was added at 
high rate of 360 mL/h in the first 3 hours. Then, feeding rate was changed to 180 mL/h for lower 
feeding rate of substrate. After a total 45 hours of fermentation, total concentration (intracellular 
and extracellular) of 7.33±0.14 g/L LNT-II was produced by a cell dry weight (CDW) 




Figure 4. 5 LNT-II production by direct fermentation. 
Blue square: Cell dry weight concentration; Red circle: Total concentration of LNT-II. 
Optimization of whole-cell catalyzed production of oligosaccharides.  
The concentrations of lactose, LNT-II, LNnT, and LNT-3FT were identified by standard 
curve of oligosaccharides concentration. By optimizing Fed-batch fermentation of Strain 1, 
7.33±0.14 g/L LNT II can be synthesized. The cells of Strain 1 were collected and resuspended 
in water and then Strain 1 were permeabilized by boiling at 100oC for 30 min. After 
centrifugation (12,000 g, 30 min), the supernatant which contained LNT-II and unconsumed 
lactose was collected. After concentration by rotovap, concentrated LNT-II and unconsumed 
lactose were obtained. Unconsumed lactose can be used as acceptor by the subsequent 
glycosyltransferase, for example, Hp3FT to produce 3-FL. Therefore, we introduced a step to 
remove the unconsumed lactose by hydrolysis with lacZ strain which can express β-galactosidase 
(LacZ). By frozen and thawed E.coli BL21 (DE3) harboring lacZ-pET22b, cell pellet of 1 L 
culture of strain LacZ can hydrolyze 811.99±40.60 g pure lactose. And then, by optimization of 
flask fermentation of Strain 2 which is E.coli BL21 (DE3) harboring pDeut-galE-lgtB, GalE 













































glycosyltransferase and can add Gal onto GlcNAc residue, were coexpressed and used for 
galactose extension. After being frozen and thawed, cell pellets from 1 L E. coli Strain 2 culture 
can make use of 2.61±0.03 g LNT-II to synthesize LNnT (UDP-Glc:LNT-II= 1.2:1).  
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After LNT II was fully consumed, Strain 2 was permeabilized by boiling at 100oC for 30 
min and centrifuge (12,000 g, 30 min). The supernatant which contained LNnT was collected 
and used for LNFP III production by Strain 3. According to our result, purified recombinant FKP 
from 1 L culture of flask fermentation can produce around 1.5 g GDP-Fuc [28]. Without 
purification, GDP-Fuc was utilized by frozen-and-thawed Strain 3 as sugar donor to extend 
LNnT to produce LNFP III. Since Hpα1,3FT can accept LacNAc (Galβ1-4GlcNAc) as a 
preferred substrate to lactose (refer to section 4.1.3), in this step, the amount of GDP-Fuc needs 
to be optimized. Otherwise, a second Fuc will be added to the Glc of LNnT and LNnDFH will be 
synthesized. By optimization of ratio of GDP-Fuc and LNnT, cell pellets of 1 L culture of Strain 
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3 can make use of 1.16±0.01 g LNnT to synthesize LNFP III (GDP-Fuc:LNnT= 1.2:1) (Figure 
4.6, Table 4.6).  
 
Figure 4. 6 Optimization of whole-cell catalyzed production of oligosaccharides. 
In addition, by changing the sequence of strains used for oligosaccharide synthesis, 
another pentasaccharide, LNnFP V can be synthesized by the similar strategy (Scheme 4.3). To 
synthesize LNnFP V, cells from 1 L E. coli Strain 3 culture can utilize 0.85±0.01 g LNT-II to 
synthesize tetrasaccharide LNT-II-3FT (GlcNAc and Gal1–4(Fuc1–3)Glc) (GDP-Fuc:LNT-II 
= 1.2:1). And cells from 1 L Strain 2 culture can make use of 1.85±0.01 g LNT-II-3FT to 



























Scheme 4. 3 LNFP III and LNnFP V synthesis in large scale by combined engineered E.coli 
strains. 
 
Multi-gram scale production of LNFP III and LNnFP V. 
By this technology we developed, purification of intermediate oligosaccharides was not 
necessary because glycosyltransferase in frozen-and-thawed whole-cell can tolerate complicated 
conditions which include high concentration of sugar nucleotide, nucleotide and salt. In the final 
step, crude LNFP III and LNnFP V were purified by activated charcoal column and P2 column.  
By the above strategy, LNFP III and LNnFP V were synthesized by combined engineered 
E.coli strains and purified by two-step purification. (1) LNFP III synthesis and purification: The 
cells of Strain 1 were collected and resuspended with water and then Strain 1 were permeabilized 
by heating at 100oC in boiling water for 30 min. After centrifugation (12,000 g, 30 min), the 
supernatant which contained 3.2 g LNT-II and about 0.3 g unconsumed lactose was collected. 
After being frozen and thawed, 0.1 mL of resuspended E. coli strain LacZ (contained cells from 
10 mL strain lacZ flask culture) was used for lactose hydrolysis. Followed by boiling at 100oC 
for 30 min and centrifugation, the supernatant which contained 3.2 g LNT-II was collected. And 
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then, 4 g UDP-Glc and 30 mL of frozen-and-thawed Strain 2 (contained cells from 1.5 L Strain 2 
flask culture) were added and shaken overnight at 25 oC to produce LNnT until no LNT-II could 
be detected by MALDI-TOF MS. Followed by heating in boiling water for 30 min and 
centrifugation, the supernatant which contained about 4.2 g LNnT was collected. Then, 45mL of 
frozen-and-thawed Strain 3 (contained cells from 4.5 L Strain 3 flask culture) and 5 g unpurified 
GDP-Fuc which was produced by FKP enzyme were added and shaken overnight at 25 oC to 
produce about 5 g LNFP III until no LNnT could be detected by MALDI-TOF MS. In the final 
step, 5 g of crude LNFP III was purified by activated charcoal column and P2 column. Finally, 
2.1 g of LNFP IIII with over 90% purity was obtained and characterized by HPLC-HILIC, 
MALDI-TOF MS and NMR (2) LNnFP V synthesis and purification: By a similar strategy, 
mixture of 1.6 g LNT-II and 0.16 g lactose were hydrolyzed by 50 µL of frozen-and-thawed 
lacZ, and then 2.2 g unpurified GDP-Fuc and 25 mL frozen-and-thawed Strain 3 (contained cells 
from 2.5 L Strain 3 flask culture) were added and shaken overnight at 25 oC to produce about 2.0 
g LNT-II-3FT. Followed by adding 2.5 g UDP-Glc and 15 mL frozen-and-thawed Strain 2 
(contained cells from 1.5 L Strain 2 flask culture), about 2.5 g LNnFP V was synthesized. By 
activated charcoal column and P2 column purification, 1.1 g of LNnFP V with 80% purity was 
obtained and characterized by HPLC-HILIC, MALDI-TOF MS and NMR. 
To sum up, herein we developed a strategy for structure-defined and complex fucosylated 
HMOs synthesis by combined engineered E.coli strains. By combining fermentation of “living 
cell factory” and whole-cell catalyzed production, multi-gram scale of LNFP-III and LNnFP V 
were efficiently synthesized by three major engineered E.coli strains. In addition, the 
oligosaccharides with high purity can be acquired by simple two-step purification. The 
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Profile of MS, HPLC and standard curve of oligosaccharides concentration. 
 
 
LNFP III was identified by MS-MS and HPLC. 
 











LNnFP V was identified by MS-MS, HPLC. 
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1H NMR of BA-36 
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NMR spectrum and data of purified N-glycan 
 
1H NMR of Compound 10b 
1H NMR (D2O, 500 MHz): 5.15 (s, 1 H), 4.88 (s, 1 H), 4.87 (s, 1 H), 4.73 (d, J = 6.6 Hz, 1.5 
H, GlcNAc-1 H-1 of α-isomer), 4.66 (d, J = 7.5 Hz, 1 H, GlcNAc-1 H-1 of -isomer), 4.56-4.59 
(m, 2 H), 4.51 (d, J = 8.0 Hz, 1 H), 4.40 (brs, 2 H), 3.93 (brs, 1 H), 3.81-3.90 (m, 11 H), 3.67-



















1H and 13C NMR NMR spectra of Gal1–4(Fuc1–3)Glc (1) 
 
 











1H and 13C NMR spectra of GlcNAc1–3Gal1–4(Fuc1–3)Glc (6)  
 



























LNFP III was identified by 2D NMR. 
 
  
LNnFP V was identified by 2D NMR. 
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